

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 November 2002 (14.11.2002)

PCT

(10) International Publication Number
WO 02/090580 A1

(51) International Patent Classification⁷: **C12Q 1/68**

[MY/SG]; 4 Tan Boon Chong Avenue, 1027 Singapore (SG).

(21) International Application Number: PCT/AU02/00558

(22) International Filing Date: 3 May 2002 (03.05.2002)

(74) Agents: **ARGAET, Victor, Peter** et al.; Davies Collison Cave, Level 3, 303 Coronation Drive, Milton, Queensland 4064 (AU).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/288,441 3 May 2001 (03.05.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(71) Applicants (*for all designated States except US*): **NATIONAL CANCER CENTRE OF SINGAPORE PTE LTD** [SG/SG]; 11 Hospital Drive, 169610 Singapore (SG). **SINGAPORE GENERAL HOSPITAL PTE LTD** [SG/SG]; 11 Third Hospital, SNEC Building, 7th Floor, 168751 Singapore (SG).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for AU only*): **ARGAET, Victor, Peter** [AU/AU]; 29 Beaconsfield Terrace, Gordon Park, Queensland 4031 (AU).

Published:
— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HUYNH, The Hung** [CA/SG]; 1 Pearlbank #26-03, 169016 Singapore (SG). **CHOW, Pierce, Kah, Hoe** [MY/SG]; 10A Siak Kew Avenue, 348081 Singapore (SG). **SOO, Khee, Chee**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IDENTIFYING LIVER CANCER BY DETECTING ABERRANT EXPRESSION OF INSULIN LIKE GROWTH FACTOR BINDING PROTEIN

(57) Abstract: The invention is the linkage of the aberrant expression of insulin like growth factor binding proteins (IGFBPs) to the development and/or progression of liver cancer. It includes a method for detecting the presence or diagnosing the risk of a liver cancer, either before or after the onset of clinical symptoms, by detecting an aberrant level and/or functional activity of an expression product of a gene encoding an IGFBP, which correlates with the presence or risk of liver cancer. Also disclosed are methods of screening for agents that modulate the level and/or functional activity of an expression product of an IGFBP gene or gene belonging to the same biosynthetic or regulatory pathway as an IGFBP gene for use in methods for modulating liver cell proliferation of tumourgenesis, or for treating and/or preventing a liver cancer or related condition.



WO 02/090580 A1

**IDENTIFYING LIVER CANCER BY DETECTING
ABERRANT EXPRESSION OF INSULIN LIKE
GROWTH FACTOR BINDING PROTEIN**

FIELD OF THE INVENTION

THIS INVENTION relates generally to polynucleotides and polypeptides linked to cancer. More particularly, the present invention relates to the aberrant expression of insulin-like growth factor binding proteins (IGFBPs), which is linked to the development and/or progression of cancer, especially a cancer of the liver such as hepatocellular carcinoma (HCC). Even more particularly, the present invention relates to a method for detecting the presence or diagnosing the risk of a liver cancer, either before or after the onset of clinical symptoms, by detecting an aberrant level and/or functional activity of an expression product of a gene encoding an insulin-like growth factor binding protein (IGFBP), which correlates with the presence or risk of liver cancer. Assessing the level and/or functional activity of the aberrant expression product is useful as a prognostic indicator of disease outcome. The invention also encompasses methods of screening for agents that modulate the level and/or functional activity of an expression product of an *IGFBP* gene or a gene belonging to the same biosynthetic or regulatory pathway as an *IGFBP* gene for use in methods for modulating liver cell proliferation or tumorigenesis, of for treating and/or preventing a liver cancer or related condition.

Bibliographic details of the publications numerically referred to in this specification are collected at the end of the description.

BACKGROUND OF THE INVENTION

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide but treatment outcomes for HCC have remained generally poor. The majority of patients with HCC have inoperable disease with very poor prognosis (1). Survival in patients with curative resection carried out at dedicated centres is between 35 - 50% at 5 years and much lower elsewhere (2, 3). Long-term survival is uncommon because of the frequent presence of recurrence, metastasis or the development of new primaries (4, 5). There is also currently no accepted adjuvant or palliative treatment modalities that have been conclusively shown to prolong survival in HCC (6).

Recent research has shown that insulin-like growth factors I and II (IGF-I and IGF-II) are potent mitogens for human hepatoma cells (7), and that both IGF-I mRNA (8) and IGF-I receptors (IGF-IR) (7, 8) are detectable in human hepatoma cell lines. Both IGF-

- 2 -

I and IGF-II bind with high affinity to specific IGF-binding proteins (IGFBPs), which modulate their bioactivity. At least six IGFBPs have been described (reviewed in (9, 10)). Expression of genes encoding the various IGFBPs has been observed in many tissues, and is subject to intricate physiological regulation (reviewed in (9, 10)). IGFBP-3 is the most
5 abundant IGF binding protein in the circulation, where it forms a 150 kDa complex with an acid-labile subunit and IGF-I or IGF-II (10). The IGFBP-3 gene is expressed in many tissues and IGFBP-3 has affinities for IGFs that are either equal to or stronger than those of the IGF receptors and therefore inhibits the IGFs by sequestration in the extracellular compartment (reviewed in (9, 10)). Recent evidence also demonstrates that IGFBP-3 has
10 growth inhibitory activity that is independent of its IGF binding properties (reviewed in (10)).

Existing evidence suggests that early diagnosis of HCC may allow modulation of its activities and the potential for therapeutical applications in the control of HCC. Conventional methods for diagnosis of HCC are based on measuring serum levels of
15 alpha-fetoprotein (AFP). Normally, AFP is a major serum protein synthesised by foetal liver cells, yolk sac cells, and in trace amounts by the foetal gastrointestinal tract. Reappearance of AFP in adult serum often signals pathologic conditions, particularly the presence of HCC and germ cell tumours containing yolk sac cell elements. Although existing assays may be used successfully for monitoring treatment of AFP-producing
20 tumours and as an independent prognostic tool, the finding of elevated serum AFP levels in some patients with nonmalignant liver diseases, particularly in acute and chronic viral hepatitis and cirrhosis, has limited the value of such assays as an independent specific test to establish the diagnosis of cancer.

An acute need, therefore, still exists in the art for an assay which is selective for
25 patients with HCC, particularly given the need for early detection of HCC in high risk populations.

SUMMARY OF THE INVENTION

The present invention is predicated in part on the determination that IGFBPs are differentially expressed in liver cancer (*e.g.*, HCC). Thus, IGFBPs and the transcripts from which they are translated have utility, for example, as markers of liver cancer, and as
5 targets for therapeutic intervention in liver cancer. Accordingly, in one aspect of the present invention, there is provided a method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient aberrant expression of a gene encoding an insulin-like growth factor binding protein (IGFBP). Preferably, the IGFBP is selected from IGFBP-1, IGFBP-2 or
10 IGFBP-3. The liver cancer is preferably a liver cell carcinoma.

In another aspect, the invention contemplates a method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient aberrant expression of at least one gene encoding an IGFBP selected from IGFBP-1, -2 and -3.

15 In yet another aspect, the invention encompasses a method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient a level and/or functional activity of an expression product of a gene encoding an IGFBP-1, which is elevated relative to a normal reference level and/or functional activity of said expression product.

20 In still yet another aspect, the invention envisions a method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient a level and/or functional activity of an expression product of a gene encoding an IGFBP-2, which is elevated relative to a normal reference level and/or functional activity of said expression product.

25 In a further aspect, the invention contemplates a method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient a level and/or functional activity of an expression product of a gene encoding an IGFBP-3, which is reduced relative to a normal reference level and/or functional activity of said expression product.

30 In yet a further aspect, the invention resides in a method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient:

- 4 -

– a level and/or functional activity of an expression product of an *IGFBP-1* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-1* expression product; and/or

5 – a level and/or functional activity of an expression product of an *IGFBP-2* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-2* expression product; and/or

– a level and/or functional activity of an expression product of an *IGFBP-3* gene, which is reduced relative to a normal reference level and/or functional activity of said *IGFBP-3* expression product.

10 In another aspect, the invention contemplates a method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient:

15 – a level and/or functional activity of an expression product of an *IGFBP-1* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-1* expression product; and

– a level and/or functional activity of an expression product of an *IGFBP-2* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-2* expression product.

20 In yet another aspect, the invention encompasses a method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient:

25 – a level and/or functional activity of an expression product of an *IGFBP-1* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-1* expression product; and

– a level and/or functional activity of an expression product of an *IGFBP-3* gene, which is reduced relative to a normal reference level and/or functional activity of said *IGFBP-3* expression product.

30 In yet another aspect, the invention envisions a method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient:

– a level and/or functional activity of an expression product of an *IGFBP-2* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-2* expression product; and

- 5 -

– a level and/or functional activity of an expression product of an *IGFBP-3* gene, which is reduced relative to a normal reference level and/or functional activity of said *IGFBP-3* expression product.

In still yet another aspect, the invention features a method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient:

– a level and/or functional activity of an expression product of an *IGFBP-1* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-1* expression product; and

– a level and/or functional activity of an expression product of an *IGFBP-2* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-2* expression product; and

– a level and/or functional activity of an expression product of an *IGFBP-3* gene, which is reduced relative to a normal reference level and/or functional activity of said *IGFBP-3* expression product.

In another aspect, the invention provides a method for diagnosis in a patient of the progression of a liver cancer, comprising detecting aberrant expression of at least one gene encoding an IGFBP in a biological sample obtained from said patient.

In yet another aspect, the invention contemplates a method for prognostic assessment of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient aberrant expression of at least one gene encoding an IGFBP.

In yet another aspect, the invention extends to the use of an agent in the manufacture of a medicament for treating and/or preventing a liver cancer, wherein said agent is optionally formulated with a pharmaceutically acceptable carrier and is identifiable by a screening assay comprising:

– contacting a preparation comprising at least a portion of an expression product of a gene selected from an *IGFBP* gene or a gene relating to the same regulatory or biosynthetic pathway as the *IGFBP* gene, or a variant or derivative of said expression product, or comprising a genetic sequence which regulates expression of said expression product and which is operably connected to a marker gene, with said agent; and

- 6 -

- detecting a change in the level and/or functional activity of said at least a portion of said expression product or said variant or derivative or a change in the level of expression of said marker gene.

In another aspect, the invention contemplates the use of an agent that reduces the level and/or functional activity of an expression product of a gene encoding an IGFBP—1 in the manufacture of a medicament for treating and/or preventing a liver cancer, wherein said agent is optionally formulated with a pharmaceutically acceptable carrier and is identifiable by a screening assay comprising:

- contacting a preparation comprising at least a portion of an expression product of an *IGFBP—1* gene, or a variant or derivative of said expression product, or comprising a genetic sequence which regulates expression of said expression product and which is operably connected to a marker gene, with said agent; and

- detecting a reduction in the level and/or functional activity of said at least a portion of said expression product or said variant or derivative or a reduction in the level and/or functional activity of an expression product of said marker gene.

In yet another aspect, the invention provides the use of an agent that reduces the level and/or functional activity of an expression product of a gene encoding an IGFBP—2 in the manufacture of a medicament for treating and/or preventing a liver cancer, wherein said agent is optionally formulated with a pharmaceutically acceptable carrier and is identifiable by a screening assay comprising:

- contacting a preparation comprising at least a portion of an expression product of an *IGFBP—2* gene, or a variant or derivative of said expression product, or comprising a genetic sequence which regulates expression of said expression product and which is operably connected to a marker gene, with said agent; and

- detecting a reduction in the level and/or functional activity of said at least a portion of said expression product or said variant or derivative or a reduction in the level and/or functional activity of an expression product of said marker gene.

In a further aspect, the invention extends to the use of an agent that increases the level and/or functional activity of an expression product of a gene encoding an IGFBP—3 in the manufacture of a medicament for treating and/or preventing a liver cancer, wherein said agent is optionally formulated with a pharmaceutically acceptable carrier and is identifiable by a screening assay comprising:

- 7 -

– contacting a preparation comprising at least a portion of an expression product of an *IGFBP-3* gene, or a variant or derivative of said expression product, or comprising a genetic sequence which regulates expression of said expression product and which is operably connected to a marker gene, with said agent; and

5 – detecting an increase in the level and/or functional activity of said at least a portion of said expression product or said variant or derivative or an increase in the level and/or functional activity of an expression product of said marker gene.

In one embodiment, the agent is selected from (1) an antisense oligonucleotide or ribozyme that binds to, or otherwise interacts specifically with, a polynucleotide selected
10 from an *IGFBP-1* polynucleotide, an *IGFBP-2* polynucleotide or complement of these, or (2) an antigen-binding molecule that is immuno-interactive with *IGFBP-1* and/or *IGFBP-2*. In another embodiment, the agent is selected from a first member comprising an *IGFBP-3* polypeptide or a biologically active fragment thereof, or variant or derivative of these or a second member comprising a polynucleotide encoding said first member, which
15 is operably connected to a regulatory polynucleotide.

In yet another aspect, the invention contemplates the use of a vector in the manufacture of a medicament, which is optionally formulated with a pharmaceutically acceptable carrier, for the treatment and/or prophylaxis of a liver cancer or related condition, wherein said vector comprises at least a portion of an *IGFBP-3* polynucleotide
20 operably linked, in the sense direction, to a regulatory polynucleotide.

In another aspect, the invention extends to the use of a vector in the manufacture of a medicament, which is optionally formulated with a pharmaceutically acceptable carrier, for the treatment and/or prophylaxis of a liver cancer or related condition, wherein said vector comprises an isolated *IGFBP-1* polynucleotide operably linked, in the
25 antisense direction, to a regulatory polynucleotide.

In yet another aspect, the invention provides the use of a vector in the manufacture of a medicament, which is optionally formulated with a pharmaceutically acceptable carrier, for the treatment and/or prophylaxis of a liver cancer or related condition, wherein said vector comprises an isolated *IGFBP-2* polynucleotide operably
30 linked, in the antisense direction, to a regulatory polynucleotide.

In still another aspect, the invention contemplates a method for modulating liver cell proliferation or tumorigenesis, comprising contacting a liver cell with an agent as

- 8 -

broadly described above for a time and under conditions sufficient to modulate the level and/or functional activity of an *IGFBP* expression product.

According to another aspect, the invention provides a method for treatment and/or prophylaxis of a liver cancer or related condition, comprising administering to a patient in
5 need of such treatment an effective amount of a compound selected from an agent as broadly described above, an agent-containing medicament as broadly described above, or a vector-containing medicament as broadly described above.

The invention also contemplates, in another aspect, the use of an agent-containing medicament as broadly described above, or a vector-containing composition as broadly
10 described above in the preparation of a medicament for treating a liver cancer or related condition.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. IGFBP-3 expression in adjacent normal liver tissue and HCC tumours. Tissue lysates from normal adjacent liver tissue and HCC tumours were analysed by Western blotting. Blots were incubated with anti-human IGFBP-3 and α -tubulin antibodies. Representative samples are shown in panels (A), (B) and (C). All normal adjacent liver tissues had high levels of IGFBP-3 while IGFBP-3 protein was either under-expressed or absent from HCC tumours. Note that the low molecular weight IGFBP-3 fragments were present in serum samples (see panel (C)).

Figure 2. Immunostaining of normal liver (A) and HCC tumours (B) for IGFBP-3. Normal adjacent liver tissue and HCC tumours were stained with anti-human IGFBP-3 as described in Example 1. Adjacent normal liver tissue, showing intense expression of normal cells for IGFBP-3 while very low staining signal was observed for the morphologically disorganised HCC cells. Representative staining are shown. (original magnification X 400).

Figure 3. Immunostaining of normal liver and HCC tumours for IGF-I and IGF-II. Normal adjacent liver tissue (AC) and HCC tumours (B,D) were stained with anti-human IGF-I (A and B) or anti-human IGF-II (C and D) as described in Example 1. Representative samples are shown. Normal adjacent liver tissue shows intense staining for IGF-I while low staining signals are seen for HCC cells. HCC tumours show more intense staining for IGF-II than normal adjacent tissue. (original magnification X 400).

Figure 4. IGF-I receptor expression in adjacent normal liver tissue and HCC tumours. Tissue lysates from normal adjacent liver tissue and HCC tumours were analysed by Western blotting as described in Example 1. Blots were incubated with anti-IGF-IR (A) and anti- α -tubulin (B) antibodies. Note that in certain pairs of samples, normal adjacent liver tissue had higher levels of IGF-IR than HCC tumours.

Figure 5. Effects of IGFs, IGFBP-3, and IGF-II antibody on HepG2 cell proliferation. Cells were cultured as described in Example 1. Cells were incubated with serum free MEM, and indicated reagents of IGF-I for 48 h. Cell number was determined as described (14). Means of triplicate experiments were plotted. Bars with different letters are significantly different from one another at ($p < 0.01$, Mann Whitney U test). SE at each point was $< 15\%$. A, Effect of IGF-I on HepG2 proliferation. IGF-I significantly increased HepG2 cell number. B, Effect of IGFBP-3 on HepG2 cell proliferation. Growth of HepG2

- 10 -

cells was significantly inhibited by exogenous IGFBP-3. *C*, Effect of hrIGFBP-3 on IGF-I-induced HepG2 cell proliferation. Cells were incubated with either serum free medium or 25 ng/mL IGF-I in the presence of various concentrations of hrIGFBP-3 for 48 h. IGF-I-induced HepG2 proliferation was significantly attenuated by hrIGFBP-3. *D*, Effect of IGF-II and anti-IGF-II antibody on HepG2 cell proliferation. Cells were incubated with serum free, 25 ng/mL hrIGF-II, rabbit preimmune serum (1:800 dilution), rabbit anti-human IGF-II antibody (2 μ g/mL) and 25 ng/mL IGF-I in combination with rabbit anti-human IGF-II (2 μ g/mL). IGF-II-induced proliferation rates were significant decreased in the presence of anti-IGF-II antibody. Note that IGF-II antibody also inhibits HepG2 cell growth.

Figure 6. Serum levels of IGFBP-1, -2, -3 and alpha fetoprotein in non-HCC and HCC patients. Serum samples from non-HCC and HCC patients were analysed by Western blotting as described in Example 2. Blots were incubated with anti-human IGFBP-1, anti-bovine IGFBP-2, anti-human IGFBP-3 and anti-human alpha fetoprotein antibodies. Representative samples are shown in panels 6A – 6P. All non-HCC serum samples had high levels of IGFBP-3 while IGFBP-1 and IGFBP-2 were low. IGFBP-3 was either low or absent from HCC. Upregulation of IGFBP-1 and IGFBP-2 was observed in most HCC serum samples. Note that AFP was absent in some HCC serum samples.

BRIEF DESCRIPTION OF THE SEQUENCES: SUMMARY TABLE**TABLE A**

<i>SEQUENCE ID</i>	<i>DESCRIPTION</i>	<i>LENGTH</i>
SEQ ID NO: 1	Nucleotide sequence corresponding to human insulin-like growth factor binding protein 1 (IGFBP-1), mRNA as set forth in GenBank Accession No. XM_004688	1514 nts
SEQ ID NO: 2	IGFBP-1 polypeptide encoded by SEQ ID NO: 1	259 aa
SEQ ID NO: 3	Nucleotide sequence corresponding to human insulin-like growth factor binding protein 2 (IGFBP-2), mRNA as set forth in GenBank Accession No. NM_000597	1433 nts
SEQ ID NO: 4	IGFBP-2 polypeptide encoded by SEQ ID NO: 3	328 aa
SEQ ID NO: 5	Nucleotide sequence corresponding to human insulin-like growth factor binding protein 3 (IGFBP-3), mRNA as set forth in GenBank Accession No. BC000013	2497 nts
SEQ ID NO: 6	IGFBP-3 polypeptide encoded by SEQ ID NO: 5	291 aa
SEQ ID NO: 7	Nucleotide sequence corresponding to human insulin-like growth factor binding protein 1 (IGFBP-1) gene as set forth in GenBank Accession No. M74587	6128 nts
SEQ ID NO: 8	IGFBP-1 polypeptide encoded by SEQ ID NO: 7	259 aa
SEQ ID NO: 9	Nucleotide sequence corresponding to human insulin-like growth factor binding protein 2 (IGFBP-2) gene as set forth in GenBank Accession No. gi 18552832:211494-242517	31024 nts
SEQ ID NO: 10	IGFBP-2 polypeptide encoded by SEQ ID NO: 7	328 aa

- 12 -

<i>SEQUENCE ID</i>	<i>DESCRIPTION</i>	<i>LENGTH</i>
SEQ ID NO: 11	Nucleotide sequence corresponding to human insulin-like growth factor binding protein 3 (IGFBP-3) gene as set forth in GenBank Accession No. M35878	10884 nts
SEQ ID NO: 12	IGFBP-3 polypeptide encoded by SEQ ID NO: 11	291 aa

DETAILED DESCRIPTION OF THE INVENTION

1. Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. For the purposes of the present invention, the following terms are defined below.

The articles “a” and “an” are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

The term “*aberrant expression product*” refers to expressed polynucleotides or polypeptide, which result from a substitution, deletion and/or addition of one or more nucleotides or amino acid residues in a “normal” reference polynucleotide or polypeptide, and which correlate with the presence or risk of a liver cancer.

“*Amplification product*” refers to a nucleic acid product generated by nucleic acid amplification techniques.

By “*antigen-binding molecule*” is meant a molecule that has binding affinity for a target antigen. It will be understood that this term extends to immunoglobulins, immunoglobulin fragments and non-immunoglobulin derived protein frameworks that exhibit antigen-binding activity.

The term “*biological sample*” as used herein refers to a sample that may be extracted, untreated, treated, diluted or concentrated from a patient. The biological sample may comprise a fluid selected from whole blood, serum, plasma, saliva, urine, sweat, ascitic fluid, peritoneal fluid, synovial fluid, amniotic fluid, cerebrospinal fluid, tissue biopsy (e.g., liver biopsy), and the like. The biological sample preferably includes serum, whole blood, plasma and lymph or other circulatory fluid, saliva, mucus secretion and respiratory fluid. More preferably, the biological sample comprises a circulatory fluid such as serum or whole blood or a fractionated portion thereof. Most preferably, the biological sample comprises serum or a fractionated portion thereof.

- 14 -

By "*biologically active fragment*" is meant a fragment of a full-length parent polypeptide which fragment retains the activity of the parent polypeptide. A biologically active fragment will therefore have, for example, the activity of an IGFBP. As used herein, the term "*biologically active fragment*" includes deletion variants and small peptides, for example of at least 10, preferably at least 20 and more preferably at least 30 contiguous amino acids, which comprise the above activities. Peptides of this type may be obtained through the application of standard recombinant nucleic acid techniques or synthesised using conventional liquid or solid phase synthesis techniques. For example, reference may be made to solution synthesis or solid phase synthesis as described, for example, in Chapter 9 entitled "*Peptide Synthesis*" by Atherton and Shephard which is included in a publication entitled "*Synthetic Vaccines*" edited by Nicholson and published by Blackwell Scientific Publications. Alternatively, peptides can be produced by digestion of a polypeptide of the invention with proteinases such as endoLys-C, endoArg-C, endoGlu-C and staphylococcus V8-protease. The digested fragments can be purified by, for example, high performance liquid chromatographic (HPLC) techniques.

Throughout this specification, unless the context requires otherwise, the words "*comprise*", "*comprises*" and "*comprising*" will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements.

By "*effective amount*", in the context of treating or preventing a condition is meant the administration of that amount of active to an individual in need of such treatment or prophylaxis, either in a single dose or as part of a series, that is effective for treatment or prophylaxis of that condition. The effective amount will vary depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated, the formulation of the composition, the assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

As used herein, the term "*function*" refers to a biological, enzymatic, or therapeutic function.

Reference herein to "*immuno-interactive*" includes reference to any interaction, reaction, or other form of association between molecules and in particular where one of the molecules is, or mimics, a component of the immune system.

- 15 -

By “*isolated*” is meant material that is substantially or essentially free from components that normally accompany it in its native state.

By “*marker gene*” is meant a gene that imparts a distinct phenotype to cells expressing the marker gene and thus allows such transformed cells to be distinguished
5 from cells that do not have the marker. A selectable marker gene confers a trait for which one can ‘select’ based on resistance to a selective agent (*e.g.*, antibiotic, radiation, heat, or other treatment damaging to untransformed cells). A screenable marker gene (or marker gene) confers a trait that one can identify through observation or testing, *i.e.*, by ‘screening’ (*e.g.* β -glucuronidase, luciferase, or other enzyme activity not present in
10 untransformed cells).

By “*obtained from*” is meant that a sample such as, for example, a polynucleotide extract or polypeptide extract is isolated from, or derived from, a particular source of the host. For example, the extract can be obtained from a tissue or a biological fluid isolated directly from the host.

The term “*oligonucleotide*” as used herein refers to a polymer composed of a multiplicity of nucleotide residues (deoxyribonucleotides or ribonucleotides, or related structural variants or synthetic analogues thereof) linked via phosphodiester bonds (or related structural variants or synthetic analogues thereof). Thus, while the term “oligonucleotide” typically refers to a nucleotide polymer in which the nucleotide residues
20 and linkages between them are naturally occurring, it will be understood that the term also includes within its scope various analogues including, but not restricted to, peptide nucleic acids (PNAs), phosphoramidates, phosphorothioates, methyl phosphonates, 2-O-methyl ribonucleic acids, and the like. The exact size of the molecule can vary depending on the particular application. An oligonucleotide is typically rather short in length, generally from
25 about 10 to 30 nucleotide residues, but the term can refer to molecules of any length, although the term “polynucleotide” or “nucleic acid” is typically used for large oligonucleotides.

The term “*operably connected*” or “*operably linked*” as used herein means placing a structural gene under the regulatory control of a promoter, which then controls
30 the transcription and optionally translation of the gene. In the construction of heterologous promoter/structural gene combinations, it is generally preferred to position the genetic sequence or promoter at a distance from the gene transcription start site that is approximately the same as the distance between that genetic sequence or promoter and the

- 16 -

gene it controls in its natural setting; *i.e.* the gene from which the genetic sequence or promoter is derived. As is known in the art, some variation in this distance can be accommodated without loss of function. Similarly, the preferred positioning of a regulatory sequence element with respect to a heterologous gene to be placed under its control is defined by the positioning of the element in its natural setting; *i.e.* the genes from which it is derived.

The term “*patient*” refers to patients of human or other mammal and includes any individual it is desired to examine or treat using the methods of the invention. However, it will be understood that “*patient*” does not imply that symptoms are present. Suitable mammals that fall within the scope of the invention include, but are not restricted to, primates, livestock animals (*eg.* sheep, cows, horses, donkeys, pigs), laboratory test animals (*eg.* rabbits, mice, rats, guinea pigs, hamsters), companion animals (*eg.* cats, dogs) and captive wild animals (*eg.* foxes, deer, dingoes).

By “*pharmaceutically acceptable carrier*” is meant a solid or liquid filler, diluent or encapsulating substance that can be safely used in topical or systemic administration to a animal, preferably a mammal including humans.

The term “*polynucleotide*” or “*nucleic acid*” as used herein designates mRNA, RNA, cRNA, cDNA or DNA. The term typically refers to oligonucleotides greater than 30 nucleotide residues in length. Polynucleotide sequences are understood to encompass complementary strands as well as alternative backbones described herein.

The terms “*polynucleotide variant*” and “*variant*” refer to polynucleotides displaying substantial sequence identity with a reference polynucleotide sequence or polynucleotides that hybridise with a reference sequence under stringent conditions that are defined hereinafter. These terms also encompasses polynucleotides in which one or more nucleotides have been added or deleted, or replaced with different nucleotides. In this regard, it is well understood in the art that certain alterations inclusive of mutations, additions, deletions and substitutions can be made to a reference polynucleotide whereby the altered polynucleotide retains the biological function or activity of the reference polynucleotide. The terms “*polynucleotide variant*” and “*variant*” also include naturally occurring allelic variants.

“*Polypeptide*”, “*peptide*” and “*protein*” are used interchangeably herein to refer to a polymer of amino acid residues and to variants and synthetic analogues of the same. Thus, these terms apply to amino acid polymers in which one or more amino acid residues

- 17 -

is a synthetic non-naturally occurring amino acid, such as a chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally-occurring amino acid polymers.

The term "*polypeptide variant*" refers to polypeptides in which one or more amino acids have been replaced by different amino acids. It is well understood in the art that some amino acids may be changed to others with broadly similar properties without changing the nature of the activity of the polypeptide (conservative substitutions).

By "*primer*" is meant an oligonucleotide which, when paired with a strand of DNA, is capable of initiating the synthesis of a primer extension product in the presence of a suitable polymerising agent. The primer is preferably single-stranded for maximum efficiency in amplification but can alternatively be double-stranded. A primer must be sufficiently long to prime the synthesis of extension products in the presence of the polymerisation agent. The length of the primer depends on many factors, including application, temperature to be employed, template reaction conditions, other reagents, and source of primers. For example, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15 to 35 or more nucleotide residues, although it can contain fewer nucleotide residues. Primers can be large polynucleotides, such as from about 200 nucleotide residues to several kilobases or more. Primers can be selected to be "substantially complementary" to the sequence on the template to which it is designed to hybridise and serve as a site for the initiation of synthesis. By "substantially complementary", it is meant that the primer is sufficiently complementary to hybridise with a target polynucleotide. Preferably, the primer contains no mismatches with the template to which it is designed to hybridise but this is not essential. For example, non-complementary nucleotide residues can be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the template. Alternatively, non-complementary nucleotide residues or a stretch of non-complementary nucleotide residues can be interspersed into a primer, provided that the primer sequence has sufficient complementarity with the sequence of the template to hybridise therewith and thereby form a template for synthesis of the extension product of the primer.

"*Probe*" refers to a molecule that binds to a specific sequence or sub-sequence or other moiety of another molecule. Unless otherwise indicated, the term "probe" typically refers to a polynucleotide probe that binds to another polynucleotide, often called the "target polynucleotide", through complementary base pairing. Probes can bind target

- 18 -

polynucleotides lacking complete sequence complementarity with the probe, depending on the stringency of the hybridisation conditions. Probes can be labelled directly or indirectly.

The term "*recombinant polynucleotide*" as used herein refers to a polynucleotide formed *in vitro* by the manipulation of a polynucleotide into a form not normally found in nature. For example, the recombinant polynucleotide can be in the form of an expression vector. Generally, such expression vectors include transcriptional and translational regulatory polynucleotide operably linked to the polynucleotide.

By "*recombinant polypeptide*" is meant a polypeptide made using recombinant techniques, *ie.* through the expression of a recombinant or synthetic polynucleotide.

By "*reporter molecule*" as used in the present specification is meant a molecule that, by its chemical nature, provides an analytically identifiable signal that allows the detection of a complex comprising an antigen-binding molecule and its target antigen. The term "reporter molecule" also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like.

By "*vector*" is meant a polynucleotide molecule, preferably a DNA molecule derived, for example, from a plasmid, bacteriophage, yeast or virus, into which a polynucleotide can be inserted or cloned. A vector preferably contains one or more unique restriction sites and can be capable of autonomous replication in a defined host cell including a target cell or tissue or a progenitor cell or tissue thereof, or be integrable with the genome of the defined host such that the cloned sequence is reproducible. Accordingly, the vector can be an autonomously replicating vector, *ie.* a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, *eg.* a linear or closed circular plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector can contain any means for assuring self-replication. Alternatively, the vector can be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. A vector system can comprise a single vector or plasmid, two or more vectors or plasmids, which together contain the total DNA to be introduced into the genome of the host cell, or a transposon. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. In the present case, the vector is preferably a viral or viral-derived vector, which is operably functional in animal and preferably mammalian cells. Such vector may be derived from a poxvirus, an adenovirus or yeast. The vector can also include a selection

- 19 -

marker such as an antibiotic resistance gene that can be used for selection of suitable transformants. Examples of such resistance genes are known to those of skill in the art and include the *nptII* gene that confers resistance to the antibiotics kanamycin and G418 (Geneticin®) and the *hph* gene which confers resistance to the antibiotic hygromycin B.

5 As used herein, underscoring or italicising the name of a gene shall indicate the gene, in contrast to its protein product, which is indicated in the absence of any underscoring or italicising. For example, “*IGFBP-1*” shall mean the *IGFBP-1* gene, whereas “IGFBP-1” shall indicate the protein product of the “*IGFBP-1*” gene.

2. *Methods of detecting aberrant IGFBP expression*

10 The present invention is predicated in part on the discovery that the sera of patients with liver cancer, particularly hepatocellular carcinoma, have aberrant levels of insulin-like growth factor binding proteins (IGFBPs) relative to sera of normal patients. Thus, the invention features a method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting aberrant expression of a gene encoding an
15 IGFBP in a biological sample obtained from said patient. The aberrant expression preferably relates to a level and/or functional activity of an expression product of said gene, which correlates with the presence or risk of said liver cancer. A correlation with the presence or risk of a liver cancer is made for example when the level and/or functional activity of an *IGFBP* expression product in the biological sample differs by at least 10%,
20 more preferably at least 50%, even more preferably at least 100%, even more preferably at least 200%, even more preferably at least 400%, even more preferably at least 600% and still even more preferably at least 1000% compared to the level and/or functional activity of said expression product in a biological sample obtained from normal patients or from patients who are not afflicted with that liver cancer. In a preferred embodiment, the level
25 and/or functional activity of an *IGFBP-1* or *IGFBP-2* expression product in said biological sample is at least 10%, more preferably at least 50%, even more preferably at least 100%, even more preferably at least 200%, even more preferably at least 400%, even more preferably at least 600% and still even more preferably at least 1000% higher than the level and/or functional activity of that expression product in a biological sample
30 obtained from normal patients or from patients who are not afflicted with said liver cancer. In another preferred embodiment, the level and/or functional activity of an *IGFBP-3* expression product in said biological sample is at least 10%, more preferably at least 50%, even more preferably at least 100%, even more preferably at least 200%, even more

- 20 -

preferably at least 400%, even more preferably at least 600% and still even more preferably at least 1000% lower than the level and/or functional activity of that expression product in a biological sample obtained from normal patients or from patients who are not afflicted with said liver cancer.

5 Accordingly, the presence or risk of liver cancer is diagnosed when (1) an expression product of *IGFBP-1* or *IGFBP-2* is expressed at a higher level, or (2) an expression product of *IGFBP-3* is expressed at a lower level, compared to the level at which it is expressed in normal patients or in patients without liver cancer. In a preferred embodiment of this type, the method comprises detecting a level and/or functional activity
10 of an expression product of an *IGFBP-1* gene or an *IGFBP-2* gene, which is elevated relative to a normal reference level and/or functional activity of that expression product. In another preferred embodiment of this type, the method comprises detecting a level and/or functional activity of an expression product of an *IGFBP-3* gene, which is reduced relative to a normal reference level and/or functional activity of that expression product.

15 Thus, it may be desirable for example to qualitatively or quantitatively determine IGFBP protein levels and/or *IGFBP* transcription levels. Alternatively or additionally, it may be desirable to search for aberrant *IGFBP* structural genes and regulatory regions, which encode aberrant *IGFBP* expression products or which produce aberrant levels of *IGFBP* expression products. Alternatively or additionally, it may be desirable to
20 qualitatively or quantitatively determine the level of an expression product (*e.g.*, transcript, protein) of a gene relating to the same regulatory or biosynthetic pathway as an *IGFBP* gene, which can modulate or otherwise influence IGFBP protein levels and/or *IGFBP* transcription levels. Likewise, it may also be desirable to search for an aberrant gene relating to the same regulatory or biosynthetic pathway as an *IGFBP* gene.

25 The biological sample can be any tissue (*e.g.*, a liver biopsy) or fluid. The biological sample is preferably a biological fluid including, but not restricted to, a circulatory fluid such as whole blood, serum, plasma and lymph as well as other circulatory fluid and saliva, mucus secretion and respiratory fluid. More preferably, the biological sample is serum or a fractionated portion thereof.

30 2.1 Genetic Diagnosis

One embodiment of the instant invention comprises a method for detecting an increase in the expression of an *IGFBP* gene by qualitatively or quantitatively determining

- 21 -

the transcripts of an *IGFBP* gene in a cell (*e.g.*, a liver cell such a Kupffer cell). Exemplary human nucleic acid sequences for *IGFBP-1*, *IGFBP-2* and *IGFBP-3* mRNA and there corresponding genes are set forth in the enclosed Sequence Listing *infra* and are summarised in TABLE A *supra*.

5 Another embodiment of the instant invention comprises a method for detecting reduction in the expression or function of an *IGFBP* gene (*e.g.*, *IGFBP-3*), or enhancement of expression or function of an *IGFBP* gene (*e.g.*, *IGFBP-1*, *IGFBP-2*), by examining the genes and transcripts of a cell. Nucleic acid used is isolated from cells contained in the biological sample, according to standard methodologies (Sambrook, *et al.*, "Molecular
10 Cloning. A Laboratory Manual", Cold Spring Harbor Press, 1989; Ausubel *et al.*, "Current Protocols in Molecular Biology", John Wiley & Sons Inc, 1994-1998). The nucleic acid may be genomic DNA or fractionated or whole cell RNA. Where RNA is used, it may be desired to convert the RNA to a complementary DNA. In one embodiment, the RNA is whole cell RNA; in another, it is poly-A RNA. In one embodiment, the nucleic acid is
15 amplified by a nucleic acid amplification technique. Suitable nucleic acid amplification techniques are well known to the skilled artisan, and include the polymerase chain reaction (PCR) as for example described in Ausubel *et al.* (*supra*); strand displacement amplification (SDA) as for example described in U.S. Patent No 5,422,252; rolling circle replication (RCR) as for example described in Liu *et al.*, (1996) and International
20 application WO 92/01813) and Lizardi *et al.*, (International Application WO 97/19193); nucleic acid sequence-based amplification (NASBA) as for example described by Sooknanan *et al.*, (1994, *Biotechniques* 17:1077-1080); and Q- β replicase amplification as for example described by Tyagi *et al.*, (1996, *Proc. Natl. Acad. Sci. USA* 93: 5395-5400).

Depending on the format, the specific nucleic acid of interest is identified in the
25 sample directly using amplification or with a second, known nucleic acid following amplification. Next, the identified product is detected. In certain applications, the detection may be performed by visual means (*e.g.*, ethidium bromide staining of a gel). Alternatively, the detection may involve indirect identification of the product via chemiluminescence, radioactive scintigraphy of radiolabel or fluorescent label or even via
30 a system using electrical or thermal impulse signals (Affymax Technology; Bellus, 1994, *J Macromol. Sci. Pure, Appl. Chem.*, A31(1): 1355-1376).

Following detection, one may compare the results seen in a given patient with a control reaction or a statistically significant reference group of normal patients. In this

- 22 -

way, it is possible to correlate the amount of an IGFBP detected with the progression or severity of the disease.

In addition to determining levels of *IGFBP* transcripts, it also may prove useful to examine various types of defects. These defect could include deletions, insertions, point mutations and duplications. Point mutations result in stop codons, frameshift mutations or amino acid substitutions. Somatic mutations are those occurring in non-germline tissues. Germ-line tissue can occur in any tissue and are inherited. Mutations in and outside the coding region also may affect the amount of IGFBP produced, both by altering the transcription of the gene or in destabilising or otherwise altering the processing of either the transcript (mRNA) or protein.

A variety of different assays are contemplated in this regard, including but not limited to, fluorescent *in situ* hybridisation (FISH), direct DNA sequencing, pulse field gel electrophoresis (PFGE) analysis, Southern or Northern blotting, single-stranded conformation analysis (SSCA), RNase protection assay, allele-specific oligonucleotide (ASO), dot blot analysis, denaturing gradient gel electrophoresis, RFLP and PCR-SSCP.

2.1.1 Primers and Probes

Primers may be provided in double-stranded or single-stranded form, although the single-stranded form is preferred. Probes, while perhaps capable of priming, are designed to bind to a target DNA or RNA and need not be used in an amplification process. In preferred embodiments, the probes or primers are labelled with radioactive species ^{32}P , ^{14}C , ^{35}S , ^3H , or other label), with a fluorophore (rhodamine, fluorescein) or a chemiluminescent label (luciferase).

2.1.2 Template Dependent Amplification Methods

A number of template dependent processes are available to amplify the target sequences present in a given template sample. An exemplary nucleic acid amplification technique is the polymerase chain reaction (referred to as PCR) which is described in detail in U.S. Pat. Nos. 4,683,195, 4,683,202 and 4,800,159, Ausubel *et al.* (*supra*), and in Innis *et al.*, ("PCR Protocols", Academic Press, Inc., San Diego Calif., 1990).

Briefly, in PCR, two primer sequences are prepared that are complementary to regions on opposite complementary strands of the target sequence. An excess of deoxynucleoside triphosphates are added to a reaction mixture along with a DNA polymerase, *e.g.*, Taq polymerase. If the target sequence is present in a sample, the primers

- 23 -

will bind to the target and the polymerase will cause the primers to be extended along the target sequence by adding on nucleotides. By raising and lowering the temperature of the reaction mixture, the extended primers will dissociate from the target to form reaction products, excess primers will bind to the target and to the reaction products and the process is repeated.

A reverse transcriptase PCR amplification procedure may be performed in order to quantify the amount of mRNA amplified. Methods of reverse transcribing RNA into cDNA are well known and described in Sambrook *et al.*, 1989. Alternative methods for reverse transcription utilise thermostable, RNA-dependent DNA polymerases. These methods are described in WO 90/07641. Polymerase chain reaction methodologies are well known in the art.

Another method for amplification is the ligase chain reaction ("LCR"), disclosed in EPO No. 320 308. In LCR, two complementary probe pairs are prepared, and in the presence of the target sequence, each pair will bind to opposite complementary strands of the target such that they abut. In the presence of a ligase, the two probe pairs will link to form a single unit. By temperature cycling, as in PCR, bound ligated units dissociate from the target and then serve as "target sequences" for ligation of excess probe pairs. U.S. Pat. No. 4,883,750 describes a method similar to LCR for binding probe pairs to a target sequence.

Q β Replicase, described in PCT Application No. PCT/US87/00880, may also be used as still another amplification method in the present invention. In this method, a replicative sequence of RNA that has a region complementary to that of a target is added to a sample in the presence of an RNA polymerase. The polymerase will copy the replicative sequence that can then be detected.

An isothermal amplification method, in which restriction endonucleases and ligases are used to achieve the amplification of target molecules that contain nucleotide 5'- α -thio-triphosphates in one strand of a restriction site may also be useful in the amplification of nucleic acids in the present invention, Walker *et al.*, (1992, Proc. Natl. Acad. Sci. U.S.A 89: 392-396).

Strand Displacement Amplification (SDA) is another method of carrying out isothermal amplification of nucleic acids which involves multiple rounds of strand displacement and synthesis, i.e., nick translation. A similar method, called Repair Chain Reaction (RCR), involves annealing several probes throughout a region targeted for

- 24 -

amplification, followed by a repair reaction in which only two of the four bases are present. The other two bases can be added as biotinylated derivatives for easy detection. A similar approach is used in SDA. Target specific sequences can also be detected using a cyclic probe reaction (CPR). In CPR, a probe having 3' and 5' sequences of non-specific DNA and a middle sequence of specific RNA is hybridised to DNA that is present in a sample. Upon hybridisation, the reaction is treated with RNase H, and the products of the probe identified as distinctive products that are released after digestion. The original template is annealed to another cycling probe and the reaction is repeated.

Still another amplification method, described in GB Application No. 2 202 328, and in PCT Application No. PCT/US89/01025, may be used in accordance with the present invention. In the former application, "modified" primers are used in a PCR-like, template- and enzyme-dependent synthesis. The primers may be modified by labelling with a capture moiety (*e.g.*, biotin) and/or a detector moiety (*e.g.*, enzyme). In the latter application, an excess of labelled probes are added to a sample. In the presence of the target sequence, the probe binds and is cleaved catalytically. After cleavage, the target sequence is released intact to be bound by excess probe. Cleavage of the labelled probe signals the presence of the target sequence.

Other nucleic acid amplification procedures include transcription-based amplification systems (TAS), including nucleic acid sequence based amplification (NASBA) and 3SR (Kwoh *et al.*, 1989, *Proc. Natl. Acad. Sci. U.S.A.*, **86**: 1173; Gingeras *et al.*, PCT Application WO 88/10315). In NASBA, the nucleic acids can be prepared for amplification by standard phenol/chloroform extraction, heat denaturation of a clinical sample, treatment with lysis buffer and minispin columns for isolation of DNA and RNA or guanidinium chloride extraction of RNA. These amplification techniques involve annealing a primer which has target specific sequences. Following polymerisation, DNA/RNA hybrids are digested with RNase H while double stranded DNA molecules are heat denatured again. In either case the single stranded DNA is made fully double stranded by addition of second target specific primer, followed by polymerisation. The double-stranded DNA molecules are then multiply transcribed by an RNA polymerase such as T7 or SP6. In an isothermal cyclic reaction, the RNAs are reverse transcribed into single stranded DNA, which is then converted to double stranded DNA, and then transcribed once again with an RNA polymerase such as T7 or SP6. The resulting products, whether truncated or complete, indicate target specific sequences.

- 25 -

Davey *et al.*, EPO No. 329 822 disclose a nucleic acid amplification process involving cyclically synthesising single-stranded RNA ("ssRNA"), ssDNA, and double-stranded DNA (dsDNA), which may be used in accordance with the present invention. The ssRNA is a template for a first primer oligonucleotide, which is elongated by reverse transcriptase (RNA-dependent DNA polymerase). The RNA is then removed from the resulting DNA:RNA duplex by the action of ribonuclease H (RNase H, an RNase specific for RNA in duplex with either DNA or RNA). The resultant ssDNA is a template for a second primer, which also includes the sequences of an RNA polymerase promoter (exemplified by T7 RNA polymerase) 5' to its homology to the template. This primer is then extended by DNA polymerase (exemplified by the large "Klenow" fragment of *E. coli* DNA polymerase I), resulting in a double-stranded DNA ("dsDNA") molecule, having a sequence identical to that of the original RNA between the primers and having additionally, at one end, a promoter sequence. This promoter sequence can be used by the appropriate RNA polymerase to make many RNA copies of the DNA. These copies can then re-enter the cycle leading to very swift amplification. With proper choice of enzymes, this amplification can be done isothermally without addition of enzymes at each cycle. Because of the cyclical nature of this process, the starting sequence can be chosen to be in the form of either DNA or RNA.

Miller *et al.* in PCT Application WO 89/06700 disclose a nucleic acid sequence amplification scheme based on the hybridisation of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. This scheme is not cyclic, *i.e.*, new templates are not produced from the resultant RNA transcripts. Other amplification methods include "RACE" and "one-sided PCR" (Frohman, M. A., In: "PCR Protocols: A Guide to Methods and Applications", Academic Press, N.Y., 1990; Ohara *et al.*, 1989, *Proc. Natl Acad. Sci. U.S.A.*, **86**: 5673-567).

Methods based on ligation of two (or more) oligonucleotides in the presence of nucleic acid having the sequence of the resulting "di-oligonucleotide", thereby amplifying the di-oligonucleotide, may also be used in the amplification step of the present invention. Wu *et al.*, (1989, *Genomics* **4**: 560).

2.1.3 Southern/Northern Blotting

Blotting techniques are well known to those of skill in the art. Southern blotting involves the use of DNA as a target, whereas Northern blotting involves the use of RNA as

- 26 -

a target. Each provide different types of information, although cDNA blotting is analogous, in many aspects, to blotting or RNA species.

Briefly, a probe is used to target a DNA or RNA species that has been immobilized on a suitable matrix, often a filter of nitrocellulose. The different species
5 should be spatially separated to facilitate analysis. This often is accomplished by gel electrophoresis of nucleic acid species followed by "blotting" on to the filter.

Subsequently, the blotted target is incubated with a probe (usually labelled) under conditions that promote denaturation and rehybridization. Because the probe is designed to base pair with the target, the probe will binding a portion of the target sequence under
10 renaturing conditions. Unbound probe is then removed, and detection is accomplished as described above.

2.1.4 Detection Methods

Products may be visualised in order to confirm amplification of the target sequences. One typical visualisation method involves staining of a gel with ethidium
15 bromide and visualisation under UV light. Alternatively, if the amplification products are integrally labelled with radio- or fluorometrically-labelled nucleotides, the amplification products can then be exposed to x-ray film or visualised under the appropriate stimulating spectra, following separation.

In one embodiment, visualisation is achieved indirectly. Following separation of
20 amplification products, a labelled nucleic acid probe is brought into contact with the amplified target sequence. The probe preferably is conjugated to a chromophore but may be radiolabelled. In another embodiment, the probe is conjugated to a binding partner, such as an antibody or biotin, and the other member of the binding pair carries a detectable moiety or reporter molecule.

In one embodiment, detection is by a labelled probe. The techniques involved are
25 well known to those of skill in the art and can be found in many standard texts on molecular protocols. See Sambrook *et al.*, 1989. For example, chromophore or radiolabel probes or primers identify the target during or following amplification.

One example of the foregoing is described in U.S. Pat. No. 5,279,721, which
30 discloses an apparatus and method for the automated electrophoresis and transfer of nucleic acids. The apparatus permits electrophoresis and blotting without external

- 27 -

manipulation of the gel and is ideally suited to carrying out methods according to the present invention.

In addition, the amplification products described above may be subjected to sequence analysis to identify specific kinds of variations using standard sequence analysis techniques. Within certain methods, exhaustive analysis of genes is carried out by sequence analysis using primer sets designed for optimal sequencing (Pignon *et al.*, 1994, *Hum. Mutat.* **3**: 126-132). The present invention provides methods by which any or all of these types of analyses may be used. Using, for example, the sequences set forth herein, oligonucleotide primers may be designed to permit the amplification of sequences throughout *IGFBP-1*, *-2*, and *-3* genes that may then be analysed by direct sequencing.

2.1.5 Kit Components

All the essential materials and reagents required for detecting and sequencing *IGFBP* genes and variants thereof may be assembled together in a kit. The kits may also optionally include appropriate reagents for detection of labels, positive and negative controls, washing solutions, dilution buffers and the like. For example, a nucleic acid-based detection kit may include (i) a polynucleotide according to the invention (which may be used as a positive control), (ii) an oligonucleotide primer according to the invention. Also included may be enzymes suitable for amplifying nucleic acids including various polymerases (Reverse Transcriptase, Taq, Sequenase™ DNA ligase etc. depending on the nucleic acid amplification technique employed), deoxynucleotides and buffers to provide the necessary reaction mixture for amplification. Such kits also generally will comprise, in suitable means, distinct containers for each individual reagent and enzyme as well as for each primer or probe. The kit may also contain instructions for performing the method of the invention.

2.1.6 Chip Technologies

Also contemplated by the present invention are chip-based DNA technologies such as those described by Hacia *et al.* (1996, *Nature Genetics* **14**: 441-447) and Shoemaker *et al.* (1996, *Nature Genetics* **14**: 450-456). Briefly, these techniques involve quantitative methods for analysing large numbers of genes rapidly and accurately. By tagging genes with oligonucleotides or using fixed probe arrays, one can employ chip technology to segregate target molecules as high density arrays and screen these molecules

- 28 -

on the basis of hybridisation. See also Pease *et al.* (1994, *Proc. Natl. Acad. Sci. U.S.A.* **91**: 5022-5026); Fodor *et al.* (1991, *Science* **251**: 767-773).

2.2 Protein-based diagnostics

2.2.1 Antigen-binding molecules

5 Antigen-binding molecules that are immuno-interactive with a target molecule of the present invention can be used in measuring an increase or decrease in *IGFBP* expression. Thus, the present invention also contemplates antigen-binding molecules that bind specifically to IGFBP-1, IGFBP-2 or IGFBP-3 polypeptides or to proteins that regulate or otherwise influence the level and/or functional activity of one or more of the
10 aforesaid IGFBP polypeptides. For example, the antigen-binding molecules may comprise whole polyclonal antibodies. Such antibodies may be prepared, for example, by injecting a target molecule of the invention into a production species, which may include mice or rabbits, to obtain polyclonal antisera. Methods of producing polyclonal antibodies are well known to those skilled in the art. Exemplary protocols which may be used are described for
15 example in Coligan *et al.*, "Current Protocols In Immunology", (John Wiley & Sons, Inc, 1991), and Ausubel *et al.*, (1994-1998, *supra*), in particular Section III of Chapter 11.

 In lieu of the polyclonal antisera obtained in the production species, monoclonal antibodies may be produced using the standard method as described, for example, by Köhler and Milstein (1975, *Nature* **256**, 495-497), or by more recent modifications thereof
20 as described, for example, in Coligan *et al.*, (1991, *supra*) by immortalising spleen or other antibody-producing cells derived from a production species which has been inoculated with target molecule of the invention. A number of human and other mammalian antibodies to IGFBP-1, -2 and -3 are known, and are available either commercially or through techniques well known to the art and industry.

25 The invention also contemplates as antigen-binding molecules Fv, Fab, Fab' and F(ab')₂ immunoglobulin fragments. Alternatively, the antigen-binding molecule may comprise a synthetic stabilised Fv fragment. Exemplary fragments of this type include single chain Fv fragments (sFv, frequently termed scFv) in which a peptide linker is used to bridge the N terminus or C terminus of a V_H domain with the C terminus or N-terminus,
30 respectively, of a V_L domain. ScFv lack all constant parts of whole antibodies and are not able to activate complement. Suitable peptide linkers for joining the V_H and V_L domains are those which allow the V_H and V_L domains to fold into a single polypeptide chain

- 29 -

having an antigen binding site with a three dimensional structure similar to that of the antigen binding site of a whole antibody from which the Fv fragment is derived. Linkers having the desired properties may be obtained by the method disclosed in U.S. Patent No 4,946,778. However, in some cases a linker is absent. ScFvs may be prepared, for example, in accordance with methods outlined in Kreber *et al* (Kreber *et al.* 1997, *J. Immunol. Methods*; **201**(1): 35-55). Alternatively, they may be prepared by methods described in U.S. Patent No 5,091,513, European Patent No 239,400 or the articles by Winter and Milstein (1991, *Nature* **349**:293) and Plünckthun *et al* (1996, In *Antibody engineering: A practical approach*. 203-252).

Alternatively, the synthetic stabilised Fv fragment comprises a disulphide stabilised Fv (dsFv) in which cysteine residues are introduced into the V_H and V_L domains such that in the fully folded Fv molecule the two residues will form a disulphide bond therebetween. Suitable methods of producing dsFv are described for example in (Glockscuther *et al.* *Biochem.* **29**: 1363-1367; Reiter *et al.* 1994, *J. Biol. Chem.* **269**: 18327-18331; Reiter *et al.* 1994, *Biochem.* **33**: 5451-5459; Reiter *et al.* 1994, *Cancer Res.* **54**: 2714-2718; Webber *et al.* 1995, *Mol. Immunol.* **32**: 249-258).

Also contemplated as antigen-binding molecules are single variable region domains (termed dAbs) as for example disclosed in (Ward *et al.* 1989, *Nature* **341**: 544-546; Hamers-Casterman *et al.* 1993, *Nature.* **363**: 446-448; Davies & Riechmann, 1994, *FEBS Lett.* **339**: 285-290).

Alternatively, the antigen-binding molecule may comprise a "minibody". In this regard, minibodies are small versions of whole antibodies, which encode in a single chain the essential elements of a whole antibody. Suitably, the minibody is comprised of the V_H and V_L domains of a native antibody fused to the hinge region and CH3 domain of the immunoglobulin molecule as, for example, disclosed in U.S. Patent No 5,837,821.

In an alternate embodiment, the antigen binding molecule may comprise non-immunoglobulin derived, protein frameworks. For example, reference may be made to (Ku & Schultz, 1995, *Proc. Natl. Acad. Sci. USA*, **92**: 652-6556) which discloses a four-helix bundle protein cytochrome b562 having two loops randomised to create complementarity determining regions (CDRs), which have been selected for antigen binding.

The antigen-binding molecule may be multivalent (*ie.* having more than one antigen-binding site). Such multivalent molecules may be specific for one or more antigens. Multivalent molecules of this type may be prepared by dimerisation of two

- 30 -

antibody fragments through a cysteinyl-containing peptide as, for example disclosed by (Adams *et al.*, 1993, *Cancer Res.* **53**: 4026-4034; Cumber *et al.*, 1992, *J. Immunol.* **149**: 120-126). Alternatively, dimerisation may be facilitated by fusion of the antibody fragments to amphiphilic helices that naturally dimerise (Pack P. Plünckthun, 1992, *Biochem.* **31**: 1579-1584), or by use of domains (such as the leucine zippers jun and fos) that preferentially heterodimerise (Kostelny *et al.*, 1992, *J. Immunol.* **148**: 1547-1553). In an alternate embodiment, the multivalent molecule may comprise a multivalent single chain antibody (multi-scFv) comprising at least two scFvs linked together by a peptide linker. In this regard, non-covalently or covalently linked scFv dimers termed “diabodies” may be used. Multi-scFvs may be bispecific or greater depending on the number of scFvs employed having different antigen binding specificities. Multi-scFvs may be prepared for example by methods disclosed in U.S. Patent No. 5,892,020.

The antigen-binding molecules of the invention may be used for affinity chromatography in isolating a natural or recombinant polypeptide or biologically active fragment of the invention. For example reference may be made to immunoaffinity chromatographic procedures described in Chapter 9.5 of Coligan *et al.*, (1995-1997, *supra*).

2.2.2 Immunodiagnostic assays

The above antigen-binding molecules have utility in measuring directly or indirectly modulation of *IGFBP* expression in healthy and diseased states, through techniques such as ELISAs and Western blotting. Illustrative assay strategies which can be used to detect a target polypeptide of the invention include, but are not limited to, immunoassays involving the binding of an antigen-binding molecule to the target polypeptide (*e.g.*, an *IGFBP* polypeptide) in the sample, and the detection of a complex comprising the antigen-binding molecule and the target polypeptide. Preferred immunoassays are those that can measure the level and/or functional activity of a target molecule of the invention. Typically, an antigen-binding molecule that is immuno-interactive with a target polypeptide of the invention is contacted with a biological sample suspected of containing said target polypeptide. The concentration of a complex comprising the antigen-binding molecule and the target polypeptide is measure in and the measured complex concentration is then related to the concentration of target polypeptide in the sample. Consistent with the present invention, the presence of an aberrant

- 31 -

concentration of the target polypeptide is indicative of the presence or risk of a liver cancer.

Any suitable technique for determining formation of an antigen-binding molecule-target antigen complex may be used. For example, an antigen-binding molecule according to the invention, having a reporter molecule associated therewith may be utilised in immunoassays. Such immunoassays include, but are not limited to, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs) and immunochromatographic techniques (ICTs), Western blotting which are well known those of skill in the art. For example, reference may be made to Coligan *et al.* (1994, *supra*) which discloses a variety of immunoassays that may be used in accordance with the present invention. Immunoassays may include competitive assays as understood in the art or as for example described *infra*. It will be understood that the present invention encompasses qualitative and quantitative immunoassays.

Suitable immunoassay techniques are described for example in US Patent Nos. 4,016,043, 4, 424,279 and 4,018,653. These include both single-site and two-site assays of the non-competitive types, as well as the traditional competitive binding assays. These assays also include direct binding of a labelled antigen-binding molecule to a target antigen.

Two site assays are particularly favoured for use in the present invention. A number of variations of these assays exist, all of which are intended to be encompassed by the present invention. Briefly, in a typical forward assay, an unlabelled antigen-binding molecule such as an unlabelled antibody is immobilised on a solid substrate and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-antigen complex, another antigen-binding molecule, suitably a second antibody specific to the antigen, labelled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of antibody-antigen-labelled antibody. Any unreacted material is washed away and the presence of the antigen is determined by observation of a signal produced by the reporter molecule. The results may be either qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of antigen. Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody. These

- 32 -

techniques are well known to those skilled in the art, including minor variations as will be readily apparent. In accordance with the present invention, the sample is one that might contain an antigen including a tissue or fluid as described above.

In the typical forward assay, a first antibody having specificity for the antigen or antigenic parts thereof is either covalently or passively bound to a solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs of microplates, or any other surface suitable for conducting an immunoassay. The binding processes are well known in the art and generally consist of cross-linking covalently binding or physically adsorbing, the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient and under suitable conditions to allow binding of any antigen present to the antibody. Following the incubation period, the antigen-antibody complex is washed and dried and incubated with a second antibody specific for a portion of the antigen. The second antibody has generally a reporter molecule associated therewith that is used to indicate the binding of the second antibody to the antigen. The amount of labelled antibody that binds, as determined by the associated reporter molecule, is proportional to the amount of antigen bound to the immobilised first antibody.

An alternative method involves immobilising the antigen in the biological sample and then exposing the immobilised antigen to specific antibody that may or may not be labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound antigen may be detectable by direct labelling with the antibody. Alternatively, a second labelled antibody, specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule.

The association of the reporter molecule with the antigen-binding molecule may include the following: (a) direct attachment of the reporter molecule to the antigen-binding molecule; (b) indirect attachment of the reporter molecule to the antigen-binding molecule; *i.e.*, attachment of the reporter molecule to another assay reagent which subsequently binds to the antigen-binding molecule; and (c) attachment to a subsequent reaction product of the antigen-binding molecule.

- 33 -

The reporter molecule may be selected from a group including a chromogen, a catalyst, an enzyme, a fluorochrome, a chemiluminescent molecule, a lanthanide ion such as Europium (Eu^{34}), a radioisotope and a direct visual label.

In the case of a direct visual label, use may be made of a colloidal metallic or non-metallic particle, a dye particle, an enzyme or a substrate, an organic polymer, a latex particle, a liposome, or other vesicle containing a signal producing substance and the like.

A large number of enzymes suitable for use as reporter molecules is disclosed in United States Patent Specifications U.S. 4,366,241, U.S. 4,843,000, and U.S. 4,849,338. Suitable enzymes useful in the present invention include alkaline phosphatase, horseradish peroxidase, luciferase, β -galactosidase, glucose oxidase, lysozyme, malate dehydrogenase and the like. The enzymes may be used alone or in combination with a second enzyme that is in solution.

Suitable fluorochromes include, but are not limited to, fluorescein isothiocyanate (FITC), tetramethylrhodamine isothiocyanate (TRITC), R-Phycoerythrin (RPE), and Texas Red. Other exemplary fluorochromes include those discussed by Dower *et al.* (International Publication WO 93/06121). Reference also may be made to the fluorochromes described in U.S. Patents 5,573,909 (Singer *et al.*), 5,326,692 (Brinkley *et al.*). Alternatively, reference may be made to the fluorochromes described in U.S. Patent Nos. 5,227,487, 5,274,113, 5,405,975, 5,433,896, 5,442,045, 5,451,663, 5,453,517, 5,459,276, 5,516,864, 5,648,270 and 5,723,218.

In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodates. As will be readily recognised, however, a wide variety of different conjugation techniques exist which are readily available to the skilled artisan. The substrates to be used with the specific enzymes are generally chosen for the production of, upon hydrolysis by the corresponding enzyme, a detectable colour change. Examples of suitable enzymes include those described *supra*. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the enzyme-labelled antibody is added to the first antibody-antigen complex. It is then allowed to bind, and excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen-antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated,

- 34 -

usually spectrophotometrically, to give an indication of the amount of antigen which was present in the sample.

Alternately, fluorescent compounds, such as fluorescein, rhodamine and the lanthanide, europium (EU), may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope. The fluorescent-labelled antibody is allowed to bind to the first antibody-antigen complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to light of an appropriate wavelength. The fluorescence observed indicates the presence of the antigen of interest. Immunofluorometric assays (IFMA) are well established in the art. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules may also be employed.

It will be well understood that other means of testing target polypeptide (e.g., IGFBP) levels are available, including, for instance, those involving testing for an altered level of IGFBP binding activity to an insulin-like growth factor (IGF), or Western blot analysis of IGFBP protein levels in tissues, cells or fluids using anti-IGFBP antigen-binding molecule, or assaying the amount of antigen-binding molecule or other IGFBP binding partner which is not bound to a sample, and subtracting from the total amount of antigen-binding molecule or binding partner added.

3. Identification of target molecule modulators

The invention also provides agents that modulate the level and/or functional activity of an expression product of a gene selected from an *IGFBP* gene or a gene relating to the same regulatory or biosynthetic pathway as an *IGFBP* gene. The method includes contacting a preparation comprising target molecules selected from (1) all or part of an expression product of an *IGFBP* gene or a gene relating to the same regulatory or biosynthetic pathway as the *IGFBP* gene, or a variant or derivative of that expression product, or (2) a genetic sequence which regulates expression of the expression product mentioned in (1) and which is operably connected to a marker gene, with a test agent and detecting a change in the level and/or functional activity of all or part of that expression product or variant or derivative thereof or a change in the level of expression of the marker gene or a change in the phenotype of a cell.

- 35 -

In accordance with the present invention, agents that test positive for such interaction are useful for treating and/or modulating tumorigenesis and especially for treating or preventing a liver cancer. Assays of a suitable nature for detecting, measuring or otherwise determining modulation of tumorigenesis (*e.g.*, such as by detecting cell proliferation) are known to persons of skill in the art. For example, tumorigenesis-modulating agents could be tested for their ability to modulate cell proliferation. Typically, for cell proliferation, cell number is determined, directly, by microscopic or electronic enumeration, or indirectly, by the use of chromogenic dyes, incorporation of radioactive precursors or measurement of metabolic activity of cellular enzymes. An exemplary cell proliferation assay comprises culturing cells in the presence or absence of a test compound, and detecting cell proliferation by, for example, measuring incorporation of tritiated thymidine or by colorimetric assay based on the metabolic breakdown of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Mosman, 1983, *J. Immunol. Meth.* **65**: 55-63). Cancer or tumour markers are known for a variety of cell or tissue types. Cells or tissues expressing cancer or tumour markers may be detected using monoclonal antibodies, polyclonal antisera or other antigen-binding molecules that are immuno-interactive with these tumour markers or by using nucleic acid analysis techniques, including, for example, detecting the level or presence of tumour marker-encoding polynucleotides.

Modulators contemplated by the present invention includes agonists and antagonists of *IGFBP* gene expression include antisense molecules, ribozymes and co-suppression molecules. Agonists include molecules which increase promoter activity or interfere with negative mechanisms. Agonists of *IGFBP* include molecules which overcome any negative regulatory mechanism. Antagonists of *IGFBP* polypeptides include antibodies and inhibitor peptide fragments.

Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 Dalton. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among

- 36 -

biomolecules including, but not limited to: peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogues or combinations thereof.

Small (non-peptide) molecule modulators of IGFBP-1, -2 and -3 are particularly preferred. In this regard, small molecules are particularly preferred because such molecules are more readily absorbed after oral administration, have fewer potential antigenic determinants, and/or are more likely to cross the cell membrane than larger, protein-based pharmaceuticals. Small organic molecules may also have the ability to gain entry into an appropriate cell and affect the expression of a gene (*e.g.*, by interacting with the regulatory region or transcription factors involved in gene expression); or affect the activity of a gene by inhibiting or enhancing the binding of accessory molecules.

Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogues.

Screening may also be directed to known pharmacologically active compounds and chemical analogues thereof.

Screening for modulatory agents according to the invention can be achieved by any suitable method. For example, the method may include contacting a cell comprising a polynucleotide corresponding to an *IGFBP* gene or a gene belonging to the same regulatory or biosynthetic pathway as an *IGFBP* gene, with an agent suspected of having said modulatory activity and screening for the modulation of the level and/or functional activity of a protein encoded by said polynucleotide, or the modulation of the level of a transcript encoded by the polynucleotide, or the modulation of the activity or expression of a downstream cellular target of said protein or said transcript. Detecting such modulation can be achieved utilising techniques including, but not restricted to, ELISA, cell-based ELISA, filter-binding ELISA, inhibition ELISA, Western blots, immunoprecipitation, slot or dot blot assays, immunostaining, RIA, scintillation proximity assays, fluorescent immunoassays using antigen-binding molecule conjugates or antigen conjugates of fluorescent substances such as fluorescein or rhodamine, Ouchterlony double diffusion analysis, immunoassays employing an avidin-biotin or a streptavidin-biotin detection

- 37 -

system, and nucleic acid detection assays including reverse transcriptase polymerase chain reaction (RT-PCR).

It will be understood that a polynucleotide from which a target molecule of interest is regulated or expressed may be naturally occurring in the cell which is the subject of testing or it may have been introduced into the host cell for the purpose of testing. Further, the naturally-occurring or introduced polynucleotide may be constitutively expressed – thereby providing a model useful in screening for agents which downregulate expression of an encoded product of the sequence wherein said downregulation can be at the nucleic acid or protein level – or may require activation – thereby providing a model useful in screening for agents that upregulate expression of an encoded product of the sequence. Further, to the extent that a polynucleotide is introduced into a cell, that polynucleotide may comprise the entire coding sequence which codes for a target protein or it may comprise a portion of that coding sequence (*e.g.* a domain such as an IGF-binding domain) or a portion that regulates expression of a product encoded by the polynucleotide (*e.g.*, a promoter). For example, the promoter that is naturally associated with the polynucleotide may be introduced into the cell that is the subject of testing. In this regard, where only the promoter is utilised, detecting modulation of the promoter activity can be achieved, for example, by operably linking the promoter to a polynucleotide encoding a suitable marker including, but not restricted to, green fluorescent protein (GFP), luciferase, β -galactosidase and catecholamine acetyl transferase (CAT). Modulation of expression may be determined by measuring the activity associated with the marker-encoding polynucleotide.

In another example, the subject of detection could be a downstream regulatory target of the target molecule, rather than target molecule itself or a marker-encoding polynucleotide operably linked to a promoter of a gene encoding a product the expression of which is regulated by the target protein.

These methods provide a mechanism for performing high throughput screening of putative modulatory agents such as proteinaceous or non-proteinaceous agents comprising synthetic, combinatorial, chemical and natural libraries. These methods will also facilitate the detection of agents which bind either the polynucleotide encoding the target molecule or which modulate the expression of an upstream molecule, which subsequently modulates the expression of the polynucleotide encoding the target molecule. Accordingly, these

- 38 -

methods provide a mechanism of detecting agents that either directly or indirectly modulate the expression and/or activity of a target molecule according to the invention.

In a series of preferred embodiments, the present invention provides assays for identifying small molecules or other compounds (*i.e.*, modulatory agents) which are capable of inducing or inhibiting the level and/or functional activity of target molecules according to the invention. The assays may be performed *in vitro* using non-transformed cells, immortalised cell lines, or recombinant cell lines. In addition, the assays may detect the presence of increased or decreased expression of genes or production of proteins on the basis of increased or decreased mRNA expression (using, for example, nucleic acid probes corresponding or complementary to a transcript of an *IGFBP* gene or of a gene relating to the same regulatory or biosynthetic pathway as the *IGFBP* gene), increased or decreased levels of protein products (using, for example, antigen binding molecules that are immuno-interactive with a polypeptide encoded by the aforementioned genes), or increased or decreased levels of expression of a marker gene (*e.g.*, GFP, β -galactosidase or luciferase) operatively linked to a target molecule-related gene regulatory region in a recombinant construct.

Thus, for example, one may culture cells which produce a particular target molecule and add to the culture medium one or more test compounds. After allowing a sufficient period of time (*e.g.*, 6-72 hours) for the compound to induce or inhibit the level and/or functional activity of the target molecule, any change in said level from an established baseline may be detected using any of the techniques described above and well known in the art. In particularly preferred embodiments, the cells are epithelial cells. Using suitable nucleic acid probes and/or antigen-binding molecules as for example described above, detection of changes in the level and or functional activity of a target molecule, and thus identification of the compound as agonist or antagonist of the target molecule, requires only routine experimentation.

In particularly preferred embodiments, a recombinant assay is employed in which a marker gene encoding, for example, GFP, β -galactosidase or luciferase is operably linked to the 5' regulatory regions of a target molecule related gene. Such regulatory regions may be easily isolated and cloned by one of ordinary skill in the art in light of the present disclosure. The marker gene and regulatory regions are joined in-frame (or in each of the three possible reading frames) so that transcription and translation of the marker gene may proceed under the control of the regulatory elements of the target molecule related gene.

- 39 -

The recombinant construct may then be introduced into any appropriate cell type although mammalian cells are preferred, and human cells are most preferred. The transformed cells may be grown in culture and, after establishing the baseline level of expression of the marker gene, test compounds may be added to the medium. The ease of detection of the expression of the marker gene provides for a rapid, high throughput assay for the identification of agonists or antagonists of the target molecules of the invention.

Compounds identified by this method will have potential utility in modifying the expression of target molecule related genes *in vivo*. These compounds may be further tested in the animal models to identify those compounds having the most potent *in vivo* effects. In addition, as described above with respect to small molecules having target polypeptide binding activity, these molecules may serve as "lead compounds" for the further development of pharmaceuticals by, for example, subjecting the compounds to sequential modifications, molecular modelling, and other routine procedures employed in rational drug design.

In another embodiment, a method of identifying agents that inhibit IGFBP activity is provided in which a purified preparation of an IGFBP protein in the presence and absence of a candidate agent under conditions in which the IGFBP is active, and the level of IGFBP activity is measured by a suitable assay. For example, an IGFBP inhibitor can be identified by measuring the ability of a candidate agent to decrease IGFBP activity in a cell (*e.g.*, a liver cell). In this method, a cell that is capable of expressing an *IGFBP* is exposed to, or cultured in the presence and absence of, the candidate agent under conditions in which the IGFBP is active in the cell, and an activity such as tumorigenesis is detected. An agent tests positive if it inhibits any of these activities.

In yet another embodiment, random peptide libraries consisting of all possible combinations of amino acids attached to a solid phase support may be used to identify peptides that are able to bind to a target molecule or to a functional domain thereof. Identification of molecules that are able to bind to a target molecule may be accomplished by screening a peptide library with a recombinant soluble target molecule. The target molecule may be purified, recombinantly expressed or synthesised by any suitable technique. Such molecules may be conveniently prepared by a person skilled in the art using standard protocols as for example described in Sambrook, *et al.*, (1989, *supra*) in particular Sections 16 and 17; Ausubel *et al.*, (1994-1998, *supra*), in particular Chapters 10 and 16; and Coligan *et al.*, (1995-1997, *supra*), in particular Chapters 1, 5 and 6.

- 40 -

Alternatively, a target polypeptide according to the invention may be synthesised using solution synthesis or solid phase synthesis as described, for example, in Chapter 9 of Atherton and Shephard (*supra*) and in Roberge *et al* (1995, *Science* **269**: 202).

To identify and isolate the peptide/solid phase support that interacts and forms a complex with a target molecule, preferably a target polypeptide, it may be necessary to label or “tag” the target polypeptide. The target polypeptide may be conjugated to any suitable reporter molecule, including enzymes such as alkaline phosphatase and horseradish peroxidase and fluorescent reporter molecules such as fluorescein isothiocyanate (FITC), phycoerythrin (PE) and rhodamine. Conjugation of any given reporter molecule, with target polypeptide, may be performed using techniques that are routine in the art. Alternatively, target polypeptide expression vectors may be engineered to express a chimeric target polypeptide containing an epitope for which a commercially available antigen-binding molecule exists. The epitope specific antigen-binding molecule may be tagged using methods well known in the art including labelling with enzymes, fluorescent dyes or coloured or magnetic beads.

For example, the “tagged” target polypeptide conjugate is incubated with the random peptide library for 30 minutes to one hour at 22° C to allow complex formation between target polypeptide and peptide species within the library. The library is then washed to remove any unbound target polypeptide. If the target polypeptide has been conjugated to alkaline phosphatase or horseradish peroxidase the whole library is poured into a petri dish containing a substrate for either alkaline phosphatase or peroxidase, for example, 5-bromo-4-chloro-3-indoyl phosphate (BCIP) or 3,3',4,4'-diaminobenzidine (DAB), respectively. After incubating for several minutes, the peptide/solid phase-target polypeptide complex changes colour, and can be easily identified and isolated physically under a dissecting microscope with a micromanipulator. If a fluorescently tagged target polypeptide has been used, complexes may be isolated by fluorescent activated sorting. If a chimeric target polypeptide having a heterologous epitope has been used, detection of the peptide/target polypeptide complex may be accomplished by using a labelled epitope specific antigen-binding molecule. Once isolated, the identity of the peptide attached to the solid phase support may be determined by peptide sequencing.

4. Method of modulating IGFBP activity

The invention also extends to a method for modulating liver cell proliferation or tumorigenesis, comprising contacting said cell with an agent for a time and under

- 41 -

conditions sufficient to modulate the level and/or functional activity of an *IGFBP* expression product, especially an IGFBP polypeptide.

In the following embodiments, an agent is suitably used to reduce, repress or otherwise inhibit cell proliferation or tumorigenesis. In one embodiment, the agent increases the level and/or functional activity of IGFBP-3. Any suitable *IGFBP-3* inducers or stabilising/activating agents may be used in this regard and these can be identified or produced by methods for example disclosed in Section 3. In an alternate embodiment, the agent decreases the level and/or functional activity of IGFBP-1 or IGFBP-2. Suitable IGFBP-1 or IGFBP-2 inhibitors may be identified or produced by methods for example disclosed in Section 3. For example, a suitable IGFBP inhibitor may comprise oligoribonucleotide sequences, that include anti-sense RNA and DNA molecules and ribozymes that function to inhibit the translation of IGFBP protein-encoding mRNA.

Anti-sense RNA and DNA molecules act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation. In regard to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site, *e.g.*, between -10 and +10 regions of a gene encoding a polypeptide according to the invention, are preferred. Ribozymes are enzymatic RNA molecules capable of catalysing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridisation of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyse endonucleolytic cleavage of *IGFBP*, especially *IGFBP-1* or *-2* RNA sequences. Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridisation with complementary oligonucleotides, using ribonuclease protection assays.

Both anti-sense RNA and DNA molecules and ribozymes may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesising oligodeoxyribonucleotides well known in the art such as for

- 42 -

example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesise antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

Various modifications to the DNA molecules may be introduced as a means of increasing intracellular stability and half-life. Possible modifications include but are not limited to the addition of flanking sequences of ribo- or deoxy- nucleotides to the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the oligodeoxyribonucleotide backbone.

5. *Methods of preparing an IGFBP polypeptide*

An IGFBP polypeptide or variant thereof may be prepared by any suitable procedure known to those of skill in the art. For example, the polypeptides may be prepared by a procedure including the steps of (a) preparing a recombinant polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising the sequence set forth in any one of SEQ ID NO: 2, 4 or 6, or variant or derivative of these, which nucleotide sequence is operably linked to transcriptional and translational regulatory nucleic acid; (b) introducing the recombinant polynucleotide into a suitable host cell; (c) culturing the host cell to express recombinant polypeptide from said recombinant polynucleotide; and (d) isolating the recombinant polypeptide. Preferred nucleotide sequences include, but are not limited to the sequences set forth in SEQ ID NO: 1, 3 and 5.

The recombinant polynucleotide is preferably in the form of an expression vector that may be a self-replicating extra-chromosomal vector such as a plasmid, or a vector that integrates into a host genome. The transcriptional and translational regulatory nucleic acid will generally be appropriate for the host cell used for expression. Numerous types of appropriate expression vectors and suitable regulatory sequences are known in the art for a variety of host cells. Typically, the transcriptional and translational regulatory nucleic acid may include, but is not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and termination sequences, and enhancer or activator sequences. Constitutive or inducible promoters as known in the art are contemplated by the invention. The promoters may be

- 43 -

either naturally occurring promoters, or hybrid promoters that combine elements of more than one promoter.

In a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

The expression vector may also include a fusion partner (typically provided by the expression vector) so that the recombinant polypeptide of the invention is expressed as a fusion polypeptide with said fusion partner. The main advantage of fusion partners is that they assist identification and/or purification of said fusion polypeptide. In order to express said fusion polypeptide, it is necessary to ligate a polynucleotide according to the invention into the expression vector so that the translational reading frames of the fusion partner and the polynucleotide coincide. Well known examples of fusion partners include, but are not limited to, glutathione-S-transferase (GST), Fc portion of human IgG, maltose binding protein (MBP) and hexahistidine (HIS₆), which are particularly useful for isolation of the fusion polypeptide by affinity chromatography. For the purposes of fusion polypeptide purification by affinity chromatography, relevant matrices for affinity chromatography are glutathione-, amylose-, and nickel- or cobalt-conjugated resins respectively. Many such matrices are available in "kit" form, such as the QIAexpress™ system (Qiagen) useful with (HIS₆) fusion partners and the Pharmacia GST purification system. In a preferred embodiment, the recombinant polynucleotide is expressed in the commercial vector pFLAG as described more fully hereinafter.

Another fusion partner well known in the art is green fluorescent protein (GFP). This fusion partner serves as a fluorescent "tag" which allows the fusion polypeptide of the invention to be identified by fluorescence microscopy or by flow cytometry. The GFP tag is useful when assessing subcellular localisation of the fusion polypeptide of the invention, or for isolating cells which express the fusion polypeptide of the invention. Flow cytometric methods such as fluorescence activated cell sorting (FACS) are particularly useful in this latter application.

Preferably, the fusion partners also have protease cleavage sites, such as for Factor X_a or Thrombin, which allow the relevant protease to partially digest the fusion polypeptide of the invention and thereby liberate the recombinant polypeptide of the invention therefrom. The liberated polypeptide can then be isolated from the fusion partner by subsequent chromatographic separation.

- 44 -

Fusion partners according to the invention also include within their scope "epitope tags", which are usually short peptide sequences for which a specific antibody is available. Well known examples of epitope tags for which specific monoclonal antibodies are readily available include c-Myc, influenza virus, haemagglutinin and FLAG tags.

5 The step of introducing into the host cell the recombinant polynucleotide may be effected by any suitable method including transfection, and transformation, the choice of which will be dependent on the host cell employed. Such methods are well known to those of skill in the art.

10 Recombinant polypeptides of the invention may be produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a polypeptide, biologically active fragment, variant or derivative according to the invention. The conditions appropriate for protein expression will vary with the choice of expression vector and the host cell. This is easily ascertained by one skilled in the art through routine experimentation.

15 Suitable host cells for expression may be prokaryotic or eukaryotic. One preferred host cell for expression of a polypeptide according to the invention is a bacterium. The bacterium used may be *Escherichia coli*. Alternatively, the host cell may be an insect cell such as, for example, *SF9* cells that may be utilised with a baculovirus expression system.

20 The recombinant protein may be conveniently prepared by a person skilled in the art using standard protocols as for example described in Sambrook, *et al.*, 1989, in particular Sections 16 and 17; Ausubel *et al.*, (1994-1998), in particular Chapters 10 and 16; and Coligan *et al.*, (1995-1997), in particular Chapters 1, 5 and 6.

25 Alternatively, the polypeptide, fragments, variants or derivatives of the invention may be synthesised using solution synthesis or solid phase synthesis as described, for example, in Chapter 9 of Atherton and Shephard (*supra*) and in Roberge *et al* (1995).

6. Compositions

30 The modulatory agents described in Sections 3 and 4 (therapeutic agents) can be used as actives for modulating liver cell proliferation or tumorigenesis or for the treatment or prophylaxis of a liver cancer, particularly hepatocellular carcinoma, or related conditions as, for example, described below. These therapeutic agents can be administered to a patient either by themselves, or in pharmaceutical compositions where they are mixed with a suitable pharmaceutically acceptable carrier.

- 45 -

Accordingly, the invention also provides a composition for treatment and/or prophylaxis of a liver cancer or related condition, comprising an IGFB-3 polypeptide and optionally a pharmaceutically acceptable carrier. The invention also provides a composition for treatment and/or prophylaxis of a liver cancer or related condition, comprising an a modulatory agent that modulates the level and/or functional activity of an IGFBP including, but not limited to, IGFBP-1, IGFBP-2 and IGFBP-3, and optionally a pharmaceutically acceptable carrier.

In one embodiment, the composition comprises a modulatory agent that reduces the level and/or functional activity of IGFBP-1 and/or IGFBP-2, together with a pharmaceutically acceptable carrier. In another embodiment, the composition comprises a modulatory agent that enhances the level and/or functional activity of IGFBP-3, together with a pharmaceutically acceptable carrier.

Depending on the specific conditions being treated, therapeutic agents may be formulated and administered systemically or locally. Techniques for formulation and administration may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, Pa., latest edition. Suitable routes may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections. For injection, the therapeutic agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. Intra-muscular and subcutaneous injection is appropriate, for example, for administration of immunogenic compositions, vaccines and DNA vaccines.

The agents can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds of the invention to be formulated in dosage forms such as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. These carriers may be selected from sugars, starches, cellulose and its derivatives, malt, gelatine, talc, calcium sulphate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonic saline, and pyrogen-free water.

- 46 -

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. The dose of agent administered to a patient should be sufficient to effect a beneficial response in the patient over time such as a reduction in the symptoms associated with a liver cancer or related condition. The quantity of the agent(s) to be administered may depend on the subject to be treated inclusive of the age, sex, weight and general health condition thereof. In this regard, precise amounts of the agent(s) for administration will depend on the judgement of the practitioner. In determining the effective amount of the agent to be administered in the treatment or prophylaxis of the liver cancer or related condition, the physician may evaluate tissue levels of an IGFBP polypeptide, and progression of the disorder. In any event, those of skill in the art may readily determine suitable dosages of the therapeutic agents of the invention.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilisers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association one or more therapeutic agents as described above with the carrier which constitutes one or more necessary ingredients. In

- 47 -

general, the pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilising processes.

5 Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterise different combinations of
10 active compound doses.

Pharmaceutical which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticiser, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium
15 stearate and, optionally, stabilisers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilisers may be added.

Dosage forms of the therapeutic agents of the invention may also include injecting or implanting controlled releasing devices designed specifically for this purpose or other
20 forms of implants modified to act additionally in this fashion. Controlled release of an agent of the invention may be effected by coating the same, for example, with hydrophobic polymers including acrylic resins, waxes, higher aliphatic alcohols, polylactic and polyglycolic acids and certain cellulose derivatives such as hydroxypropylmethyl cellulose. In addition, controlled release may be effected by using other polymer matrices, liposomes
25 and/or microspheres.

Therapeutic agents of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulphuric, acetic, lactic, tartaric, malic, succinic, *etc.* Salts tend to be more soluble in aqueous or other protonic
30 solvents that are the corresponding free base forms.

For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes

- 48 -

the IC₅₀ as determined in cell culture (*e.g.*, the concentration of a test agent, which achieves a half-maximal inhibition or enhancement of IGFBP activity). Such information can be used to more accurately determine useful doses in humans.

Toxicity and therapeutic efficacy of such therapeutic agents can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds that exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilised. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See for example Fingl *et al.*, 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p1).

Dosage amount and interval may be adjusted individually to provide plasma levels of the active agent which are sufficient to maintain IGFBP-inhibitory or enhancement effects. Usual patient dosages for systemic administration range from 1-2000 mg/day, commonly from 1-250 mg/day, and typically from 10-150 mg/day. Stated in terms of patient body weight, usual dosages range from 0.02-25 mg/kg/day, commonly from 0.02-3 mg/kg/day, typically from 0.2-1.5 mg/kg/day. Stated in terms of patient body surface areas, usual dosages range from 0.5-1200 mg/m²/day, commonly from 0.5-150 mg/m²/day, typically from 5-100 mg/m²/day.

Alternately, one may administer the compound in a local rather than systemic manner, for example, *via* injection of the compound directly into a tissue, which is preferably a heart muscle tissue or a liver tissue, often in a depot or sustained release formulation. Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with tissue-specific antibody. The liposomes will be targeted to and taken up selectively by the tissue. In cases of local administration or selective uptake, the effective local concentration of the agent may not be related to plasma concentration.

- 49 -

Thus, the present invention also contemplates a method of gene therapy of a mammal. Such a method utilises a gene therapy construct which includes an isolated polynucleotide comprising a nucleotide sequence encoding an IGFBP-3 or a biologically active fragment thereof, wherein said polynucleotide is ligated into a gene therapy vector which provides one or more regulatory sequences that direct expression of said polynucleotide in said mammal.

Typically, gene therapy vectors are derived from viral DNA sequences such as adenovirus, adeno-associated viruses, herpes-simplex viruses and retroviruses. Suitable gene therapy vectors currently available to the skilled person may be found, for example, in Robbins *et al.*, 1998.

If “anti-sense” therapy is contemplated (*e.g.*, IGFBP-1 and/or -2), then one or more selected portions of a *IGFBP-1* and/or *IGFBP-2* nucleic acid may be oriented 3'→5' in the gene therapy vector.

Administration of the gene therapy construct to said mammal, preferably a human, may include delivery *via* direct oral intake, systemic injection, or delivery to selected tissue(s) or cells, or indirectly *via* delivery to cells isolated from the mammal or a compatible donor. An example of the latter approach would be stem-cell therapy, wherein isolated stem cells having potential for growth and differentiation are transfected with the vector comprising an *IGFBP* nucleic acid. The stem-cells are cultured for a period and then transferred to the mammal being treated.

Delivery of said gene therapy construct to cells or tissues of said mammal or said compatible donor may be facilitated by microprojectile bombardment, liposome mediated transfection (*e.g.*, lipofectin or lipofectamine), electroporation, calcium phosphate or DEAE-dextran-mediated transfection, for example. A discussion of suitable delivery methods may be found in Chapter 9 of Ausubel *et al.*, (1994-1998, *supra*). For example, a nucleic acid encoding IGFBP-3 may be introduced into a cell to enhance the ability of that cell to differentiate or to decrease proliferation. Alternatively, this may be achieved by introducing into a cell *IGFBP-1* and/or *IGFBP-2* antisense sequences such as 3'→5' oligonucleotides.

In an alternate embodiment, a polynucleotide encoding a modulatory agent of the invention may be used as a therapeutic or prophylactic composition in the form of a “naked DNA” composition as is known in the art. For example, an expression vector comprising said polynucleotide operably linked to a regulatory polynucleotide (*e.g.* a promoter,

transcriptional terminator, enhancer *etc*) may be introduced into an animal, preferably a mammal, where it causes production of a modulatory agent *in vivo*, preferably in a heart muscle tissue or a liver tissue.

The step of introducing the expression vector into a target cell or tissue will differ
5 depending on the intended use and species, and can involve one or more of non-viral and viral vectors, cationic liposomes, retroviruses, and adenoviruses such as, for example, described in Mulligan, R.C., (1993). Such methods can include, for example:

A. Local application of the expression vector by injection (Wolff *et al.*, 1990), surgical
implantation, instillation or any other means. This method can also be used in
10 combination with local application by injection, surgical implantation, instillation or any other means, of cells responsive to the protein encoded by the expression vector so as to increase the effectiveness of that treatment. This method can also be used in combination with local application by injection, surgical implantation, instillation or any other means, of another factor or factors required for the activity of said protein.

15 B. General systemic delivery by injection of DNA, (Calabretta *et al.*, 1993), or RNA, alone or in combination with liposomes (Zhu *et al.*, 1993), viral capsids or nanoparticles (Bertling *et al.*, 1991) or any other mediator of delivery. Improved targeting might be achieved by linking the polynucleotide/expression vector to a targeting molecule (the so-called "magic bullet" approach employing, for example, an
20 antigen-binding molecule), or by local application by injection, surgical implantation or any other means, of another factor or factors required for the activity of the protein encoded by said expression vector, or of cells responsive to said protein.

C. Injection or implantation or delivery by any means, of cells that have been modified *ex vivo* by transfection (for example, in the presence of calcium phosphate: Chen *et al.*,
25 1987, or of cationic lipids and polyamines: Rose *et al.*, 1991), infection, injection, electroporation (Shigekawa *et al.*, 1988) or any other way so as to increase the expression of said polynucleotide in those cells. The modification can be mediated by plasmid, bacteriophage, cosmid, viral (such as adenoviral or retroviral; Mulligan, 1993; Miller, 1992; Salmons *et al.*, 1993) or other vectors, or other agents of modification
30 such as liposomes (Zhu *et al.*, 1993), viral capsids or nanoparticles (Bertling *et al.*, 1991), or any other mediator of modification. The use of cells as a delivery vehicle for genes or gene products has been described by Barr *et al.*, 1991 and by Dhawan *et al.*,

- 51 -

1991. Treated cells can be delivered in combination with any nutrient, growth factor, matrix or other agent that will promote their survival in the treated subject.

In order that the invention may be readily understood and put into practical effect,
5 particular preferred embodiments will now be described by way of the following non-limiting examples.

EXAMPLES

EXAMPLE 1

Reduction of IGFBP-3 expression in human hepatocellular carcinoma

Methods

5 Collection of human HCC and adjacent non-tumour liver specimens

Tissue samples were obtained intra-operatively from tumours and adjacent non-tumour livers during liver resection for HCC in 28 patients treated at the Singapore General Hospital. The samples were snap frozen in liquid nitrogen and stored at -80° C until analysis. A similar set of samples was fixed in 10% formalin and paraffin embedded.

- 10 The diagnosis of HCC was confirmed histologically in all cases. Prior written informed consent was obtained from all patients and the study received ethics board approval at both institutions.

Immunolocalisation of IGFBP-3

- Formalin- and paraffin-embedded sections were used for IGFBP-3, IGF-II, and
15 IGF-I immunolocalisation. This was performed using rabbit anti-human IGFBP-3 (1:500) (Upstate Biotechnology, Lake Placid, NY), rabbit anti-human IGF-I (3 µg/mL) (Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit anti-human IGF-II (3 µg/mL) (Austral Biologicals, San Ramon, CA) antibodies as described (14). Non-specific staining was evaluated for each specimen using either a similar concentration of IgG or by absorbing the
20 primary with appropriate specific immunogen. The slides were evaluated and intensity of the staining was scored. Specific staining was semi-quantitated by assigning a score of 0 to +++ based on increasing green fluorescence intensity. The results shown in TABLE 1 represent the average score obtained from twice staining.

Cell culture

- 25 Human hepatoma HepG2 cells were obtained from ATCC and maintained as monolayer cultures in Modified Eagle's Media (MEM) (Gibco, Grand Island, NY) supplemented with 10% foetal calf serum (FCS) (Gibco, Grand Island, NY) growth medium. For proliferation study, confluent cultures of HepG2 cells were trypsinised and plated at 2.0×10^4 cells in 24-well plates with growth medium. After 48h, the cell
30 monolayers were rinsed twice with MEM phenol-red serum free (PSF) media and incubated further in PSF medium for 24h. After 24h, various concentrations of human

- 53 -

recombinant IGFBP-3 (hrIGFBP-3) (Celtrix, CA), human recombinant IGF-I (hrIGF-I, GroPep, Adelaide, Australia) or 25 ng/mL hrIGF-I in conjunction with various concentrations of hrIGFBP-3 were added in triplicate in SPF media for 48 h. Cell number was determined as previously described (14).

- 5 To determine the effect of exogenous IGF-II and autocrine IGF-II production on HepG2 cell proliferation, HepG2 cells were plated and grown as described above and the cells subsequently treated with rabbit pre-immune serum (1:800), 25 ng/mL hrIGF-II (GroPep, Adelaide, Australia), rabbit anti-human IGF-II antibody (2 µg/mL) or with combination for 48 h. Cell number was determined as described above.

10 Western Blotting

- To determine changes in the expression of IGFBP-3 and IGF-IR, snap-frozen HCC tumours and normal adjacent liver tissues were thawed and homogenised in lysis buffer (1 mM CaCl₂, 1 mM MgCl₂, 1% NP-40, 1 µg/mL leupeptin, 1 µg/mL aprotinin, 1 µM PMSF, and 100 µM NaVO₄). Proteins were subjected to Western blot analysis as
15 described (15). Blots were incubated with 1:5000 anti-human IGFBP-3 (Upstate Biotechnology), 1 µg/mL anti-human IGF-IR (Santa Cruz, CA), 0.5 µg/mL anti α-tubulin (Santa Cruz, CA) antibodies and 1:7500 horseradish peroxidase-conjugated donkey anti-mouse or anti-rabbit secondary antibody (Pierce, Rockford, Illinois). The blots were then visualised with a chemiluminescent detection system as described by the manufacturer
20 (ECL, Amersham).

Results

- In the adult human, the liver is the main source of circulating IGF-I and IGFBP-3 (12, 13). Since local expression of IGF-I is important in autocrine and paracrine stimulation and the IGFBP-3 appears to decrease the mitogenic activity of free IGF-I,
25 presumably by competing with type I IGF receptors for the ligand, the IGFBP-3 levels in the HCC samples were determined. Total tissue lysates from both HCC cancers and adjacent morphologically normal liver cells were subjected to Western blot analysis. The resulting blots were incubated with IGFBP-3 antibody. Figure 1 shows that IGFBP-3 protein (a complex spanning 38-42 kDa) was either absent or low in HCC compared to
30 adjacent normal tissues. Unlike IGFBP-3 detected in the serum, which comprises two forms (42 and 38 kDa bands) of equal intensity, the 38 kDa IGFBP-3 was the predominant form in all normal liver tissue. This band was undetectable in 28.5% (8 of 28) of HCC

samples examined (TABLE 1). Although the remaining tumours (20 of 28; 71.5%) expressed IGFBP-3, the level was significantly lower than that observed in normal adjacent tissue ($p < 0.01$). Densitometric scanning showed IGFBP-3 levels to be 4 to 100-fold higher in normal liver tissue than in HCC. Subsequent blotting with anti- α -tubulin antibody showed relatively equal amounts of total protein loaded per lane (Figure 1). Figure 1C also demonstrated that proteolysis of IGFBP-3 was unlikely to be responsible for the low levels or absence of IGFBP-3 from HCC samples because low molecular weight IGFBP-3 fragments were not clearly detected on Western blot analysis of the tissue samples. The IGFBP-3 fragments, however, were detected in serum samples.

To confirm the above observation, immunohistochemical staining of HCC and normal adjacent liver tissues was performed using anti-human IGFBP-3 antibody which recognised both intact and fragmented IGFBP-3 protein. IGFBP-3 protein was clearly localised to almost all cells in the adjacent normal tissue (Figure 2A). However, this signal was absent (Figure 2B) in HCC, indicating that IGFBP-3 expression was either inactivated or decreased in these neoplastic cells.

To determine if HCC also expressed IGF-I and IGF-II, HCC and adjacent normal liver tissues were stained with anti-IGF-I and anti-IGF-II antibodies, respectively. Although normal adjacent tissues stained positively for IGF-I (Figure 3A), the expression was significantly decreased in HCC (Figure 3B). Approximately 64% (18/28) and 36% (10/28) of HCC samples examined had moderate and low IGF-I expression, respectively (TABLE 1) which is consistent with a previous report (28). IGF-II staining (Figures 3C and 3D), in contrast, was approximately equal (68%; 19 of 28) or more intense (32%; 9 of 28) in HCC compared to normal liver tissue (TABLE 1). These observations are in agreement with previous reports demonstrating over-expression of IGF-II in HCC (9-11). Our data suggests that IGF autocrine and paracrine loops exist in HCC.

Since IGFs stimulate growth responses in liver cells by binding to the IGF-I receptor (IGF-IR), IGF-IR levels in HCC and normal adjacent tissue samples were examined. Approximate 39% of HCC tumours had significantly lower IGF-IR levels than non-neoplastic adjacent liver tissues ($p < 0.01$) (Figure 4, TABLE 1).

To test the hypothesis that IGF-I and IGF-II play a role in mediating tumour cell growth, HepG2 cells were treated with various concentrations of human recombinant IGF-I or IGF-II for 48 h. Figure 5A shows dose-dependent growth stimulation by IGF-I. Similar

- 55 -

effects were observed when HepG2 cells were treated with IGF-II (data not shown). Four-fold increase in cell number was observed at the dose of 25 ng/mL IGF-I ($p < 0.01$).

As IGFBP-3 protein was undetectable or lost in the majority of HCC samples (Figure 1) and IGFBP-3 has been shown to inhibit cancer cells in an IGF-independent pathway (14), the inventors attempted to demonstrate the antiproliferative action of IGFBP-3 on HepG2 cells. Approximate 40% and 52% inhibition of basal proliferation by 250 ng/mL and 500 ng/mL hrIGFBP-3, respectively ($p < 0.01$) was obtained (Figure 5B). Concentrations of rhIGFBP-3 up to 1 μ g/mL did not further inhibit proliferation.

To determine if the proliferative action of IGF-I can be attenuated in the presence of IGFBP-3, HepG2 cells were treated with hrIGFBP-3 in the presence and absence of IGF-I for 48 h. As shown in Figure 5C, treatment of HepG2 with 25 ng/mL IGF-I for 48h resulted in a 2.8-fold increase in cell number ($p < 0.01$). IGF-induced HepG2 proliferation was significantly attenuated ($p < 0.01$) in the presence of 250 ng/mL IGFBP-3 and completely abolished at the concentration of 500 ng/mL. This result suggests that IGFBP-3 attenuated IGF-I-induced HepG2 proliferation by reducing IGF-I bioavailability.

To test the hypothesis that autocrine production of IGF-II by liver cancer cells plays a role in mediating liver cancer cell growth, HepG2 cells, which has been shown to secrete IGF-II (8), were treated with anti-IGF-II, IGF-II or with a combination for 48 h. Figure 5D shows a 3-fold induction of basal proliferation by 25 ng/mL IGF-II ($p < 0.01$). This induction was significantly attenuated by IGF-II antibody ($p < 0.01$), whereas pre-immune serum was not significantly affected. IGF-II antibody alone caused a 35% reduction in cell number ($p < 0.05$). These results suggest that the rapid proliferation of liver cancer cells *in vivo* and *in vitro* may at least, in part, be a consequence of autocrine stimulation mediated by IGF-II expression.

EXAMPLE 2

Insulin-like growth factor binding protein levels in serum of hepatocellular carcinoma patients: Potential Markers for HCC

Methods

Serum collection from human HCC, prostate cancer, BPH and healthy patients.

Prior written informed consent was obtained from all patients and the study received ethics board approval at both institutions. HCC serum samples (n=116) were

- 56 -

obtained from patients from intra-venous access line during surgery (n=17) and from venous blood samples obtained from patients during index outpatient visit and on every monthly outpatient visit (n=99) at the Singapore General Hospital. The diagnosis of HCC was confirmed histologically in all cases. Serum from non-HCC (n=45), prostate cancer (n=29) and benign prostate hyperplasia (n=36) were obtained from venous blood samples obtained from patients during outpatient visit at Urology Centre, Singapore General Hospital. The serum was separated from blood samples and were snap frozen in liquid nitrogen and stored at -80° C until analysis.

Western blot analysis

To determine changes in the expression of IGFBP-3, IGFBP-1, IGFBP-2 and alpha fetoprotein, 3.5 μ L serum were subjected to Western blot analysis as described (14). Blots were incubated with rabbit anti-human IGFBP-3 (1:5000), rabbit anti-bovine IGFBP-2 (1:2500), rabbit anti-human IGFBP-1 (1:2000) and rabbit anti-human-alpha fetoprotein (1:200) antibodies and 1:7500 horseradish peroxidase-conjugated donkey anti-mouse or anti-rabbit secondary antibody (Pierce, Rockford, Illinois). The blots were then visualised with a chemiluminescent detection system as described by the manufacturer (ECL, Amersham). IGFBP-1, IGFBP-2 and IGFBP-3 were purchased from (Upstate Biotechnology).

Results

In the adult human, the liver is the main source of circulating, IGF-I, IGFBP-1 and IGFBP-3 (12, 13). Since local expression of IGF-I is important in autocrine and paracrine stimulation and the IGFBPs appear to regulate the mitogenic activity of free IGF-I, the IGFBP-3, IGFBP-2 and IGFBP-1 levels in the HCC serum samples were determined. Serum from HCC patients were subjected to Western blot analysis. The serums derived from prostate cancer, BPH and healthy patients served as controls.

While IGFBP-3 detected in the serum comprises two forms, 42 and 38 kDa, these forms were undetectable in 70% (81 of 116) of HCC serum samples examined. Although the remaining HCC serum samples had detectable IGFBP-3, the levels were significantly lower than that observed in control serum samples (Figure 6A-6P). Unlike IGFBP-3, IGFBP-2 and IGFBP-1 levels were low in control serum samples. Both IGFBP-2 and IGFBP-1 levels were increased in HCC serum but not others. IGFBP-3 levels were inversely correlated with HCC while IGFBP-1 and IGFBP-2 levels were positively

- 57 -

correlated with HCC. The elevation of IGFBP-1 was more closely associated with HCC conditioned than IGFBP-2. Since AFP levels have been shown to be useful in detecting hepatocellular carcinoma (HCC), the AFP levels were determined. As shown for example in Figure 6E, approximately 20% of HCC serum samples did not show any increase in AFP. Thus, the serum AFP was not always correlated with the presence of HCC.

The disclosure of every patent, patent application, and publication cited herein is hereby incorporated herein by reference in its entirety.

The citation of any reference herein should not be construed as an admission that such reference is available as "Prior Art" to the instant application

Throughout the specification the aim has been to describe the preferred embodiments of the invention without limiting the invention to any one embodiment or specific collection of features. Those of skill in the art will therefore appreciate that, in light of the instant disclosure, various modifications and changes can be made in the particular embodiments exemplified without departing from the scope of the present invention. All such modifications and changes are intended to be included within the scope of the appended claims.

- 58 -

TABLES**TABLE 1**

Expression of IGFs, IGFBP-3 and IGF-IR in normal adjacent liver tissues and HCC Tumours

Genes Examined	Normal adjacent Liver Tissues (n - 28)	HCC Tumours (n = 28)
Intense staining of IGF-I	+++ (100%)	++ 18/28 (64%) + 10/28 (36%)
Intense staining of IGF-II	+++ (100%)	+++ 19/28 (68%) ++++ 9/28 (32%)
Expression levels of IGFBP-3 levels: (compared with normal and adjacent tissue of the same patient)		
• Normal	28/28 (100%)	0/28 (0%)
• Low	0/28 (0%)	8/28 (28.5%)
• Undetectable	0/28 (0%)	20/28 (71.5%)
IGF-IR expression levels: (compared with normal and adjacent tissue of the same patient)		
• Normal	28/28 (100%)	17/28 (61%)
• Low	0/28 (0%)	11/28 (39%)

BIBLIOGRAPHY

1. Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., Nakajima, Y., and Ohnishi, K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. *Cancer*, 56: 918-928, 1985.
2. Lai, E. C., Fan, S. T., Lo, C. M., Chu, K. M., Liu, C. L., and Wong, J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. *Ann.Surg.*, 221: 291-298, 1995.
3. Takenaka, K., Kawahara, N., Yamamoto, K., Kajiyama, K., Maeda, T., Itasaka, H., Shirabe, K., Nishizaki, T., Yanaga, K., and Sugimachi, K. Results of 280 liver resections for hepatocellular carcinoma. *Arch.Surg.*, 131: 71-76, 1996.
4. Huguet, C., Stipa, F., and Gavelli, A. Primary hepatocellular cancer: Western experience. *In* L.Blumgart (ed.), *Surgery of the liver and biliary tract*, pp. 1365-1369. Churchill Livingstone: London, 2000.
5. Lai, E. and Wong, J. Hepatocellular carcinoma: the Asian experience. *In* L. Blumgart (ed.), *Surgery of the Liver and the biliary tract*, pp. 1349-1363. London: Churchill Livingstone, 1994.
6. Chan, E., Chow PKH, Tai, B. C., Martin D, and Soo KC Neoadjuvant and adjuvant thereapy for operable hepatocellular carcinoma. *Cochrane Database System Rev.*, 2: 2000.
7. Scharf, J. G., Schmidt-Sandte, W., Pahernik, S. A., Ramadori, G., Braulke, T., and Hartmann, H. Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC). *Carcinogenesis*, 19: 2121-2128, 1998.
8. Tsai, T. F., Yauk, Y. K., Chou, C. K., Ting, L. P., Chang, C., Hu, C. P., Han, S. H., and Su, T. S. Evidence of autocrine regulation in human hepatoma cell lines. *Biochem.Biophys.Res.Comm.*, 153: 39-45, 1988.
9. Su, T. S., Liu, W. Y., Han, S. H., Jansen, M., Yang-Fen, T. L., P'eng, F. K., and Chou, C. K. Transcripts of the insulin-like growth factors I and II in human hepatoma. *Cancer Res.*, 49: 1773-1777, 1989.

- 60 -

10. Ng, I. O., Lee, J. M., Srivastava, G., and Ng, M. Expression of insulin-like growth factor II mRNA in hepatocellular carcinoma. *J.Gastroenterol.Hepatol.*, 13: 152-157, 1998.
11. Cariani, E., Lasserre, C., Seurin, D., Hamelin, B., Kemeny, F., Franco, D., Czech, M. P., Ullrich, A., and Brechot, C. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. *Cancer Res.*, 48: 6844-6849, 1988.
12. Khandwala, H. M., McCutcheon, I. E., Flyvbjerg, A., and Friend, K. E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth [In Process Citation]. *Endocr.Rev.*, 21: 215-244, 2000.
13. Clemmons, D. R. Insulin-like growth factor binding proteins and their role in controlling IGF actions. *Cytokine and Growth Factor Reviews*, 8: 45-62, 1997.
14. Huynh, H., Larsson, C., Narod, S., and Pollak, M. Tumour suppressor activity of the gene encoding mammary-derived growth inhibitor. *Cancer Res.*, 55: 2225-2231, 1995.
15. Arany, E., Afford, S., Strain, A. J., Winwood, P. J., Arthur, M. J., and Hill, D. J. Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. *J.Clin.Endocrinol.Metab*, 79: 1871-1876, 1994.
16. Huynh, H., Nickerson, T., Yang, X., and Pollak, M. Regulation of insulin-like growth factor I receptor by the pure antiestrogen ICI 182,780. *Clinical Cancer Res.*, 2: 2037-2042, 1996.
17. Huynh, H., Yang, X., and Pollak, M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. *J.Biol.Chem.*, 271: 1016-1021, 1996.
18. Oh, Y., Mullers, H. L., Ng, L., and Rosenfeld, R. G. Transforming growth factor- β -induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. *J.Biol.Chem.*, 270: 13589-13592, 1995.

- 61 -

19. LeRoith, D., Adamo, M. L., Shemer, J., Lanau, F., Shen-Orr, Z., Yaron, A., Roberts, C. T., Clemmons, D. R., Sheikh, M. S., Shao, Z. M., and. Retinoic acid inhibits growth of breast cancer cell lines: the role of insulin-like growth factor binding proteins. *Growth Regul.*, 3: 78-80, 1993.
20. Herman, J. G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., Samid, D., and et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. *Proc.Natl.Acad.Sci.USA*, 91: 9700-9704, 1994.
21. Huynh, H., Alpert, L., and Pollak, M. Silencing of the mammary derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes. *Cancer Res.*, 56: 4865-4870, 1996.
22. Wong, I. H., Johnson, P. J., Lai, P. B., Lau, W. Y., and Lo, Y. M. Tumor-derived epigenetic changes in the plasma and serum of liver cancer patients. Implications for cancer detection and monitoring. *Ann N.Y.Acad Sci.*, 906: 102-105, 2000.
23. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavitgian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. *Science*, 264: 436-440, 1994.
24. Montesano, R., Hainaut, P., and Wild, C. P. Hepatocellular carcinoma: from gene to public health. *J.Natl.Cancer Inst.*, 89: 1844-1851, 1997.
25. Chen, C. J., Yu, M. W., and Liaw, Y. F. Epidemiological characteristics and risk factors of hepatocellular carcinoma. *J.Gastroenterol.Hepatol.*, 12: 5294-5308, 1997.
26. Oh, Y., Muller, H. L., Lamson, G., and Rosenfeld, R. G. Insulin-like growth factor (IGF)independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. *J.Biol.Chem.*, 268: 14964-14971, 1993.
27. Oh, Y., Muller, H. L., Pham, H., and Rosenfeld, R. G. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. *J.Biol.Chem.*, 268: 26045-26048, 1993.
28. Wakeling, A. E., Dukes, M., and Bowler, J. A potent specific pure antiestrogen with clinical potential. *Cancer Res.*, 51: 3867-3873, 1991.

- 62 -

29. Cameron, R. G., Imaida, K., Tsuda, H., and Ito, N. Promotive effects of steroids and bile acids on hepatocarcinogenesis initiated by diethylnitrosamine. *Cancer Res.*, 42: 2426-2428, 1982.
30. Coe, J. E., Ishak, K. G., and Ross, M. J. Estrogen induction of hepatocellular carcinomas in Armenian hamsters. *Hepatology*, 11: 570-577, 1990.

CLAIMS

1. A method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient aberrant expression of a gene encoding an insulin-like growth factor binding protein (IGFBP).
2. The method of claim 1, wherein said IGFBP is selected from IGFBP-1, IGFBP-2 or IGFBP-3.
3. The method of claim 1, wherein said aberrant expression is detected by detecting a level and/or functional activity of an expression product of an *IGFBP-1* gene, which is elevated relative to a normal reference level and/or functional activity of said expression product.
4. The method of claim 1, wherein said aberrant expression is detected by detecting a level and/or functional activity of an expression product of an *IGFBP-2* gene, which is elevated relative to a normal reference level and/or functional activity of said expression product.
5. The method of claim 1, wherein said aberrant expression is detected by detecting a level and/or functional activity of an expression product of an *IGFBP-3* gene, which is reduced relative to a normal reference level and/or functional activity of said expression product.
6. The method of any one of claims 3 to 5, wherein the level and/or functional activity of said expression product in the biological sample obtained from said patient differs by at least 10% compared to the level and/or functional activity of said expression product in a biological sample obtained from normal patients or from patients who are not afflicted with said liver cancer.
7. The method of any one of claims 3 to 5, wherein said expression product is a transcript.
8. The method of any one of claims 3 to 5, wherein said expression product is a polypeptide.
9. The method of claim 1, wherein said liver cancer is liver cell carcinoma.
10. The method of claim 1, wherein said biological sample comprises a fluid selected from whole blood, plasma, lymph, saliva, mucus secretion and respiratory fluid.

- 64 -

11. The method of claim 1, wherein said biological sample comprises a circulatory fluid selected from serum or whole blood or a fractionated portion thereof.
12. The method of claim 1, wherein said biological sample comprises serum or a fractionated portion thereof.
13. A method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient:
 - a level and/or functional activity of an expression product of an *IGFBP-1* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-1* expression product; and/or
 - a level and/or functional activity of an expression product of an *IGFBP-2* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-2* expression product; and/or
 - a level and/or functional activity of an expression product of an *IGFBP-3* gene, which is reduced relative to a normal reference level and/or functional activity of said *IGFBP-3* expression product.
14. A method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient:
 - a level and/or functional activity of an expression product of an *IGFBP-1* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-1* expression product; and
 - a level and/or functional activity of an expression product of an *IGFBP-2* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-2* expression product.
15. A method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient:
 - a level and/or functional activity of an expression product of an *IGFBP-1* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-1* expression product; and
 - a level and/or functional activity of an expression product of an *IGFBP-3* gene, which is reduced relative to a normal reference level and/or functional activity of said *IGFBP-3* expression product.

- 65 -

16. A method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient:
 - a level and/or functional activity of an expression product of an *IGFBP-2* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-2* expression product; and
 - a level and/or functional activity of an expression product of an *IGFBP-3* gene, which is reduced relative to a normal reference level and/or functional activity of said *IGFBP-3* expression product.
17. A method for detecting the presence or diagnosing the risk of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient:
 - a level and/or functional activity of an expression product of an *IGFBP-1* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-1* expression product; and
 - a level and/or functional activity of an expression product of an *IGFBP-2* gene, which is elevated relative to a normal reference level and/or functional activity of said *IGFBP-2* expression product; and
 - a level and/or functional activity of an expression product of an *IGFBP-3* gene, which is reduced relative to a normal reference level and/or functional activity of said *IGFBP-3* expression product.
18. A method for prognostic assessment of a liver cancer in a patient, comprising detecting in a biological sample obtained from said patient aberrant expression of at least one gene encoding an IGFBP.
19. Use of an agent in the manufacture of a medicament for treating and/or preventing a liver cancer, wherein said agent is optionally formulated with a pharmaceutically acceptable carrier and is identifiable by a screening assay comprising:
 - contacting a preparation comprising at least a portion of an expression product of a gene selected from an *IGFBP* gene or a gene relating to the same regulatory or biosynthetic pathway as the *IGFBP* gene, or a variant or derivative of said expression product, or comprising a genetic sequence which regulates expression of said expression product and which is operably connected to a marker gene, with said agent; and

- 66 -

- detecting a change in the level and/or functional activity of said at least a portion of said expression product or said variant or derivative or a change in the level of expression of said marker gene.

20. Use of an agent that reduces the level and/or functional activity of an expression product of an *IGFBP-1* gene in the manufacture of a medicament for treating and/or preventing a liver cancer, wherein said agent is optionally formulated with a pharmaceutically acceptable carrier and is identifiable by a screening assay comprising:

- contacting a preparation comprising at least a portion of an expression product of an *IGFBP-1* gene, or a variant or derivative of said expression product, or comprising a genetic sequence which regulates expression of said expression product and which is operably connected to a marker gene, with said agent; and

- detecting a reduction in the level and/or functional activity of said at least a portion of said expression product or said variant or derivative or a reduction in the level and/or functional activity of an expression product of said marker gene.

21. Use of an agent that reduces the level and/or functional activity of an expression product of an *IGFBP-2* gene in the manufacture of a medicament for treating and/or preventing a liver cancer, wherein said agent is optionally formulated with a pharmaceutically acceptable carrier and is identifiable by a screening assay comprising:

- contacting a preparation comprising at least a portion of an expression product of an *IGFBP-2* gene, or a variant or derivative of said expression product, or comprising a genetic sequence which regulates expression of said expression product and which is operably connected to a marker gene, with said agent; and

- detecting a reduction in the level and/or functional activity of said at least a portion of said expression product or said variant or derivative or a reduction in the level and/or functional activity of an expression product of said marker gene.

22. Use of an agent that increases the level and/or functional activity of an expression product of an *IGFBP-3* gene in the manufacture of a medicament for treating and/or preventing a liver cancer, wherein said agent is optionally formulated with a pharmaceutically acceptable carrier and is identifiable by a screening assay comprising:

- contacting a preparation comprising at least a portion of an expression product of an *IGFBP-3* gene, or a variant or derivative of said expression product, or comprising a

- 67 -

genetic sequence which regulates expression of said expression product and which is operably connected to a marker gene, with said agent; and

– detecting an increase in the level and/or functional activity of said at least a portion of said expression product or said variant or derivative or an increase in the level and/or functional activity of an expression product of said marker gene.

23. The use of claim 20 or claim 21, wherein said agent is an antisense oligonucleotide or ribozyme that binds to, or otherwise interacts specifically with, a polynucleotide selected from an *IGFBP-1* polynucleotide, an *IGFBP-2* polynucleotide or complement of these.
24. The use of claim 20 or claim 21, wherein said agent is an antigen-binding molecule that is immuno-interactive with *IGFBP-1* and/or *IGFBP-2*.
25. The use of claim 22, wherein said agent comprises an *IGFBP-3* polypeptide or a biologically active fragment thereof, or variant or derivative of these.
26. The use of claim 22, wherein said agent comprises a polynucleotide encoding an *IGFBP-3* polypeptide or a biologically active fragment thereof, or variant or derivative of these, wherein said polynucleotide is operably connected to a regulatory polynucleotide.
27. Use of a vector in the manufacture of a medicament, which is optionally formulated with a pharmaceutically acceptable carrier, for the treatment and/or prophylaxis of a liver cancer or related condition, wherein said vector comprises at least a portion of an *IGFBP-3* polynucleotide operably linked, in the sense direction, to a regulatory polynucleotide.
28. Use of a vector in the manufacture of a medicament, which is optionally formulated with a pharmaceutically acceptable carrier, for the treatment and/or prophylaxis of a liver cancer or related condition, wherein said vector comprises an isolated *IGFBP-1* polynucleotide operably linked, in the antisense direction, to a regulatory polynucleotide.
29. Use of a vector in the manufacture of a medicament, which is optionally formulated with a pharmaceutically acceptable carrier, for the treatment and/or prophylaxis of a liver cancer or related condition, wherein said vector comprises an isolated *IGFBP-2*

- 68 -

polynucleotide operably linked, in the antisense direction, to a regulatory polynucleotide.

30. A method for modulating liver cell proliferation or tumorigenesis, comprising contacting a liver cell with an agent for a time and under conditions sufficient to modulate the level and/or functional activity of an *IGFBP* expression product, wherein said agent is optionally formulated with a pharmaceutically acceptable carrier and is identifiable by a screening assay comprising:
- contacting a preparation comprising at least a portion of an expression product of a gene selected from an *IGFBP* gene or a gene relating to the same regulatory or biosynthetic pathway as the *IGFBP* gene, or a variant or derivative of said expression product, or comprising a genetic sequence which regulates expression of said expression product and which is operably connected to a marker gene, with said agent; and
 - detecting a change in the level and/or functional activity of said at least a portion of said expression product or said variant or derivative or a change in the level of expression of said marker gene.
31. A method for modulating liver cell proliferation or tumorigenesis, comprising contacting a liver cell with an agent for a time and under conditions sufficient to reduce the level and/or functional activity of an *IGFBP-1* expression product, wherein said agent is optionally formulated with a pharmaceutically acceptable carrier and is identifiable by a screening assay comprising:
- contacting a preparation comprising at least a portion of an expression product of an *IGFBP-1* gene, or a variant or derivative of said expression product, or comprising a genetic sequence which regulates expression of said expression product and which is operably connected to a marker gene, with said agent; and
 - detecting a reduction in the level and/or functional activity of said at least a portion of said expression product or said variant or derivative or a reduction in the level and/or functional activity of an expression product of said marker gene.
32. A method for modulating liver cell proliferation or tumorigenesis, comprising contacting a liver cell with an agent for a time and under conditions sufficient to reduce the level and/or functional activity of an *IGFBP-2* expression product, wherein said

- 69 -

agent is optionally formulated with a pharmaceutically acceptable carrier and is identifiable by a screening assay comprising:

- contacting a preparation comprising at least a portion of an expression product of an *IGFBP-2* gene, or a variant or derivative of said expression product, or comprising a genetic sequence which regulates expression of said expression product and which is operably connected to a marker gene, with said agent; and
- detecting a reduction in the level and/or functional activity of said at least a portion of said expression product or said variant or derivative or a reduction in the level and/or functional activity of an expression product of said marker gene.

33. A method for modulating liver cell proliferation or tumorigenesis, comprising contacting a liver cell with an agent for a time and under conditions sufficient to increase the level and/or functional activity of an *IGFBP-3* expression product, wherein said agent is optionally formulated with a pharmaceutically acceptable carrier and is identifiable by a screening assay comprising:

- contacting a preparation comprising at least a portion of an expression product of an *IGFBP-3* gene, or a variant or derivative of said expression product, or comprising a genetic sequence which regulates expression of said expression product and which is operably connected to a marker gene, with said agent; and
- detecting an increase in the level and/or functional activity of said at least a portion of said expression product or said variant or derivative or an increase in the level and/or functional activity of an expression product of said marker gene.

34. A method for treatment and/or prophylaxis of a liver cancer or related condition, comprising administering to a patient in need of such treatment an effective amount of an agent that modulates the level and/or functional activity of an *IGFBP* expression product.

35. A method for treatment and/or prophylaxis of a liver cancer or related condition, comprising administering to a patient in need of such treatment an effective amount of an agent that decreases the level and/or functional activity of an *IGFBP-1* expression product.

36. A method for treatment and/or prophylaxis of a liver cancer or related condition, comprising administering to a patient in need of such treatment an effective amount of

- 70 -

an agent that decreases the level and/or functional activity of an *IGFBP-2* expression product.

37. A method for treatment and/or prophylaxis of a liver cancer or related condition, comprising administering to a patient in need of such treatment an effective amount of an agent that increases the level and/or functional activity of an *IGFBP-3* expression product.





FIGURE 1

A



B




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6A




FIGURE 6B

19/12/00 Serum 3




FIGURE 6C

19/12/00 Serum 4




FIGURE 6D

19/12/00 Serum 5




FIGURE 6E




FIGURE 6F

19/12/00 Serum7




FIGURE 6G

19/12/00 Serum 8




FIGURE 6H

28/12/00 Serum1




FIGURE 6I

28/12/00 Serum 2




FIGURE 6J

28/12/00 Serum 3




FIGURE 6K

28/12/00 Serum 6





FIGURE 6L



N: Normal

T: Prostate Cancer

B: Benign Prostate Hyperplasia

FIGURE 6M





FIGURE 6N



N: Normal
T: Prostate Cancer
B: Benign Prostate Hyperplasia

FIGURE 60

**FIGURE 6P**

- 1 -

SEQUENCE LISTING

<110> National Cancer Centre of Singapore (all states, except U.S.)
 Singapore General Hospital Pte Ltd (all states, except U.S.)
 Huynh, The Hung (U.S. only)
 Chow, Pierce Kah Hoe (U.S. only)
 Soo, Khee Chee (U.S. only)

<120> Polynucleotides and polypeptides linked to cancer

<130> 2521505/VPA

<140> Yet to be assigned

<141> 2002-05-03

<150> U.S. 60/288,441

<151> 2001-05-03

<160> 12

<170> PatentIn version 3.1

<210> 1

<211> 1514

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (166)..(945)

<223>

<400> 1

atcggccacc gccatcccat ccagcgagca tctgccgccg cgccgccgcc accctcccag 60

agagcactgg ccaccgctcc accatcactt gccagagtt tggggccaccg cccgccgcc 120

ccagcccaga gagcatcggc cctgtctgctc tgctcgcgcc tggag atg tca gag gtc 177

Met Ser Glu Val

1

ccc gtt gct cgc gtc tgg ctg gta ctg ctc ctg ctg act gtc cag gtc 225

Pro Val Ala Arg Val Trp Leu Val Leu Leu Leu Thr Val Gln Val

5 10 15 20

ggc gtg aca gcc ggc gct ccg tgg cag tgc gcg ccc tgc tcc gcc gag 273

Gly Val Thr Ala Gly Ala Pro Trp Gln Cys Ala Pro Cys Ser Ala Glu

25 30 35

aag ctc gcg ctc tgc ccg ccg gtg tcc gcc tcg tgc tcg gag gtc acc 321

Lys Leu Ala Leu Cys Pro Pro Val Ser Ala Ser Cys Ser Glu Val Thr

40 45 50

cgg tcc gcc ggc tgc ggc tgt tgc ccg atg tgc gcc ctg cct ctg ggc 369

Arg Ser Ala Gly Cys Gly Cys Cys Pro Met Cys Ala Leu Pro Leu Gly

55 60 65

gcc gcg tgc ggc gtg gcg act gca cgc tgc gcc cgg gga ctc agt tgc 417

Ala Ala Cys Gly Val Ala Thr Ala Arg Cys Ala Arg Gly Leu Ser Cys

70 75 80

- 2 -

cgc gcg ctg ccg ggg gag cag caa cct ctg cac gcc ctc acc cgc ggc	465
Arg Ala Leu Pro Gly Glu Gln Gln Pro Leu His Ala Leu Thr Arg Gly	
85 90 95 100	
caa ggc gcc tgc gtg cag gag tct gac gcc tcc gct ccc cat gct gca	513
Gln Gly Ala Cys Val Gln Glu Ser Asp Ala Ser Ala Pro His Ala Ala	
105 110 115	
gag gca ggg agc cct gaa agc cca gag agc acg gag ata act gag gag	561
Glu Ala Gly Ser Pro Glu Ser Pro Glu Ser Thr Glu Ile Thr Glu Glu	
120 125 130	
gag ctc ctg gat aat ttc cat ctg atg gcc cct tct gaa gag gat cat	609
Glu Leu Leu Asp Asn Phe His Leu Met Ala Pro Ser Glu Glu Asp His	
135 140 145	
tcc atc ctt tgg gac gcc atc agt acc tat gat ggc tgc aag gct ctc	657
Ser Ile Leu Trp Asp Ala Ile Ser Thr Tyr Asp Gly Ser Lys Ala Leu	
150 155 160	
cat gtc acc aac atc aaa aaa tgg aag gag ccc tgc cga ata gaa ctc	705
His Val Thr Asn Ile Lys Lys Trp Lys Glu Pro Cys Arg Ile Glu Leu	
165 170 175 180	
tac aga gtc gta gag agt tta gcc aag gca cag gag aca tca gga gaa	753
Tyr Arg Val Val Glu Ser Leu Ala Lys Ala Gln Glu Thr Ser Gly Glu	
185 190 195	
gaa att tcc aaa ttt tac ctg cca aac tgc aac aag aat gga ttt tat	801
Glu Ile Ser Lys Phe Tyr Leu Pro Asn Cys Asn Lys Asn Gly Phe Tyr	
200 205 210	
cac agc aga cag tgt gag aca tcc atg gat gga gag gcg gga ctc tgc	849
His Ser Arg Gln Cys Glu Thr Ser Met Asp Gly Glu Ala Gly Leu Cys	
215 220 225	
tgg tgc gtc tac cct tgg aat ggg aag agg atc cct ggg tct cca gag	897
Trp Cys Val Tyr Pro Trp Asn Gly Lys Arg Ile Pro Gly Ser Pro Glu	
230 235 240	
atc agg gga gac ccc aac tgc cag ata tat ttt aat gta caa aac tga	945
Ile Arg Gly Asp Pro Asn Cys Gln Ile Tyr Phe Asn Val Gln Asn	
245 250 255	
aaccagatga aataatgttc tgtcacgtga aatatttaag tatatagtat atttatactc	1005
tagaacatgc acatttatat atatatgtat atgtatatat atatagtaac tactttttat	1065
actccataca taacttgata tagaaagctg tttatttatt cactgtaagt ttattttttc	1125
tacacagtaa aaacttgtag tatgttaata acttgtccta tgtcaatttg tatatcatga	1185
aacactttctc atcatattgt atgtaagtaa ttgcatttct gctcttccaa agctcctgcg	1245
tctgtttttta aagagcatgg aaaaatactg cctagaaaat gcaaaatgaa ataagagaga	1305
gtagttttttc agctagtttg aaggaggacg gttaacttgt atattccacc attcacattt	1365
gatgtacatg tgtagggaaa gttaaaaagt ttgattacat aatcaaagct acctgtggtg	1425
atgttgccac ctgttaaaat gtacactgga tatgttggtta aacacgtgtc tataatggaa	1485

- 3 -

acattttacaa taaatattct gcatggaaa

1514

<210> 2
 <211> 259
 <212> PRT
 <213> Homo sapiens

<400> 2

Met Ser Glu Val Pro Val Ala Arg Val Trp Leu Val Leu Leu Leu Leu
 1 5 10 15

Thr Val Gln Val Gly Val Thr Ala Gly Ala Pro Trp Gln Cys Ala Pro
 20 25 30

Cys Ser Ala Glu Lys Leu Ala Leu Cys Pro Pro Val Ser Ala Ser Cys
 35 40 45

Ser Glu Val Thr Arg Ser Ala Gly Cys Gly Cys Cys Pro Met Cys Ala
 50 55 60

Leu Pro Leu Gly Ala Ala Cys Gly Val Ala Thr Ala Arg Cys Ala Arg
 65 70 75 80

Gly Leu Ser Cys Arg Ala Leu Pro Gly Glu Gln Gln Pro Leu His Ala
 85 90 95

Leu Thr Arg Gly Gln Gly Ala Cys Val Gln Glu Ser Asp Ala Ser Ala
 100 105 110

Pro His Ala Ala Glu Ala Gly Ser Pro Glu Ser Pro Glu Ser Thr Glu
 115 120 125

Ile Thr Glu Glu Glu Leu Leu Asp Asn Phe His Leu Met Ala Pro Ser
 130 135 140

Glu Glu Asp His Ser Ile Leu Trp Asp Ala Ile Ser Thr Tyr Asp Gly
 145 150 155 160

Ser Lys Ala Leu His Val Thr Asn Ile Lys Lys Trp Lys Glu Pro Cys
 165 170 175

Arg Ile Glu Leu Tyr Arg Val Val Glu Ser Leu Ala Lys Ala Gln Glu
 180 185 190

Thr Ser Gly Glu Glu Ile Ser Lys Phe Tyr Leu Pro Asn Cys Asn Lys
 195 200 205

- 4 -

Asn Gly Phe Tyr His Ser Arg Gln Cys Glu Thr Ser Met Asp Gly Glu
 210 215 220

Ala Gly Leu Cys Trp Cys Val Tyr Pro Trp Asn Gly Lys Arg Ile Pro
 225 230 235 240

Gly Ser Pro Glu Ile Arg Gly Asp Pro Asn Cys Gln Ile Tyr Phe Asn
 245 250 255

Val Gln Asn

<210> 3
 <211> 1433
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (118) .. (1104)
 <223>

<400> 3
 attcggggcg agggaggagg aagaagcgga ggaggcggct cccgctcgca gggccgtgca 60
 cctgccccgcc cgcccgctcg ctgctcgcc cgccgcgccg cgctgccgac cgccagc 117
 atg ctg ccg aga gtg ggc tgc ccc gcg ctg ccg ctg ccg ccg ccg ccg 165
 Met Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu Pro Pro Pro Pro
 1 5 10 15
 ctg ctg ccg ctg ctg ccg ctg ctg ctg ctg cta ctg ggc gcg agt ggc 213
 Leu Leu Pro Leu Leu Pro Leu Leu Leu Leu Leu Leu Gly Ala Ser Gly
 20 25 30
 ggc ggc ggc ggg gcg cgc gcg gag gtg ctg ttc cgc tgc ccg ccc tgc 261
 Gly Gly Gly Gly Ala Arg Ala Glu Val Leu Phe Arg Cys Pro Pro Cys
 35 40 45
 aca ccc gag cgc ctg gcc gcc tgc ggg ccc ccg ccg gtt gcg ccg ccc 309
 Thr Pro Glu Arg Leu Ala Ala Cys Gly Pro Pro Pro Val Ala Pro Pro
 50 55 60
 gcc gcg gtg gcc gca gtg gcc gga ggc gcc cgc atg cca tgc gcg gag 357
 Ala Ala Val Ala Ala Val Ala Gly Gly Ala Arg Met Pro Cys Ala Glu
 65 70 75 80
 ctc gtc cgg gag ccg ggc tgc ggc tgc tgc tgc gtg tgc gcc cgg ctg 405
 Leu Val Arg Glu Pro Gly Cys Gly Cys Cys Ser Val Cys Ala Arg Leu
 85 90 95
 gag ggc gag gcg tgc ggc gtc tac acc ccg cgc tgc ggc cag ggg ctg 453
 Glu Gly Glu Ala Cys Gly Val Tyr Thr Pro Arg Cys Gly Gln Gly Leu
 100 105 110
 cgc tgc tat ccc cac ccg ggc tcc gag ctg ccc ctg cag gcg ctg gtc 501

- 5 -

Arg	Cys	Tyr	Pro	His	Pro	Gly	Ser	Glu	Leu	Pro	Leu	Gln	Ala	Leu	Val		
115						120						125					
atg	ggc	gag	ggc	act	tgt	gag	aag	cgc	cgg	gac	gcc	gag	tat	ggc	gcc	549	
Met	Gly	Glu	Gly	Thr	Cys	Glu	Lys	Arg	Arg	Asp	Ala	Glu	Tyr	Gly	Ala		
130						135						140					
agc	ccg	gag	cag	gtt	gca	gac	aat	ggc	gat	gac	cac	tca	gaa	gga	ggc	597	
Ser	Pro	Glu	Gln	Val	Ala	Asp	Asn	Gly	Asp	Asp	His	Ser	Glu	Gly	Gly		
145				150						155				160			
ctg	gtg	gag	aac	cac	gtg	gac	agc	acc	atg	aac	atg	ttg	ggc	ggg	gga	645	
Leu	Val	Glu	Asn	His	Val	Asp	Ser	Thr	Met	Asn	Met	Leu	Gly	Gly	Gly		
				165				170						175			
ggc	agt	gct	ggc	cgg	aag	ccc	ctc	aag	tcg	ggg	atg	aag	gag	ctg	gcc	693	
Gly	Ser	Ala	Gly	Arg	Lys	Pro	Leu	Lys	Ser	Gly	Met	Lys	Glu	Leu	Ala		
			180				185						190				
gtg	ttc	cgg	gag	aag	gtc	act	gag	cag	cac	cgg	cag	atg	ggc	aag	ggg	741	
Val	Phe	Arg	Glu	Lys	Val	Thr	Glu	Gln	His	Arg	Gln	Met	Gly	Lys	Gly		
		195				200						205					
ggc	aag	cat	cac	ctt	ggc	ctg	gag	gag	ccc	aag	aag	ctg	cga	cca	ccc	789	
Gly	Lys	His	His	Leu	Gly	Leu	Glu	Glu	Pro	Lys	Lys	Leu	Arg	Pro	Pro		
210						215				220							
cct	gcc	agg	act	ccc	tgc	caa	cag	gaa	ctg	gac	cag	gtc	ctg	gag	cgg	837	
Pro	Ala	Arg	Thr	Pro	Cys	Gln	Gln	Glu	Leu	Asp	Gln	Val	Leu	Glu	Arg		
225				230						235				240			
atc	tcc	acc	atg	cgc	ctt	ccg	gat	gag	cgg	ggc	cct	ctg	gag	cac	ctc	885	
Ile	Ser	Thr	Met	Arg	Leu	Pro	Asp	Glu	Arg	Gly	Pro	Leu	Glu	His	Leu		
				245				250						255			
tac	tcc	ctg	cac	atc	ccc	aac	tgt	gac	aag	cat	ggc	ctg	tac	aac	ctc	933	
Tyr	Ser	Leu	His	Ile	Pro	Asn	Cys	Asp	Lys	His	Gly	Leu	Tyr	Asn	Leu		
			260				265						270				
aaa	cag	tgc	aag	atg	tct	ctg	aac	ggg	cag	cgt	ggg	gag	tgc	tgg	tgt	981	
Lys	Gln	Cys	Lys	Met	Ser	Leu	Asn	Gly	Gln	Arg	Gly	Glu	Cys	Trp	Cys		
		275				280						285					
gtg	aac	ccc	aac	acc	ggg	aag	ctg	atc	cag	gga	gcc	ccc	acc	atc	cgg	1029	
Val	Asn	Pro	Asn	Thr	Gly	Lys	Leu	Ile	Gln	Gly	Ala	Pro	Thr	Ile	Arg		
290						295				300							
ggg	gac	ccc	gag	tgt	cat	ctc	ttc	tac	aat	gag	cag	cag	gag	gct	tgc	1077	
Gly	Asp	Pro	Glu	Cys	His	Leu	Phe	Tyr	Asn	Glu	Gln	Gln	Glu	Ala	Cys		
305				310						315				320			
ggg	gtg	cac	acc	cag	cgg	atg	cag	tag	accgcagcca	gccggtgcct						1124	
Gly	Val	His	Thr	Gln	Arg	Met	Gln										
				325													
ggcgcgccctg cccccgcgcc ctctccaaac accggcagaa aacggagagt gcttggggtgg																1184	
tgggtgctgg aggattttcc agttctgaca cacgtattta tatttggaag gagaccagca																1244	
ccgagctcgg cacctccccg gc																	

- 6 -

agggggaaga gaaattttta tttttgaacc cctgtgtccc ttttgcataa gattaaagga 1424

aggaaaagt 1433

<210> 4

<211> 328

<212> PRT

<213> Homo sapiens

<400> 4

Met Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu Pro Pro Pro Pro
1 5 10 15

Leu Leu Pro Leu Leu Pro Leu Leu Leu Leu Leu Leu Gly Ala Ser Gly
20 25 30

Gly Gly Gly Gly Ala Arg Ala Glu Val Leu Phe Arg Cys Pro Pro Cys
35 40 45

Thr Pro Glu Arg Leu Ala Ala Cys Gly Pro Pro Pro Val Ala Pro Pro
50 55 60

Ala Ala Val Ala Ala Val Ala Gly Gly Ala Arg Met Pro Cys Ala Glu
65 70 75 80

Leu Val Arg Glu Pro Gly Cys Gly Cys Cys Ser Val Cys Ala Arg Leu
85 90 95

Glu Gly Glu Ala Cys Gly Val Tyr Thr Pro Arg Cys Gly Gln Gly Leu
100 105 110

Arg Cys Tyr Pro His Pro Gly Ser Glu Leu Pro Leu Gln Ala Leu Val
115 120 125

Met Gly Glu Gly Thr Cys Glu Lys Arg Arg Asp Ala Glu Tyr Gly Ala
130 135 140

Ser Pro Glu Gln Val Ala Asp Asn Gly Asp Asp His Ser Glu Gly Gly
145 150 155 160

Leu Val Glu Asn His Val Asp Ser Thr Met Asn Met Leu Gly Gly Gly
165 170 175

Gly Ser Ala Gly Arg Lys Pro Leu Lys Ser Gly Met Lys Glu Leu Ala
180 185 190

Val Phe Arg Glu Lys Val Thr Glu Gln His Arg Gln Met Gly Lys Gly

- 7 -

195	200	205
Gly Lys His His Leu Gly Leu Glu Glu Pro Lys Lys Leu Arg Pro Pro 210 215 220		
Pro Ala Arg Thr Pro Cys Gln Gln Glu Leu Asp Gln Val Leu Glu Arg 225 230 235 240		
Ile Ser Thr Met Arg Leu Pro Asp Glu Arg Gly Pro Leu Glu His Leu 245 250 255		
Tyr Ser Leu His Ile Pro Asn Cys Asp Lys His Gly Leu Tyr Asn Leu 260 265 270		
Lys Gln Cys Lys Met Ser Leu Asn Gly Gln Arg Gly Glu Cys Trp Cys 275 280 285		
Val Asn Pro Asn Thr Gly Lys Leu Ile Gln Gly Ala Pro Thr Ile Arg 290 295 300		
Gly Asp Pro Glu Cys His Leu Phe Tyr Asn Glu Gln Gln Glu Ala Cys 305 310 315 320		
Gly Val His Thr Gln Arg Met Gln 325		

<210> 5
 <211> 2497
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (108)..(983)
 <223>

<400> 5
 ggcacgaggg cgcgttctg cctggattcc acagcttcgc gccgtgtact gtcgccccat 60
 ccctgcgcgc ccagcctgcc aagcagcgtg ccccggttgc aggcgtc atg cag cgg 116
 Met Gln Arg
 1
 gcg cga ccc acg ctc tgg gcc gct gcg ctg act ctg ctg gtg ctg ctc 164
 Ala Arg Pro Thr Leu Trp Ala Ala Ala Leu Thr Leu Leu Val Leu Leu
 5 10 15
 cgc ggg ccg ccg gtg gcg cgg gct ggc gcg agc tcg ggg ggc ttg ggt 212
 Arg Gly Pro Pro Val Ala Arg Ala Gly Ala Ser Ser Gly Gly Leu Gly
 20 25 30 35
 ccc gtg gtg cgc tgc gag ccg tgc gac gcg cgt gca ctg gcc cag tgc 260

- 8 -

Pro	Val	Val	Arg	Cys	Glu	Pro	Cys	Asp	Ala	Arg	Ala	Leu	Ala	Gln	Cys	
				40					45					50		
gcg	cct	ccg	ccc	gcc	gtg	tgc	gcg	gag	ctg	gtg	cgc	gag	ccg	ggc	tgc	308
Ala	Pro	Pro	Pro	Ala	Val	Cys	Ala	Glu	Leu	Val	Arg	Glu	Pro	Gly	Cys	
			55					60					65			
ggc	tgc	tgc	ctg	acg	tgc	gca	ctg	agc	gag	ggc	cag	ccg	tgc	ggc	atc	356
Gly	Cys	Cys	Leu	Thr	Cys	Ala	Leu	Ser	Glu	Gly	Gln	Pro	Cys	Gly	Ile	
		70					75					80				
tac	acc	gag	cgc	tgt	ggc	tcc	ggc	ctt	cgc	tgc	cag	ccg	tgc	ccc	gac	404
Tyr	Thr	Glu	Arg	Cys	Gly	Ser	Gly	Leu	Arg	Cys	Gln	Pro	Ser	Pro	Asp	
	85					90					95					
gag	gcg	cga	ccg	ctg	cag	gcg	ctg	ctg	gac	ggc	cgc	ggg	ctc	tgc	gtc	452
Glu	Ala	Arg	Pro	Leu	Gln	Ala	Leu	Leu	Asp	Gly	Arg	Gly	Leu	Cys	Val	
100					105					110					115	
aac	gct	agt	gcc	gtc	agc	cgc	ctg	cgc	gcc	tac	ctg	ctg	cca	gcg	ccg	500
Asn	Ala	Ser	Ala	Val	Ser	Arg	Leu	Arg	Ala	Tyr	Leu	Leu	Pro	Ala	Pro	
			120						125					130		
cca	gct	cca	gga	aat	gct	agt	gag	tgc	gag	gaa	gac	cgc	agc	gcc	ggc	548
Pro	Ala	Pro	Gly	Asn	Ala	Ser	Glu	Ser	Glu	Glu	Asp	Arg	Ser	Ala	Gly	
			135					140					145			
agt	gtg	gag	agc	ccg	tcc	gtc	tcc	agc	acg	cac	cgg	gtg	tct	gat	ccc	596
Ser	Val	Glu	Ser	Pro	Ser	Val	Ser	Ser	Thr	His	Arg	Val	Ser	Asp	Pro	
		150					155					160				
aag	ttc	cac	ccc	ctc	cat	tca	aag	ata	atc	atc	atc	aag	aaa	ggg	cat	644
Lys	Phe	His	Pro	Leu	His	Ser	Lys	Ile	Ile	Ile	Ile	Lys	Lys	Gly	His	
	165					170					175					
gct	aaa	gac	agc	cag	cgc	tac	aaa	gtt	gac	tac	gag	tct	cag	agc	aca	692
Ala	Lys	Asp	Ser	Gln	Arg	Tyr	Lys	Val	Asp	Tyr	Glu	Ser	Gln	Ser	Thr	
180					185					190					195	
gat	acc	cag	aac	ttc	tcc	tcc	gag	tcc	aag	cgg	gag	aca	gaa	tat	ggc	740
Asp	Thr	Gln	Asn	Phe	Ser	Ser	Glu	Ser	Lys	Arg	Glu	Thr	Glu	Tyr	Gly	
				200					205					210		
ccc	tgc	cgt	aga	gaa	atg	gaa	gac	aca	ctg	aat	cac	ctg	aag	ttc	ctc	788
Pro	Cys	Arg	Arg	Glu	Met	Glu	Asp	Thr	Leu	Asn	His	Leu	Lys	Phe	Leu	
			215					220					225			
aat	gtg	ctg	agt	ccc	agg	ggc	gta	cac	att	ccc	aac	tgt	gac	aag	aag	836
Asn	Val	Leu	Ser	Pro	Arg	Gly	Val	His	Ile	Pro	Asn	Cys	Asp	Lys	Lys	
		230					235					240				
gga	ttt	tat	aag	aaa	aag	cag	tgt	cgc	cct	tcc	aaa	ggc	agg	aag	cgg	884
Gly	Phe	Tyr	Lys	Lys	Lys	Gln	Cys	Arg	Pro	Ser	Lys	Gly	Arg	Lys	Arg	
	245					250					255					
ggc	ttc	tgc	tgg	tgt	gtg	gat	aag	tat	ggg	cag	cct	ctc	cca	ggc	tac	932
Gly	Phe	Cys	Trp	Cys	Val	Asp	Lys	Tyr	Gly	Gln	Pro	Leu	Pro	Gly	Tyr	
260					265					270					275	
acc	acc	aag	ggg	aag	gag	gac	gtg	cac	tgc	tac	agc	atg	cag	agc	aag	980
Thr	Thr	Lys	Gly	Lys	Glu	Asp	Val	His	Cys	Tyr	Ser	Met	Gln	Ser	Lys	
				280					285					290		

- 9 -

```

tag acgcctgccg caaggttaat gtggagctca aatatgcctt attttgaca      1033
aaagactgcc aaggacatga ccagcagctg gctacagcct cgatttatat ttctgtttgt 1093
ggtgaactga ttttttttta aaccaaagtt tagaaagagg tttttgaaat gcctatggtt 1153
tctttgaatg gttaaacttga gcatcttttc actttccagt agtcagcaaa gagcagtttg 1213
aattttcttg tcgcttctta tcaaaatatt cagagactcg agcacagcac ccatacttca 1273
tgcgcccgtg gaatgctcac cacatgttgg tcgaagcggc cgaccactga ctttgtgact 1333
taggcggctg tgttgccat gtagagaaca cgcttcaccc ccactccccg tacagtgcgc 1393
acaggcttta tcgagaatag gaaaaccttt aaaccccggc catccggaca tcccaacgca 1453
tgctcctgga gctcacagcc ttctgtgggtg tcatttctga aacaagggcg tggatccctc 1513
aaccaagaag aatgtttatg tcttcaagtg acctgtactg cttggggact attggagaaa 1573
ataagggtga gtcctacttg tttaaaaaat atgtatctaa gaatgttcta gggcactctg 1633
ggaacctata aaggcaggta tttcgggccc tcctcttcag gaatcttctt gaagacatgg 1693
cccagtcgaa ggcccaggat ggcttttgct gcggccccgt ggggtaggag ggacagagag 1753
acaggggagag tcagcctcca cattcagagg catcacaagt aatggcacaa ttcttcggat 1813
gactgcagaa aatagtgttt tgtagttaa caactcaaga cgaagcttat ttctgaggat 1873
aagctcttta aaggcaaagc tttattttca tctctcatct tttgtcctcc ttagcacaat 1933
gtaaaaaaga atagtaatat cagaacagga aggaggaatg gcttgctggg gagcccatcc 1993
aggacactgg gagcacatag agattcaccc atgtttgttg aacttagagt cattctcatg 2053
cttttcttta taattcacac atatatgcag agaagatatg ttcttgtaa cattgtatac 2113
aacatagccc caaatatagt aagatctata ctagataatc ctagatgaaa tgtagagat 2173
gctatatgat acaactgtgg ccatgactga ggaaaggagc tcacgcccag agactgggct 2233
gctctcccgg aggccaaacc caagaaggtc tggcaaagtc aggctcaggg agactctgcc 2293
ctgctgcaga cctcgggtg gacacacgct gcatagagct ctcttgaaa acagaggggt 2353
ctcaagacat tctgcctacc tattagcttt tctttatfff tttactfff tggggggaaa 2413
agtatfffft agaagtttgt cttgcaatgt atttataaat agtaaataaa gtttttacca 2473
ttaaaaaaaaa aaaaaaaaaa aaaa      2497

```

```

<210> 6
<211> 291
<212> PRT
<213> Homo sapiens

```

```

<400> 6

```

```

Met Gln Arg Ala Arg Pro Thr Leu Trp Ala Ala Ala Leu Thr Leu Leu

```

- 10 -

1	5	10	15
Val	Leu	Leu	Arg
	20		
Gly	Pro	Pro	Val
		25	
Ala	Arg	Ala	Gly
			30
Ala	Ser	Ser	Gly
Gly	Leu	Gly	Pro
	35		
Val	Val	Arg	Cys
			40
Glu	Pro	Cys	Asp
			45
Ala	Arg	Ala	Leu
Ala	Gln	Cys	Ala
	50		
Pro	Pro	Pro	Ala
		55	
Val	Cys	Ala	Glu
			60
Leu	Val	Arg	Glu
Pro	Gly	Cys	Gly
Cys	Cys	Cys	Leu
		70	
Thr	Cys	Ala	Leu
			75
Ser	Glu	Gly	Gln
			80
Cys	Gly	Ile	Tyr
Thr	Glu	Arg	Cys
			85
Gly	Ser	Gly	Leu
			90
Arg	Cys	Gln	Pro
			95
Ser	Pro	Asp	Glu
			100
Ala	Arg	Pro	Leu
			105
Gln	Ala	Leu	Leu
Asp	Gly	Arg	Gly
			110
Leu	Cys	Val	Asn
			115
Ala	Ser	Ala	Val
			120
Ser	Arg	Leu	Arg
			125
Ala	Tyr	Leu	Leu
Pro	Ala	Pro	Pro
			130
Ala	Pro	Gly	Asn
			135
Ala	Ser	Glu	Ser
			140
Glu	Glu	Glu	Asp
Ser	Ala	Gly	Ser
Val	Glu	Ser	Pro
			150
Ser	Val	Ser	Ser
			155
Thr	His	Arg	Val
			160
Ser	Asp	Pro	Lys
Phe	His	Pro	Leu
			165
His	Ser	Lys	Ile
			170
Ile	Ile	Ile	Ile
			175
Lys	Gly	His	Ala
			180
Lys	Asp	Ser	Gln
			185
Arg	Tyr	Lys	Val
Asp	Tyr	Glu	Ser
			190
Gln	Ser	Thr	Asp
			195
Thr	Gln	Asn	Phe
			200
Ser	Ser	Glu	Ser
			205
Lys	Arg	Glu	Thr
Glu	Tyr	Gly	Pro
			210
Cys	Arg	Arg	Glu
			215
Met	Glu	Asp	Thr
			220
Leu	Asn	His	Leu
Lys	Phe	Leu	Asn
			225
Val	Leu	Ser	Pro
			230
Arg	Gly	Val	His
			235
Ile	Pro	Asn	Cys
			240
Asp	Lys	Lys	Gly
Phe	Tyr	Lys	Lys
			245
Lys	Lys	Lys	Gln
			250
Cys	Arg	Pro	Ser
Lys	Gly		
			255

- 11 -

Arg Lys Arg Gly Phe Cys Trp Cys Val Asp Lys Tyr Gly Gln Pro Leu
260 265 270

Pro Gly Tyr Thr Thr Lys Gly Lys Glu Asp Val His Cys Tyr Ser Met
275 280 285

Gln Ser Lys
290

<210> 7
<211> 6128
<212> DNA
<213> Homo sapiens

<220>
<221> mRNA
<222> (597) .. (1110)
<223> Exon 1

<220>
<221> mRNA
<222> (2657) .. (2826)
<223> Exon 2

<220>
<221> mRNA
<222> (4041) .. (4169)
<223> Exon 3

<220>
<221> mRNA
<222> (5069) .. (5769)
<223> Exon 4

<220>
<221> CDS
<222> (762) .. (1110)
<223>

<220>
<221> CDS
<222> (2657) .. (2826)
<223>

<220>
<221> CDS
<222> (4041) .. (4169)
<223>

<220>
<221> CDS

- 12 -

<222> (5069) .. (5197)

<223>

<400> 7

```

gggggagcttg gcagagccct aggatgaact gtgttttgtt ttgttttgtt ttgttgcagg      60
ttggagcctt tttcctgcag aaagagaagc aattccgggc ttttccacag ataacctgct      120
agggctcgca gagacctgga ttctaacccc atctcgccct tcctcacctg gggcatttgt      180
ttctgcattt gagaactgct ggggtgggctg gtgttaccca ggatttttaa atttttgcag      240
gagacgcttt gcaggagatc tctagggctt ttttctgtgt caattaaaga gcctggccag      300
ctggacctgg gctgtctttt tgacaaaaac aaacgtcatc cccctcccag ctgagcactt      360
gttagaactg gactttaact gagggcctga accccctaac aacgggacaa acagtatgaa      420
atcaaaaccg tttaccctcc tcccaccagc ggtttgcgta gggccttggg tgcactagca      480
aaacaaactt attttgaaca ctcagctcct agcgtgcggc gctgccaatc attaacctcc      540
tggtgcaagt ggcgcggcct gtgcccttta taagggtgcgc gctgtgtcca gcgagcatcg      600
gccaccgcca tcccatccag cgagcatctg ccgccgcgcc gccgccaccc tcccagagag      660
cactggccac cgctccacca tcaattgccc agagtttggg ccaccgcccg ccgccaccag      720
cccagagagc atcgccccct gtctgctgct cgcgcctgga g atg tca gag gtc ccc      776
                                   Met Ser Glu Val Pro
                                   1             5

gtt gct cgc gtc tgg ctg gta ctg ctc ctg ctg act gtc cag gtc ggc      824
Val Ala Arg Val Trp Leu Val Leu Leu Leu Leu Thr Val Gln Val Gly
                        10                        15                        20

gtg aca gcc ggc gct ccg tgg cag tgc gcg ccc tgc tcc gcc gag aag      872
Val Thr Ala Gly Ala Pro Trp Gln Cys Ala Pro Cys Ser Ala Glu Lys
                        25                        30                        35

ctc gcg ctc tgc ccg ccg gtg tcc gcc tcg tgc tcg gag gtc acc cgg      920
Leu Ala Leu Cys Pro Pro Val Ser Ala Ser Cys Ser Glu Val Thr Arg
                        40                        45                        50

tcc gcc ggc tgc ggc tgt tgc ccg atg tgc gcc ctg cct ctg ggc gcc      968
Ser Ala Gly Cys Gly Cys Cys Pro Met Cys Ala Leu Pro Leu Gly Ala
                        55                        60                        65

gcg tgc ggc gtg gcg act gca cgc tgc gcc ccg gga ctc agt tgc cgc      1016
Ala Cys Gly Val Ala Thr Ala Arg Cys Ala Arg Gly Leu Ser Cys Arg
                        70                        75                        80                        85

gcg ctg ccg ggg gag cag caa cct ctg cac gcc ctc acc cgc ggc caa      1064
Ala Leu Pro Gly Glu Gln Gln Pro Leu His Ala Leu Thr Arg Gly Gln
                        90                        95                        100

ggc gcc tgc gtg cag gag tct gac gcc tcc gct ccc cat gct gca g      1110
Gly Ala Cys Val Gln Glu Ser Asp Ala Ser Ala Pro His Ala Ala
                        105                        110                        115

gtaccacagt cccgcccctg ctccagcacc tctgtccgcc cgccccgcc cggcacctcc      1170

```


- 13 -

cgccccact	cccctaacta	ctgggtgggg	ctgcagccgg	gcaggggctt	gtccacaact	1230
agagcttgaa	accagagcac	gtagttgggg	aaggagcttg	ggtcacccag	tggagcccgc	1290
tcattgcacg	gtcttggcag	gacgtgccct	gggagaagaa	ggaagatgtt	ccagggcaca	1350
catagcttag	tggagactca	aggaggaagc	tcccacttgg	ccctcgtagc	ccagggatct	1410
ttagagaccc	agacagcaag	agtagagggg	ggcgggtggg	ctgcctccgc	agttgggatg	1470
ccaccctggg	tccccacca	gtctccttgc	cagcacgtgg	gcagccccag	tggctggagc	1530
atccgggaag	gcctaagaag	ggaatccctc	ctgctggcct	ccccaggagg	tgtttggaat	1590
gtcctttgta	atatacgtcc	tggatacagt	atgtgcttcc	cagatgttta	cagaacataa	1650
tgtgagagtt	gaggctaaaa	gcttcacttc	cattcattgc	catagaaaaa	caatgtttga	1710
tgtgtatgtt	gccccctaag	aacatgacaa	tcaggttctt	tcctggattt	aagcaggcat	1770
ttgtttgtag	cggaagtgg	aggaaatgcc	tctttctcta	ctccagcccc	tatctcctca	1830
tctggactgc	ttgcacgtcc	tgtcctgtgc	cattcttggg	ggaattagga	cttccatacc	1890
ctgatagggt	gttagagtga	gtgtgtgaga	gtcagtgacc	cttccaagga	gggaacaggg	1950
atttcctgcg	gattctctgc	ccttcagagg	aaatgaaagg	gagtcgtctc	actgatcctc	2010
aaggagatgg	atttccacag	ggggtccctt	ataggccagt	gtgctgattc	tgttcatgta	2070
cctttggact	ctatctgcaa	gatactctcg	ccatgggggt	ggaggggggtg	ttgcagagaa	2130
gtccattagg	acgtgggaag	gcagggggccc	caaaatagaa	gagggtagta	gtttgggtca	2190
ggagagctgc	attctagact	ccacttctag	atgaactgta	ccatccattc	agggatatta	2250
gtaaaatccc	cattttaagg	atggagaagc	tgaggtttcg	aggctcccta	ctaatacggt	2310
taggaactga	actctaatac	tggcttcttt	agggttggtc	tcaacctcag	caaatgcatt	2370
tgttgctctg	ctcccttget	gctttaaaag	cagaaacgtg	gggcaccctt	gccaggccct	2430
gaaacttact	attgtcagga	acagagctgg	catgctgttg	ggacataact	cttctctggaa	2490
accattacaa	ggtcctttac	agtgagagtc	agtgaaaatc	aggttaggga	atgtggccat	2550
cctcatggcc	cagcctgggt	ttgaggggaag	gaagtgatct	cctggggggcc	cgaaaggggc	2610
agatgctttg	ggaggggtca	tgggggtctgc	aatgtttcct	ttccag ag	gca ggg	2664
				Glu Ala Gly		
agc cct gaa agc cca gag agc acg gag ata act gag gag gag ctc ctg						2712
Ser Pro Glu Ser Pro Glu Ser Thr Glu Ile Thr Glu Glu Glu Leu Leu						
120 125 130 135						
gat aat ttc cat ctg atg gcc cct tct gaa gag gat cat tcc atc ctt						2760
Asp Asn Phe His Leu Met Ala Pro Ser Glu Glu Asp His Ser Ile Leu						
140 145 150						
tgg gac gcc atc agt acc tat gat ggc tcg aag gct ctc cat gtc acc						2808

- 14 -

Trp	Asp	Ala	Ile	Ser	Thr	Tyr	Asp	Gly	Ser	Lys	Ala	Leu	His	Val	Thr		
			155					160					165				

aac atc aaa aaa tgg aag gtgaggccca gcaggtgggt ggtgggaact	2856
Asn Ile Lys Lys Trp Lys	
170	

ctcctgtcag aggatgtagc ttgagtcggc tgtgacaagc agacctggcc cactccttcc	2916
tggtcctgat gccctggaaa gaaatgcttt tcccccaaaa cctagtggcc atttctcagt	2976
taaactttgt caaactgtga acacatggac tttcaggaga ggagcccact ggatgcaaag	3036
aaaatgtagt tccggacgat aggttacttc atgtctctga gctcctctct aaaggggtgtg	3096
agaacattga gttacattgt tccaaaactt agtacaaggc cctaactgct ttcacccccca	3156
ttgtatgatt tgcctccctt taaaaaagtt gtcataaaat agacataaaa tgtactgttt	3216
taactatttt gaagcatagg tttctgtggc attaagtaac aataagtaat gcatgttatt	3276
ctgcaaccac taccaatatc taccttcaga attttcatct tcccaaactg aagctcggaa	3336
ctcattaaac atcaactctc cattatctta attatgtctg ttttgaattc taccacttga	3396
gggcgacaga gaatcaaagt cggagtgatt tgatttgaga aaataaatta cttccacaaa	3456
catgcctacc cagaaaaagg gaggattaaa ccattttctc aacatttttg aatttcatct	3516
gagaataacg ataaatggag gaaagttaat tcttaaatta tccaaatgaa tgccttaatc	3576
ctcacttgat ttagtttatg taaaagaacc ttgtagattg cagaggaaaag ttattcaaaa	3636
tctagaaatg tcttctgcta aattcttaat taagagttat gccactctt ctaaccagat	3696
ggcgggtgcc aaaagtattc agtaggtggc aggaagagtt ggaagagtt ttgtgggtgtt	3756
ggtgaggctc ttgccagggg atgtctctgt gcaggtgttg agagagtgat tggtagggga	3816
gagaatggtg ttcttggtct ttatctgaac aacttaagac agactaactg caggtgggaa	3876
aaagaggccc agaggagca catcacatga cacctagtcc caggtccccg tggccagatc	3936
gtagggccac tctgtcttct acaaaacctc ttccatcagt cattgtctag gctgataatt	3996
cactgtgtct tgtagatat gctaattgtca agttattctc ttag gag ccc tgc cga	4052
	Glu Pro Cys Arg
	175

ata gaa ctc tac aga gtc gta gag agt tta gcc aag gca cag gag aca	4100
Ile Glu Leu Tyr Arg Val Val Glu Ser Leu Ala Lys Ala Gln Glu Thr	
180	185
190	

tca gga gaa gaa att tcc aaa ttt tac ctg cca aac tgc aac aag aat	4148
Ser Gly Glu Glu Ile Ser Lys Phe Tyr Leu Pro Asn Cys Asn Lys Asn	
195	200
205	

gga ttt tat cac agc aga cag gtaggtggcc ttgccagtgt gcgtcgtcag	4199
Gly Phe Tyr His Ser Arg Gln	
210	215

ggtgaaaggg actactgccc tacattcctg ccaagccacg gtcattcatg tcaaagaagg	4259
---	------

- 15 -

tccactccaa	agtagacacc	agaagtgggt	gtattgagcc	agatccaccc	ctctgggaac	4319
ctggaacagc	taggtgaaga	aagcctattg	aacaggtcaa	tatgtcacca	ccagaggtgg	4379
aaaacctgcg	ctggaccagg	ggccctgggg	ctaagcctga	gctccatcac	tcagcaagcc	4439
aatagctatg	gaagactttc	ctaggccccc	taacgcttgg	atcttggggt	cctcacctat	4499
acaagagagg	aagggaacaa	acttaactta	gaaaagcaag	tatctatttg	gacagctctt	4559
aacacttttt	tctccttgaa	ctgtcttaata	aaacacaaca	acattttttgt	ggcttgccag	4619
ataataaatg	agatcaaaca	gaccaagatt	tcatattgag	gagtgcctta	ggtctcagtg	4679
aagtacaggt	tctgtagatt	ttattgggag	aaactgagga	ctaggccctg	cttcacgggc	4739
aatgaacagt	ggggcacaca	cgagacatgt	tccctctggg	atgggctccc	ctgacatcag	4799
gctatgaagc	agacagctgt	acacacactg	tactgtttaa	cacacatggg	aagtcattat	4859
tgcacatgcc	actcggtcac	tgtctctatt	ttatgatgag	aaccaggagg	gtgtgagatt	4919
tgcttgcac	atgggcagct	ggtttcacag	ccgggactct	tggttgggct	ctgcagtgct	4979
cggctgcact	gaaaaaaggg	ccagctatgg	ctctactttc	cctgtcagct	tgtcatctgc	5039
tgctcttgac	cttgggtcttg	tctttgcag	tgt gag aca	tcc atg gat	gga gag	5092
			Cys Glu Thr	Ser Met Asp	Gly Glu	
				220		
gcg gga ctc tgc tgg tgc gtc tac cct tgg aat	ggg aag agg atc cct	5140				
Ala Gly Leu Cys Trp Cys Val Tyr Pro Trp Asn	Gly Lys Arg Ile Pro					
225 230 235 240						
ggg tct cca gag atc agg gga gac ccc aac tgc cag atg tat ttt aat	5188					
Gly Ser Pro Glu Ile Arg Gly Asp Pro Asn Cys Gln Met Tyr Phe Asn						
245 250 255						
gta caa aac tgaaaccaga tgaaataatg ttctgtcacg tgaaatattt	5237					
Val Gln Asn						
aagtatatag tatatttata ctctagaaca tgcacattta tatatatatg tatatgtata	5297					
tatatatagt aactactttt tatactccat acataacttg atatagaaag ctgtttattt	5357					
attcactgta agtttatttt ttctacacag taaaaacttg tactatgtta ataacttgtc	5417					
ctatgtcaat ttgtatatca tgaaacactt ctcatcatat tgtatgtaag taattgcatt	5477					
tctgctcttc caaagctcct gcgtctgttt ttaaagagca tggaaaaata ctgcctagaa	5537					
aatgcaaaat gaaataagag agagtagttt ttcagctagt ttgaaggagg acggttaact	5597					
tgtatatattcc accattcaca tttgatgtac atgtgtaggg aaagttaaaa gtgttgatta	5657					
cataatcaaa gctacctgtg gtgatgttgc cacctgttaa aatgtacact ggatatgttg	5717					
ttaaacacgt gtctataatg gaaacattta caataaatat tctgcatgga aatactgtta	5777					
tctctgtgga tgttttattta gtgatattat ctttttgaaa tccctttgtc cttcaccctc	5837					

- 16 -

```

accttcctta tgcattttgt gcttttgtga taccaagatg gtgttttggg tctgcagagc 5897
cccttgctct aactacccta gatcttgccc cggctgcccc agggtttcca cttcccagtg 5957
gcattgggac cttcctcctc tgccctggcca ggctgggcat tcctgtgtcc cacctctcca 6017
ttagtcccca tcctccccag ggtcctcagc ctcttcctct tggtttggtt tgtcccttcc 6077
gttcaactta taaataggaa cagggtttct ttcctcttaa acacaagaca g 6128

```

```

<210> 8
<211> 259
<212> PRT
<213> Homo sapiens

```

```

<400> 8

```

```

Met Ser Glu Val Pro Val Ala Arg Val Trp Leu Val Leu Leu Leu Leu
1          5          10          15

```

```

Thr Val Gln Val Gly Val Thr Ala Gly Ala Pro Trp Gln Cys Ala Pro
          20          25          30

```

```

Cys Ser Ala Glu Lys Leu Ala Leu Cys Pro Pro Val Ser Ala Ser Cys
          35          40          45

```

```

Ser Glu Val Thr Arg Ser Ala Gly Cys Gly Cys Cys Pro Met Cys Ala
          50          55          60

```

```

Leu Pro Leu Gly Ala Ala Cys Gly Val Ala Thr Ala Arg Cys Ala Arg
65          70          75          80

```

```

Gly Leu Ser Cys Arg Ala Leu Pro Gly Glu Gln Gln Pro Leu His Ala
          85          90          95

```

```

Leu Thr Arg Gly Gln Gly Ala Cys Val Gln Glu Ser Asp Ala Ser Ala
          100          105          110

```

```

Pro His Ala Ala Glu Ala Gly Ser Pro Glu Ser Pro Glu Ser Thr Glu
          115          120          125

```

```

Ile Thr Glu Glu Glu Leu Leu Asp Asn Phe His Leu Met Ala Pro Ser
          130          135          140

```

```

Glu Glu Asp His Ser Ile Leu Trp Asp Ala Ile Ser Thr Tyr Asp Gly
145          150          155          160

```

```

Ser Lys Ala Leu His Val Thr Asn Ile Lys Lys Trp Lys Glu Pro Cys
          165          170          175

```

- 17 -

Arg Ile Glu Leu Tyr Arg Val Val Glu Ser Leu Ala Lys Ala Gln Glu
180 185 190

Thr Ser Gly Glu Glu Ile Ser Lys Phe Tyr Leu Pro Asn Cys Asn Lys
195 200 205

Asn Gly Phe Tyr His Ser Arg Gln Cys Glu Thr Ser Met Asp Gly Glu
210 215 220

Ala Gly Leu Cys Trp Cys Val Tyr Pro Trp Asn Gly Lys Arg Ile Pro
225 230 235 240

Gly Ser Pro Glu Ile Arg Gly Asp Pro Asn Cys Gln Met Tyr Phe Asn
245 250 255

Val Gln Asn

<210> 9
<211> 31024
<212> DNA
<213> Homo sapiens

<220>
<221> gene
<222> (1) .. (31024)
<223>

<220>
<221> mRNA
<222> (1) .. (556)
<223> Exon 1

<220>
<221> mRNA
<222> (27148) .. (27377)
<223> Exon 2

<220>
<221> mRNA
<222> (28449) .. (28589)
<223> Exon 3

<220>
<221> mRNA
<222> (30531) .. (31024)
<223> Exon 4

<220>
<221> CDS

- 18 -

<222> (115) .. (556)
 <223>

<220>
 <221> CDS
 <222> (27148) .. (27377)
 <223>

<220>
 <221> CDS
 <222> (28449) .. (28589)
 <223>

<220>
 <221> CDS
 <222> (30531) .. (30692)
 <223>

<400> 9
 ggcgaggggag gaggaagaag cggaggaggc ggctcccgcg ctcgcagggc cgtgccacct 60
 gcccgccgc cgcctcgtc gctcgccgc cgcgccgcg tgccgaccgc cagc atg 117
 Met
 1
 ctg ccg aga gtg ggc tgc ccc gcg ctg ccg ctg ccg ccg ccg ccg ctg 165
 Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu Pro Pro Pro Pro Leu
 5 10 15
 ctg ccg ctg ctg ctg ctg cta ctg ggc gcg agt ggc ggc ggc ggc ggc 213
 Leu Pro Leu Leu Leu Leu Leu Gly Ala Ser Gly Gly Gly Gly Gly
 20 25 30
 gcg cgc gcg gag gtg ctg ttc cgc tgc ccg ccc tgc aca ccc gag cgc 261
 Ala Arg Ala Glu Val Leu Phe Arg Cys Pro Pro Cys Thr Pro Glu Arg
 35 40 45
 ctg gcc gcc tgc ggc ccc ccg ccg gtt gcg ccg ccc gcc gcg gtg gcc 309
 Leu Ala Ala Cys Gly Pro Pro Pro Val Ala Pro Pro Ala Ala Val Ala
 50 55 60 65
 gca gtg gcc gga ggc gcc cgc atg cca tgc gcg gag ctc gtc cgg gag 357
 Ala Val Ala Gly Gly Ala Arg Met Pro Cys Ala Glu Leu Val Arg Glu
 70 75 80
 ccg ggc tgc ggc tgc tgc tcg gtg tgc gcc ccg ctg gag ggc gag gcg 405
 Pro Gly Cys Gly Cys Cys Ser Val Cys Ala Arg Leu Glu Gly Glu Ala
 85 90 95
 tgc ggc gtc tac acc ccg cgc tgc ggc cag ggc ctg cgc tgc tat ccc 453
 Cys Gly Val Tyr Thr Pro Arg Cys Gly Gln Gly Leu Arg Cys Tyr Pro
 100 105 110
 cac ccg ggc tcc gag ctg ccc ctg cag gcg ctg gtc atg ggc gag ggc 501
 His Pro Gly Ser Glu Leu Leu Leu Gln Ala Leu Val Met Gly Glu Gly
 115 120 125
 act tgt gag aag cgc cgg gac gcc gag tat ggc gcc agc ccg gag cag 549

- 20 -

tagccaggaa	cagatgcggc	agattttctc	ccattcactt	ttccctggag	cctgaagggg	2346
gtggggggta	gttgtcaggg	gaggccaggg	acaatggggg	gagttcatgg	gaagaatgtc	2406
actctggatt	ttctgcctgg	ttatgggact	cccttccgcc	agcttgcccc	agctgcgttc	2466
tcctccccag	tgcccagacg	ccttccgcat	ttttgtgcac	cggcctggga	agaggggatg	2526
ttaagcaggg	gtggaaggtg	gggggtgggg	ctggaagctg	agtgggtgca	ctcaaaagaa	2586
gtgaccaatg	tcaggggtgc	ctgagaaaga	gtcgggctgg	gggaggggag	cactttggga	2646
aggagcctga	gcttgcaagg	gtgcaggaga	aaaaggggtc	aaggttggag	gcttttgtgt	2706
gggagagggg	cttaggctgg	ggcagagact	ggagtcactg	gatggagagt	gctgggtccg	2766
agttgggtgg	ggcctggccc	agacggagat	cttagcactg	aatcctctgc	ctcccactcc	2826
atctcccgtc	ccgtcttctc	tcctctccga	agaatgagca	ccccccctcc	agcctgcatt	2886
cctctttgag	caggttgctt	ttgagaattt	taaacatacc	ctcttatttc	gaggcagcga	2946
acctcagcag	ttccggcttt	gctgttagct	cttttgtctt	tgttcccggg	actcaggggc	3006
tgtgttgctg	ctggcttcc	ggggatggca	aggatgcagg	ggtgggggtg	ggcacatcag	3066
tgggtggaag	gagtgggtgg	tggtgagcct	gtatcccacg	gggacgatgg	gctggggctt	3126
gttggttcaa	agaaactgag	aagtcagtct	tgggggaagg	ggtgggtagg	cctagaagaa	3186
aaaccgaaag	gagaccctga	gatctgcttg	aagttgggac	tctaaaagcg	tgtgtatgtg	3246
tttggtggtg	gagtggatag	aagtgcctag	aaatgtcagg	gtcgaggagg	gaacaggggt	3306
gggccagtcc	aggccctttc	agaattaagg	ctgggctaga	ccggttccct	cagtatctcc	3366
ccagcctcct	tcctaccgt	gtacaatgca	ggggattatg	ctgaggggag	gggccgccc	3426
agtgccggtt	tggcccgtg	cacgtataaa	ggtgctacag	aaatgtgtag	tcgttcaaag	3486
tcccagggcg	ggcagacagg	caggcaggca	ggcgggcggg	cgggcgggag	ggcgggcctg	3546
gggaggctct	gcactctcag	ttgccgggga	agaataaagg	ggggaagagg	caagcactga	3606
tttacagtgg	ttcagtgcag	cttcaaaaaa	aaagggggaa	aaagcaatgg	gacttctggc	3666
tcagagtact	gctttgcac	tcgtcttgca	taaatttgca	tactgagttc	aaagtcgtaa	3726
aatagactag	ggaaatgagt	gggatctact	gtcactgatt	gttaacacca	ctacctcca	3786
cctccccctc	ccccatctgg	acagaactcc	cggcactagt	tctgctaagc	agcgtgcct	3846
gagtcaccag	tcaccactgt	tcatgaaaga	aggagatggg	gaagcgcctg	tctaggagac	3906
caagcagggg	gtggcagtgt	gcaccctggc	ctcggaggca	gggcctctct	gaaggggtgtg	3966
gcccagacaga	ttctggacca	gtgaggcaag	tggtgttctt	tctgacgcct	ggggctgccg	4026
ttgcccattg	tgggctgcag	tttgaggaag	ctgcagaatc	cgggtcttct	ttgtttgaaa	4086
ttccctact	cagcttccac	atatgtccaa	aacatttact	gtgataagtc	cctttgtgtg	4146

- 21 -

gtggtaaatga	cccactttctt	tagacaagat	at ttgaggaa	ggttcgagaa	cagaaaaatt	4206
ctacttaaca	atgttaagga	atctgagaaa	agtggggcac	aggagtctct	aggttagaat	4266
agggtggtaga	gcctggaagg	agagaagaac	ccatctgttg	tattcccgag	ggctctgcca	4326
cacaatggct	cttggccaag	tggactgttg	agcttctgt	caggcagagg	gaagagggag	4386
gcttagatag	ttctcactgt	tggcctactt	cagcactgag	cttcaagact	ttcaggcaaa	4446
tcattccttc	aggctcagag	gctggaaatt	agttctataa	aaatgccatg	gggccggctc	4506
cattggctca	tgctgtaat	cccagcactt	tgggaggccg	aggcaggtgg	atcacaaggt	4566
caggagtttg	gagaccagcc	tggccagtat	agtgaaacct	cttctctgct	acaaatacaa	4626
aaattagctg	ggcatgggtg	agcatgcctg	tagtcccagc	tgcttgggag	gctgaggcag	4686
gagaattgct	tgaacccggg	agggtggagct	tgcagtgagc	tgggattgca	tactgtctct	4746
ccagcccggg	caacagagca	aaaaaactcc	gtctcaaaaa	ataaataaaa	taaaaatgcc	4806
acgggttggc	caggcgcggt	ggctcacgcc	tgtaattcca	gcacttaggg	aggctgaggt	4866
gggcagatca	cctaaggcca	ggagttcaag	accagcctgg	ctaacatagt	gaaaccccat	4926
ctctactaaa	aatgcaaaaa	ttagttgggc	atgggtggcac	ctgcctgtag	tcccagctgc	4986
tcgggactct	gaggtaggag	aatcgcttga	acctgggaac	tggaggttgc	agtgagccga	5046
gatggcgcca	ctccactcca	gcctgggcaa	caagagtga	actccgtctc	aaaaataaaa	5106
taaaaataaaa	ataaaaaataa	aaagccatgg	gttacctgaa	agtaggagca	tatccattca	5166
ctcattatct	gacctttgag	ggctgacttg	gagagaactg	ttctctggcc	cagtcatcag	5226
gtggcttcca	gttggttctc	agctgggctg	ttcacacca	tagaaaatgg	gaggtacgac	5286
tgttcaattt	cttttttttt	ttgagacgga	gactcgctct	cttgcccagg	ctggagtgca	5346
gtggtgcat	ctcggtcac	tgcaagctcc	gtctcctggg	ttcacgccat	tctcctgcct	5406
cagcctcccg	agtagttggg	actacaggca	cctgccacca	cggccggcta	actttttgta	5466
tttttttagta	gagacggggg	ttcacagtgt	tagccaggat	ggctctgate	tctgacctc	5526
atgatccgcc	cacctcggcc	tcccaaagtg	ctggggatta	caggcatgag	ccacgggtgcc	5586
cgaccaggct	aatttttttt	tttttttttt	tttttgagac	ggagtcttgc	tccgtcgccc	5646
aggctggagt	gcagtcgccc	agcctggagt	gcagtggcgt	gatcttggct	cactgcaagc	5706
tctgcttctt	gggttcacgc	cattgtcctg	cctcagcctc	ccgagtagtt	gggaattcac	5766
gcatgcacca	ccatacacgg	ttaatatattt	tgtattttta	gtagaggcag	ggttttacca	5826
tgttggccag	gttggtctca	aactcgtgaa	cctcaagtga	tctgcccgcc	ttggcctccc	5886
aaagtgctgg	gattacaggc	atgagctacc	gcacctggcc	acaactgttc	gatattgata	5946
tgaggaagtt	ctgaaaattc	tgcaccaaag	ggaatggaga	acaggtaa	acctatgatg	6006

- 22 -

cctggcagga	taggacaggg	ggctgctgaa	aggaatgaag	gaggagcaga	acaaaaaggg	6066
gctgtgaggc	cacatccaca	tctgcttttg	ttgttggtcc	ttcccgcgta	ctagaagact	6126
gtacccaaaa	gaaaagaaaa	aagcttgttt	tttttttggt	tgtttttttg	tttttacaaa	6186
gagtctgtgt	atctgggaat	tggtattttt	atttgtatta	ttatttttat	tcattttatt	6246
atttcaagac	cgagttttgc	tctgtcacc	aggctggagt	gcagtggcgc	aatctcggtt	6306
cacggcaacc	tctgcctccc	gagttcaagc	aattctcctg	cctcagcccc	ccaagtagct	6366
ggaattatag	acacctgcca	ccatgcctgg	ctaatttttg	tatttttagt	agagacaggt	6426
tttcaccatg	ttggccaggc	tggtctcgaa	ctctggacct	caggtgatcc	tcccgcttg	6486
gcctcccaaa	gtgctgtgag	tacaggcgtg	aaccactgca	cctggcctat	tttaattttt	6546
taaggaactc	tgtatccagg	gagtgcattt	cgtctcagcc	tttctctgta	tggtcccgac	6606
tcctctcttc	tcctcctgcc	ttctccatgc	tgtcctcttt	gtccctgcag	accattcttt	6666
cctttcccac	acttctccct	tccatgcctt	tcctactccg	gctcagctag	aacacctgct	6726
tgctaggtag	gtgggtgggg	ctcaaaaatg	gtgtggaaaa	tatagtggtc	tcagcctcag	6786
agatccatcc	aatcagaggg	atattatgta	ggtgactgga	gactataatg	cttgaaaaaa	6846
ctagaatcct	taaatgagga	gggtggttga	ctgggccttg	agggaaagga	cttctatagg	6906
ccagggaatg	ggattctctc	ctataagagt	tagcactagc	gctgcttctg	ctgaaaccaa	6966
ggcatagaag	cgggagatga	tgtttgaatt	catgagggaa	gctggtaacg	tggttggcag	7026
atattctaga	tcctctgtct	tatcctgtct	ctggccagca	attcactgag	atggcaggca	7086
gccgccagga	gattggtggt	gctcgcatct	gtcctcacc	tattatgaac	tggtctctgt	7146
gcctgctttg	tctcctgtct	tccacctccc	tgcgagggag	gccgttctac	ctccattttg	7206
caggtgtgga	cactgggtga	ctcagcgata	cgaaaatgct	gagaggctaa	cctgggtacc	7266
ttcccactgc	acctctctac	ctccgtggcc	gggtaaggag	ttgggctggt	ggtagagaaa	7326
agcttttgac	cgtatcaacc	agcagttttg	ttcctggaca	gctgccatgt	gcaggtgatg	7386
tatggggcac	agtaaatttc	tgccagattt	caattatgta	gattcccttg	actccatgga	7446
cagttacaag	tcctggagtt	tggggacctc	acagttgtaa	gtagccagca	tacagaggtc	7506
agtcaagagg	gacaagaagg	tcacagggtg	ggcctcttga	gagaagagct	gctgggtagc	7566
agatgatggt	gcaggcagcc	tggcctttgc	tgtcatattg	accgggggtg	gttccattgc	7626
aacctgtct	cttaataact	cagtagttag	taaggctctt	cctccaatgc	cagttccctg	7686
ttggtaaaat	agcaatgatt	ttacctcttt	cccagggtgc	gtgttggggg	ggctgtgata	7746
atggcaagta	cctggcacat	agtatgttct	tgtacatggt	agctgcctta	atcttggcaa	7806
gtgacatctc	ctccttgaca	attagctggc	ctttaaaatg	aaggccaaac	tggaaaggtc	7866

- 23 -

aggcaggcca	ctcctctctg	gaggttcaaa	tcccagggtg	tctaccatgt	actaatcacc	7926
caaggtaaga	gattttcttg	taagcctcag	ttttcttatt	tgcaaatacag	aaattgatag	7986
tattttcattg	ggtcaactac	acagatgtgt	gtaaagatat	aaactatata	taaaacctaa	8046
gctcttgcat	tttggtgatg	agtcacttga	tttccatctc	ttcacctatg	aatggaaata	8106
tccatacctc	tccaacctac	tttcacaggg	ctgtagttag	gtgggtttatg	gaaagggcaa	8166
tgaaactgta	ctttaaatgc	aatacaaatg	caattgataa	atgcaatata	aatgcaactg	8226
ataagtgc	tataaatgca	gtgcataaac	ggttggagac	catcgggctt	gcattttttt	8286
tttttttttt	tttagacaga	gtcttgctct	gtcgcccagg	ctggagtgca	gtggcgcgat	8346
ctcagctcac	tgcaagctcc	acctcctggg	ttcacgccat	tctcctgcct	cagcctcccc	8406
agtagctggg	actacaggca	cccgccacca	cgcccggtta	attttttgta	tttttttagta	8466
gagacggggg	ttcacagtgt	tagccaggat	ggtctcgatc	tcttgacctc	atgatccgcc	8526
tacctcagcc	tcccaaagtg	ctgatgatta	caggcgtgag	ccatgggtgcc	cgaccaggct	8586
tacatttttt	tttttttttc	gtgagacgga	gtctcgctgt	gtcgcccagg	ctggagtcca	8646
gtggcacgat	ctcggtcac	tgcaagctcc	atctcccggg	ttcatgccat	tctcctgcct	8706
cagcctcctg	agtagctgga	ctataggcac	ttgccaccac	gccagctaa	ttttttgcat	8766
tttttagtaga	gatgggggtt	cacagtgtta	gccaggatgg	tctcgatctc	ttgacctcat	8826
gatccgcccc	cctcggcctc	ccaaagtgt	gggattacag	gtgtgagcca	ccccgtctgg	8886
ctaggcttgc	attttttttt	tttttttttg	agacggagtc	ttgtctgtgc	accaggctg	8946
gagtgcagtg	gcgcgatctc	ggctcactgc	aagcccgcct	cctgggggtg	atgccatttt	9006
cctgcctcag	cctccccagc	agctgggact	acaggcgcac	gccgccacgc	tcggctaatt	9066
ttttgtattt	ttagtagaga	cggggtttca	ccgtgttagc	caggatggtc	tcgatctcct	9126
gaccttgatga	tccgcccgcc	tcggcctccc	aaagtgtgtg	gattgcaggc	gtgagctacc	9186
acgcctggcc	taggcttgca	tttttaaatg	attagttggg	cagtgtctct	tggatccgat	9246
gtgctgatgt	ctaggactga	ctgttttttg	tatgggagct	tctgtctgca	gtgtctagaa	9306
tgggggttg	agggactatg	gggaacagag	gtggccccag	agcttgga	tctgggttct	9366
catgctggcc	ttgtgtctca	taagcaggta	acacagggtt	gagttcctcc	ttgcctggc	9426
cagccaacct	ggaagacct	gccttctggc	tgtcagtgtc	cagagctctg	gagaatccct	9486
gaggctacat	ctctgggtgg	gggaaggtcc	tctctgtata	gatggccctc	caggggaagt	9546
ctgcaaggat	ccagacttca	gaataataga	gttaagtatt	aactaatcca	agtggtccta	9606
gcacatttag	cacatatggc	atgctcaagg	gtgtgcaatt	gtgcagtc	caaagccagt	9666
gagggcacc	gatgccacc	atttcttgca	ccaggaaaat	ggacctttca	cgtctctgaa	9726

- 24 -

cctgggatgc	cagaatgcac	tgaacttgat	cctggcaa	aaattggaag	ctgtttccaa	9786
aaaagtgata	tgttcttgct	acattgtctc	cagagtttac	tcctgagttg	gggagcagca	9846
tctcattttg	caaggggctg	ttggattctc	catagaaacg	ctgggttggg	ggagtgtctt	9906
ctgagtactg	gggctctacc	taatgtctga	ttccatctgt	ggtaccaaaa	agccctctga	9966
atggcagcct	gtctgtgcac	aatgatgccg	aagactttct	tttcagcat	ctaagaggc	10026
atggccccag	gaaagcagag	aaggcggatg	cttgagtctc	tgagggtcag	aatacgctta	10086
tggtgaaatc	agaactgggg	acaaggcaaa	gtactgccat	tggaatccg	gggtggatgg	10146
tcatgttaga	ccaggggtgt	ccaatctttt	ggcttcctg	ggccacttgg	aagaagaatt	10206
gtcgtgggtc	acacataaaa	tacactaaca	ctaaccatag	ctgatgagct	aaaaaaaaaa	10266
aaattgcaaa	aaaatctcat	aatgttttaa	gaaagtttac	gaaattgtgt	tgggccacat	10326
tcaaagctct	cctgggctgc	aggttggaca	agcttggcgt	agactcttgg	agggctttca	10386
tggtggaggc	aggaaaggaa	aagccccttt	tacagatggg	atagtaggtc	cagagaaatg	10446
tgttggtttt	cagttccaga	gtaatttcac	ctgctccac	cctccacact	cacaaagagc	10506
aggctgggtg	ggatgtcgat	ttttttttct	tctggagaat	ggaccatctc	cctatgcctc	10566
tcctcctcct	tggtactaa	cccctgactt	ttccctcccc	cttctctggc	cactcctgtt	10626
cctgaacaaa	gccagggaag	atctgggctg	gtcagcccc	tgggtgtcag	tcaagactca	10686
gaggagact	ttgctcaaaa	agccagccct	cccggaaaga	aatacagagc	aactgtagtc	10746
aggaattttt	ccctttcctt	ttttctgtgg	gcggggggag	ggacacttgg	cagtctttgg	10806
ggcccttctg	gctgccagcc	ccacatctct	tcctggctgt	tgggaggcag	ggcaggaggg	10866
aagattgggg	agaagggggc	aggggctggc	aaacaccag	ctgctgggca	gtggaattcg	10926
tccataggcc	ctggtggagt	tggcctctag	tgaagcctgg	ggaggtttct	aattagtgga	10986
ggacggtgaa	ggtgtggcag	cctgtgttca	ttcaaggaa	tgagctctct	gagccaggaa	11046
gtcaaaggga	agagggggac	tgagtcccgg	aaggccttgg	taggtgggga	ggaagtgtga	11106
cctactcagt	gtgttccatc	ctattagaag	ttgagaagag	gggggtgttt	cagctggagt	11166
gattcagggt	ggactctggg	ggtgcagaga	gtcagtcatt	ggcactaagc	aaaggagacc	11226
acctcaaaga	ataagtgata	taacagtgat	aaacaaaatg	gctttgttct	agacattgcc	11286
tgcttctacc	agaaagctca	ttttgttttt	ttgtttgtt	ttatattctt	cccctctccc	11346
acttctctgc	ccagctctgt	tttagcctcg	agattctctc	cacttaacaa	atgaagaaat	11406
caaggctaca	ttcaggttca	actgccaaag	caagcacaga	ccagattgta	gtctgggtct	11466
ctagattctt	ccagctctcc	atttcaccag	actcacacat	gcagaaaagc	agtgaattat	11526
atactgcttc	ttggaagagc	tccttttccc	tgggaagtag	taattaaggc	atatcttctc	11586

- 25 -

aaaaatgttc ctttatgcaa ctctctagga agtttctttt aggtctattg tctttacttc 11646
tggaatggagg tgccaagttg cctctgggtg gtgaacttgt tttctaaaat gcccagaggcc 11706
aagaacaaaa tgaaaatggc aattcccttg tgccctgtgc cctgccccgt gacttcctga 11766
taatgctgag cagttgctat agcaacagtg gtgggaggtg tgtcaggcag gataaagggg 11826
gtgggggtag gacaggttta ctggatcaaa gaggcttttg cggttgagta gggctgctga 11886
catgactgat agcctacttc tagggaaaga tgggggtccc atagagatgg ggaggggaag 11946
aaatgaagcc ctgggggctaa aaggtcttgc ttgagagtct ttccttaggt gatgccaagt 12006
gaccaggtgc catctggttg gttaacaacc tgggcttggg tttggccact ggctacatga 12066
ctttgtgcag ttggcctcca gctctatagt tcatttatca agtgtgaggg ggataagaaa 12126
ttaccaacct catgtgctg cttgataaca aaggtaaaca tgcaagccac gtagcacaga 12186
aactcagata atcaaatgag gtagtgcagg ttctgattct tgcaatacag gagaacagga 12246
gaatggcaga caccgctttt ggacgttttc tgattggtca tttcaagaat cctgttagca 12306
ggtgtgactt attcccttga gtgtggctta cctggacagc tgccactttg ctttgaaaag 12366
cctccagtga gtccagagag gagtcaatgg ttgagagttt tccagggggc agtcatgacc 12426
ctcgatgcca ttgtgctgt ggttctacca acagcttaat gaccaaccat gtcccattta 12486
tgccccagaa gttaggactc ccacttgagg ctctgctggg tgtctctggg ttggttcact 12546
gcctcttaaa ccttgagagc atagccaagg aaggtaatg atgtgatata ctatcagaca 12606
aaattagtga acttttagttg aagacagaga aaagcatggg gacctattta aagacactta 12666
tttatattca agacacttct tgtgctgggt tgagagtggc cggcaatcct ggacatcttt 12726
gcagggtttta aatttctttt tgcactctgt gggttcaatt tgtcaggcct ggaatatctg 12786
agagcagagt tatggggatg gagaagagga cagtggaagg ggaggggtgg gggaaagggt 12846
ggtaggattc agcctttgtt aactatggg agtggggctg tgggattgca tcatcgaaac 12906
tgaattgttt gaatgtgggt cttaggacag gcatgtgtcc ttcccatccc atctcatggg 12966
tccacttgct cactgccttt cttgacttgc tctgctctt tcttgactct taaccactct 13026
tgctgatacg ggctctagat gaggcaaagg ccagaagaat gagaaaaaga gttaatgtaa 13086
cagggtactc ttgggcaagt gctagatgct ctttgatagt gtattagtct gttttcacgc 13146
tgctgataaa gacataccca agactgggta atttcaaaa gaaagagggt taatagactc 13206
acagttccat gtggctgggg aggcctcaca atcatggtgg gaggtgaagg cacgtctcac 13266
atgggtggcag acaagagagc ttgtgcaggg aaactcccct ttataaaacc atcagatctc 13326
atgagacttg ttcactatca cgagaacagc atgggaaaga cctaccccca tgattcaatt 13386
acctcccact gggctccctcc tacaacatgt aggaattgtg ggagctacaa ttcattgggtga 13446

- 26 -

gatttgggtg	gggacacagc	caaaccatat	cagatgggtca	ccttttctaa	tgtgtaaaca	13506
ttaattgagc	acatgctgtg	tgtcagctag	gagaccatat	gaaaaagcag	ttgtcatacc	13566
acctgtaaca	catgcttttt	catgctggag	ggggacaaga	aaagcatttt	agaaagggtga	13626
ataaagaaga	aaccaaggca	gcagagatgt	atatacatcc	tatgcaaata	aacaggtagc	13686
tcttgggtcac	taaaagagct	taaccaagtc	tcttgggaag	agcttgatgt	taaataatga	13746
agtccttca	tggtaaataa	agttatgaaa	gtaagagaat	caagttggac	aggcttctac	13806
ttcttcagtc	ttggaagaaa	aaaaaaagca	gtgtcttctt	tcctaaaatg	ttaattgagg	13866
acacagaatg	tcttctcacc	tgctcttcat	tcactaagta	tggaaagctg	tacggaagct	13926
aagaccaagt	ttatgtcttc	aggaagcttc	tgctcttagg	aggactaaga	aaatgcacag	13986
acctacagct	ttttggcaat	ggactcaggc	tagagtgtgt	tgaagaaagt	tgggtcaaata	14046
taccagaaga	ctttaccag	cagtgttttt	cttttttaaa	attttgtaaa	atttttattt	14106
atttatttat	tttatttatt	ttgagacaga	gtccccctgt	tatgccagg	ctggagtgc	14166
gtggcgtgat	ctcggettac	cgcaagctcc	gcctcccggg	tttgccaccat	tctcctgcct	14226
cagcctcctg	agtagctggg	actacaggcg	cccaccacca	cgcttggtta	attttttgta	14286
tttttttagta	gagacggggg	ttcaccatgt	tagccaggat	ggtctcgatt	tgctgacctc	14346
gtgatctgcc	cgcttgggcc	tcccaaagt	ctgggattac	aggggtgagc	cactgcgccc	14406
ggcccttatt	tattttgttt	tttgagacaa	gctctggctc	tgtcacctag	gctggaatgc	14466
aattgcacga	tctcagctca	ctgcaacctc	cacctcccgg	gctcaagcca	tcctcccagc	14526
tatggcagtg	cttttcatca	atgcaatcaa	gtgacctttg	gacacttgga	ggccatattg	14586
ttcatccttc	ttccttctca	aaagggtttct	cctaagttat	accagagggga	gtctgtgcaa	14646
tttcttccca	tctgcaattt	atcagatttg	ttttgttctt	tcttatgaaa	ttcttggtatg	14706
gcttctaact	tggatctctc	ctgttttagt	ttaaggctgt	tttctctctg	gtccttgggg	14766
agacagaacg	gctccttccc	ttcccttggg	ttttcctggc	ccttggaacac	ctccaccact	14826
cagcaccttc	tggcagcacc	aggatggatt	tgctccttgg	ctttcagttc	tcaggcctga	14886
gtcatcttga	ttacttcate	ttcccccttct	taattctgtg	accctcttct	actacctttg	14946
ggtcttcttt	ctgactcatt	tccgagttct	tcatggcata	gagaacaggc	caggagccca	15006
gggctaggtt	ctgactgggtg	gacaagtgtg	cctggtaaca	tcattgccct	ggccagtgag	15066
agtggtgggtg	aagtccgcca	tgctactatc	gtttgggtcct	cttcagtag	ggcttcaggg	15126
acacttgagg	ttactgatag	ctctgcttga	tgaggaagat	gaggggtggg	tggtgtgaga	15186
ggtgactttt	ttgtttttgt	ttttattttt	gagacagagc	ctctcactct	gtcaccagc	15246
ctggagtcag	tggcgcgatc	ttggctcact	gcaaccttcg	cctcccgggt	tcaagcgatt	15306

- 27 -

cttctgcctc	agcctcctga	gtagctggga	ttacaggcat	gcaccaccat	gcctggctaa	15366
tttttgtatt	tttactagag	acgggggttc	accatattgg	ccaggctggg	ctcgaactcc	15426
tgacctcgtg	atccacctgt	cttggcctcc	caaagtgcg	ggattacagg	catgagccac	15486
cgcgcccagc	cctgagaggt	gactttttta	aaagaatatt	taaaaaatgc	agaaaagtac	15546
aaagaacaat	gtaataacac	aagtctacca	cccagaaccg	tgggcgggtg	atattttgtc	15606
cactagcacg	cagtacttac	ttagtgttta	tctttcttag	ctaagcagac	ttgcatatat	15666
gtgatagatg	actaatatgc	ctatgtttgc	atatattgca	tctatatgca	tatatatgat	15726
agatgaccaa	tattgtccaa	attgttttgt	gaaaataaat	tgaaaatgca	cataaagggt	15786
ttattttccc	tcttaacatt	agggtgtctga	gatctaattg	tgacatccat	aggtcagaaa	15846
tattcttttt	aactgctata	tattgttcct	ttgtattacc	ctactgggtt	tatttatcca	15906
ttcacctggt	gaaacacttt	tggatctggg	tgctaatagt	gtttttacaa	ctacaagtaa	15966
tgctgtaatg	accatttttg	tacatgtgtc	cctgtgcaca	tgtagagaga	agaattgctg	16026
ggtcaggcac	attcttccca	ttcccatagt	ccctgggtca	agtttgaatc	aaagcacagt	16086
ctactcactt	gggcctcagc	aactagggtca	ccttgccagg	ttcctggatg	gcttttagttg	16146
aaccaagga	gaaatgtttg	ggaccctggt	aaaggagtga	aagctgatag	tgctgtttgc	16206
catcttgata	tcagttttct	tggctcttca	aggacagctt	ggctcacggg	gccccagagg	16266
accttggctg	aatttgagca	tgtttttggt	ttctcaaact	gtctgcctca	gccctgaccc	16326
tccccagggt	tttgcaattc	caggaatgac	cctgatgttt	ataaaggagc	cctttggaga	16386
gtgcacaggc	agggagggtc	tggagagggt	gtgctgtttc	tgttcactcg	gggggagccc	16446
gagatgagat	ggcagcatga	gggcatactc	tagaaacctc	catgacgcca	ggccaggaga	16506
ggcccctctg	catgtatcca	agcaagcata	tgtgtctgtt	tacaaacca	tgagtggatg	16566
agcttacaag	gctgtgtctc	tgcaaagctt	atacccgaga	ccacctctct	tgaaaagaag	16626
aggcattggt	ctgcctcac	caggaagttc	ttcaggaaac	agacagaaca	gagagaatca	16686
caaaggcatg	ggggcctggc	aatgccagag	cttgagagga	gaggtatcat	tcaacataca	16746
gattccttag	tccttgccct	tgactttctg	gggctggggg	ccagggtctc	tatttttagc	16806
aagctcatca	gatgatttct	gatgaagagc	tatgtttggg	aacttctgac	tgggtctaata	16866
tccctgaatt	tacagatgag	tacactgaca	cctgcgcaag	ttgaacaccc	tgcttagcgt	16926
cactcagaat	cccaggggtg	gtggtgaagt	caggatcgaa	cctcagtcct	tcctcccaca	16986
ctgggactgc	ttggccaagg	cttcgaaccc	aaaagctggg	gctccaaagg	aaatccaaaa	17046
agagtttgca	gagtggtttg	acgtggaggg	gattcatcgg	ccagggtggg	gctctctgcc	17106
ctcccttggt	ggtgcatcat	ctcctgtagg	tgttttgtca	ccgtggaagg	gcagtagcct	17166

- 28 -

gtgcctgttg	ggcttgccac	tcaacagagg	tactgagct	cttccgcact	cagctgggtg	17226
attggcctgt	ggtagctgca	ggtggagggg	gatgattctc	agaagagaaa	ggccagttct	17286
tgcagtcgtg	tgatcttata	acctagggga	cttgtggatc	tgaacatct	gagaaggctg	17346
tttgagttta	tttactacca	caaaggaaac	tgggagagga	gggaccacct	gttggaaaac	17406
catgctcaga	agtgactggg	ctgttgctga	aggatggaag	gatatcaggt	gttgcattgg	17466
tggctccctt	gcaggaagga	agggtcagg	gggtgagaag	gaataggaag	ggagttttaca	17526
atgaatgaag	ctgggtgtcc	tcaggagata	gatggaccag	ttgggggtgat	gtcatttaact	17586
aagctggaat	gtgtcctgag	tgccagccta	taccgcgaca	gacatctgtg	cacactattc	17646
agaattccag	tgtgagaggc	cactgcccc	tctgaccttt	tgaaaaaaaa	agtcagggga	17706
agacacataa	acagtgtcac	tcaccacaaa	agtctcagga	cctcagggtta	aacttttagct	17766
aaagaagtaa	caaatagaac	ccccatttta	ccttcctctt	tcctaacttc	tgccctccctc	17826
cctcccacca	gcatggcctg	aattactaat	cccagcctgt	tgggtgggctg	tgctattgaa	17886
catagtggcc	acatgctaga	tggagtgttg	tgaccacat	cagccatcca	aagaggactg	17946
gcttcaaatt	ctctccaaca	aaagctgttt	cttgtatgtg	ctggcgtgtt	tatgagccct	18006
gtctcaactg	agcatgcgtg	gtgattatga	gctactgcct	gacctccttc	cctttgtccc	18066
tcccgctaaa	ttctgtaaac	aaagttaaag	taatttaggc	aaattcatte	ttgcttaagg	18126
acttctatta	aatggcagag	agctttgata	tttagcaatg	tataaaattt	gtacaatcaa	18186
aaccaagctt	tagaagaaat	atgcaataga	tcattattgca	gaactctcat	gactcatttt	18246
ttccatgcat	ttggccattc	tacaaatcag	acattaccta	gccttcccct	cacatggcag	18306
atataacttt	tattttacca	ttcaagaaat	tgattgttca	cacattcctt	tttctttgaa	18366
acaaggtctt	gctttgtcgc	ccaggctgga	gtgtagtggt	gtaatcttgg	ctcactgcaa	18426
gaagtgaact	ccgcctgctg	ggttcaagcg	attcttgtgc	ctcagcctct	caagtagctg	18486
ggacctcagg	catgtgccac	catgccacgc	taatttttgt	attttttggt	gagacagggt	18546
tttgctatgt	tggccaggct	ggtcttgaac	tcctggcctc	aatgacccg	cccacctcag	18606
cctcccaaag	tgctgggatt	acaggcatga	gccaccatgc	ctggccacca	cacatttttt	18666
tctaaagctt	ggttttggcc	acagtgagag	tttcttgggc	tgtaggggt	aaaaatacca	18726
tgtcttggtt	aacagcagcc	atcatttttag	cagaattttt	tttttttttt	tttttgagac	18786
tgagctttgc	tcttggtgcc	caggctggag	cgcaatggcg	cgatcttggc	tactgcaaac	18846
ctccgcttcc	cgggttcaag	tgattctcct	gcctcagcct	cctgagtagc	tgagattaca	18906
ggcatgcgcc	accatgcctg	gctaattttt	atgtattttt	agtagagacg	gtgttactcc	18966
atgttggtca	gactgggtct	gaactcctga	cctcagggtga	tctgcccgc	tcggcctccc	19026

- 29 -

aaaatgctgg	gattacaggc	gtgagccacc	gcgccccgcc	ccttagcaga	attgttaata	19086
tcattttttca	gacttgagaa	attagagctc	agagagggtta	aagggttctga	ctcgtgagtg	19146
aatctcaaag	ggcaaagctg	gcattcaggg	ttcttgactg	ctgggttcat	tgctcattcc	19206
agtttggttaa	tgaatcgtcc	actgctatgg	atattaatgg	agtcgtctag	agagcagggg	19266
gaggaggatg	gtgggttagta	tttattctgt	tgcccaacat	atgtcaaggc	taagtgcctt	19326
ttgggagaaa	ttaacaaaga	cggagccatg	tgagttttct	gccagctag	ggtggaacca	19386
ggaagctgcg	gccagccttc	attccccctg	cccattactc	agaattaact	cttgaaaggc	19446
ttggaatgct	attacctgtt	gcaagagggtg	agttcattgg	aggaatgata	agttcagggg	19506
tggcttagat	catctctgtg	gtactcctct	ttcccaaccc	tgctcttaga	ttttaagata	19566
atcatgagat	aggaggagaa	ggctggaaaa	tggtaaagtct	ttcttcagaa	taaagaaaag	19626
aagaaagaag	agagacacat	gagctgttag	gaagatgtga	ttgttctagg	tagggaaaag	19686
gtcttatttc	ctcaccaggt	ctggataagg	accggggcca	cacactctga	ggaggaagga	19746
ccagggaggt	gcttttagat	tcttggggct	tagtttccta	agaaagcttt	ttaaggctct	19806
tcttagatca	ggaatcacca	atttccaaat	agagcactga	ggtcagaaca	ttgtgctagg	19866
agaaaatgag	attttgtggg	agtccgtttc	tatcaaacac	aagagtttga	tttgttgagt	19926
aagatcattg	atgcaacaaa	caggattaca	ttggaaaaat	gagctgtgcc	aaaattaggt	19986
ctgaaaacct	gggtatgaat	gcatagaagt	gaacaataaa	ggctctttct	cttgggctgt	20046
cagcttcag	ctgctctcct	tggctaaatt	agtaagggtg	ggccaaaaga	caatgtaggg	20106
accccatgat	aattgtgaag	aatggcagag	aggttgtttg	ctcctgtgaa	ttcaaagtgt	20166
agtccatctg	ggctcaggtt	tgccatctgt	aaaatgggac	aacgatccat	ttcttttcat	20226
cccatctgcc	ttcctcatct	ccagctctcc	tctaggggtc	ttaggtagaa	aggtgtggca	20286
gtctacccaa	ggcaggggtg	ggagttctcc	cctgcccttc	aagccccga	ctaatggctc	20346
tgggggtgtc	tgtcatctcc	ctgacttctc	tttggaaaag	cttgaccttc	tatatgtgaa	20406
atcccttget	tctgtgttga	ccattttccc	taggtgctat	gtagggaaga	agagctaattg	20466
cttactaatc	tacagggaaa	gtctcttcag	gggccttgga	ggtttctatc	aaccattttct	20526
aagcccatga	gcctttttcca	ttgatgtcat	ttgggggttg	taagaacctat	ttcttatagt	20586
gacctttgca	ccatagccca	tggagttgca	tacataagtg	gttgcttaat	aaatattatt	20646
ctgaacttaa	ctctcttagg	cagaaaaaaa	atacaacttg	gtatttttgt	tctgagggca	20706
aattccatct	ctagctggag	ttcgacatct	ggaatgtttt	cctgtggatt	gttcttgcag	20766
cctataagag	gatatatggg	aagaacttgg	taacatgtga	taatgccctt	gtctgactga	20826
ggggaggagg	ggcgctatgt	gggtacttcc	tggtaggcag	gaaatggaag	tggctaagag	20886

- 30 -

ctaaccat	gtgtgcctac	tgtgtgccag	gccctctctg	tagatgcagg	cagcatctct	20946
ttggatcctc	ccagttgccc	ataggaggtg	catactgttt	gtccttttac	agatgaacaa	21006
tggaagcaca	gagagcttaa	gaaagttgtc	tggtgctgca	cagctcagta	gtaaaagctt	21066
gaattccaac	tcaggcagtt	agattttggg	gtttgaatct	ctttggctgg	gaacagtaac	21126
aaggaatgca	ggcttttctc	agcctacaat	gctttctgat	ctctgcctgg	tcaactcttt	21186
catttccctt	ccctgggctt	ctacttcaag	atgtggagtt	cagatctggc	tacgggattt	21246
gagtccagaa	gcctcttcct	gagaaagaaa	cagatgctga	tgcatgggtct	tggttaaacca	21306
tctttaaaag	accttgcctc	agcaaaccag	gcctgtggat	ttcttcatct	tattggcatg	21366
ttcgttggca	ctgctgagat	caataaagaa	atggaatgaa	acataccctt	gaatccaggt	21426
ggcctctgtg	aggggtggaca	aacttgacct	tcacctcaga	gagtttggga	catctcaggg	21486
caggaaatca	actttgtcct	cctggaggaa	cactgccaa	ttgacccag	cctcctggga	21546
cctggagcca	gggttgcata	tgacatctgt	gggccctgga	cactgcctct	gtgggccctt	21606
ctataaaaac	atatattttt	aaaatttaaa	aattattatt	tttcgttttt	gagacagggg	21666
ctcactctgt	caccagggt	ggagtgcagt	ggcatgatca	tggtcactg	cagcctctaa	21726
cccctgggct	caagtaattt	cccacctcag	cctcccaggt	agctgggacc	acaggtgtgc	21786
atcaccatgc	ctggctattt	ttttattttt	agcagagaca	aggtgatata	gttaggcttt	21846
gtgtcgccac	ccaaatgtca	tcttgaattg	taatcccat	aatcccagg	tgttgatgga	21906
gagatcaggt	ggaggttaact	gaatcatggg	ggtgggtccc	ccatgttggt	ctcgtgatag	21966
cgagtgagtt	ctcctgagat	ctgatgggtt	tataaggagc	tcttccccgc	ttcacctggc	22026
acttcttctc	gccaccttgt	gaagaagggtg	ccttgcttcc	cggacctttg	gcttctacca	22086
cgattgtgag	tttctgagg	cctccccgcc	atgctgaact	gtgagtcaat	taaagctctt	22146
tcctttataa	attaccaggt	ctcaggcaggt	tttttatagc	agtgtgaaaa	tggaactaata	22206
cagtcaggcg	tggtggctca	tgccataaat	cccagcactt	tggaagaccg	aggtgggcct	22266
cctgtggcaa	ggagttcaag	accagcctgg	ccaacatggt	gaaatcctgt	ctgtactaaa	22326
aatacaaata	ttaaccaggc	gtggtgacac	atgcctgtag	ttccagctac	tcgagaagct	22386
gaggcaggag	aattgctcaa	accaggagg	cggagggtgc	agtgagccaa	gatcgtgcca	22446
ctgtactcca	gcctgggtga	cagagcgata	ctctgtctca	aaaaaacaaa	aaaaaaaaat	22506
caaaaaacca	tattttataa	cttgtttaaat	aaatgcaaat	gtattaatat	tatatagtaa	22566
gacttttttaa	cctaaaagtt	atTTTTTTTT	tctgatgtta	atagaaataa	aaatatgtcc	22626
taggcactgt	gcctccagag	cccaatggac	aagttggccc	tgctgggcgc	cttcaggccc	22686
gaatgcacat	ttatctgtgt	gtgcccctct	cctttttcaa	atgtgtttcc	agagattgca	22746

- 31 -

gagggccttc	ttctgaggat	taatgttggg	ttgacctctg	ggacgcagcc	aagggatggt	22806
tctttggcca	ctgtctgtgg	tacaagaggg	cttcgtgaag	atggggagct	gcaggctgaa	22866
agtcctctag	gaagcccagg	gaagatcctg	tgccctgccc	ccaagaaact	gtggactatt	22926
gtggctgcag	atggaagggg	agcggagggg	tcttagccgt	ggatgcggaa	tatagtggag	22986
ctagatttgc	tttatatggg	gcctggagcc	atttcagcaa	tgggctatca	gcttacagggt	23046
cttgggctaa	aagcctgact	ccagaagagt	gattctcacc	ctgggcagtt	ttgcctctcc	23106
ggggccattt	ggcaacgaat	gaagacacat	tttttgttgt	tccaacctgg	ggaggggtgct	23166
actggtttct	ggtgggtaga	ggccaggaat	gctgcccac	atctggagta	cactggatgt	23226
tccaggcatt	gagttcgggt	gagcggctcc	ttcccagaag	ctcatggata	gaggtacaca	23286
tgagctgcct	ttcccgtctc	caaccagaca	acgtgttgtt	atagccataa	tagagactgt	23346
ctgccttcac	ccaagccact	tccaagagg	gcagagccag	gtgagcctct	gagcatcaca	23406
gacttcatgt	ccacagattg	gagagttcca	gaaatggtgg	caggggtgcag	taccagcaga	23466
ctcccagagc	tctgtcttct	tctaacaccc	tgtgagcaga	atgcggtgtc	gaggtctcca	23526
gaaacccttc	ctgcctctgt	gggcacaaag	ctgggtaggg	tgcggttaagc	aggggtgatgc	23586
caaggggtgat	ctcaggtacc	aaggggttcgg	gtgagggcga	actggaggtt	cccacttcat	23646
tttgtcttct	tcattttgat	cctgagtagc	tgggagggag	tcaaagggct	cttctctatg	23706
ttccaatgca	ggtggtggga	gtggggagac	tttctagcta	ctttgctctc	ctcctgtgtt	23766
tttggtgtct	gcagagggca	ggggcagggg	gcttgagatg	gtcccactca	ggtctggggg	23826
cagagaggcc	tgtctgggaa	gggcagcggg	gcggaggcag	ggaggctggg	gatgagtgcg	23886
tgcgctgcac	ggcatctgtg	tgctgcgtta	gaggtcagtg	ttgagatgga	aagttgactg	23946
aacctgatct	cttctgtttg	ttgtccagggt	ttgtctgac	tcagactttc	cccggccttt	24006
ctctttcacc	cttttgtttc	tgacctctgg	ggtccatctg	aagaggggaag	gggggctctt	24066
ctaggagggg	gtggacctgg	tggcgctgaa	gaaatctgcc	gcacgggtggg	gtgactcagc	24126
gtccctgttc	ttgggaacct	ggcaggcagc	tgagcagggg	cactcactca	gcctgcctct	24186
ctgggtccct	gggtgtctgc	tgctctccat	gtggaggagc	acagaggggca	gggcaggatg	24246
gatgaggaaa	gctgtgggct	ggtgcctggg	tctgattaga	catggtggag	caggactcca	24306
acctagcctg	gaggcgcacg	ctaaatcggc	cttttcctgc	cgggtggtgct	gggctgccgg	24366
gctgctggaa	caatttaatc	tgtgctggct	tcatttatgg	tacaaccag	gctcccaga	24426
gccctgtgg	gaataaccat	tctaaataaa	atatttttcc	aggtttcagg	tttatacatt	24486
taacatttaa	atTTTTTTTT	tcctggagtt	caacaatttt	ggataaaaagt	cttttaaaat	24546
gatgaatagg	tagaatttta	attccctccc	ctttttgatg	tccaagatc	atcgtcatca	24606

- 32 -

acgtaattct	tgttttgggc	tgtaagacat	ggaaatcccc	agggttcatt	gaggggcatt	24666
cattgtttgc	cacacacaaa	atgtacccgg	agtttgtatg	ttttgttttc	ttagtgtcct	24726
ctttcctctc	tgccatttga	tccttccttg	tactgtccac	atgcattcct	tctttgtccc	24786
ttcaattttg	ttgactttct	tctgcggtgg	ccttggaaac	cagacatcca	gaagccaggc	24846
ttcctggagc	agcactgttg	tgaactgtct	cgaggctcct	cacgagatga	ttctcccctc	24906
atcttgagtg	gaaagtgcc	acatttgaac	atgctcagcc	gtggtaacag	ctattaggat	24966
gttcagagct	tattttcctt	ggtttccctg	ttctcggttg	ggttccatgc	tgctgaagta	25026
gtagataact	ggggcattcg	tcattgtcat	catcatcagt	gtaataacca	gcagcaacat	25086
ggatatagaa	tttctgtgct	ccaggtcgtc	ttttatttat	ttatttattt	atttatttat	25146
ttatttattt	ttgaggcagt	gtcttgctct	gtcgcccagg	ctggagtaca	atgggtgcga	25206
ctcagctcac	tgcaacctcc	acctcctggg	ttcaagcaat	tgtcctgtgt	cacctttctg	25266
agtagctggg	attacagggtg	tgtgccacca	cacccggcta	atttttttgt	attttttagca	25326
gagatggggg	ttcaccatgt	tggccaggct	ggtcttgaat	tcctgacctc	aagtgatcca	25386
catgcctcag	cctcccaaag	tgtctgggatt	ataggcatga	gccaccacac	ccggcctaag	25446
tcacttttta	actgcttttc	tttcgtcata	ctctcaacag	ctctatgaag	aaagaactgt	25506
tattatccag	caacttacag	ttaagaaagt	agaggcacag	agagggctctg	tgtggggaga	25566
acacgtgcag	ctgatataga	aaatggcaga	gctggacttt	aacccggcta	caccttttta	25626
accagagctg	ctacctggg	gacggcgtgc	tggcttctaa	aggaagctgc	tgcatggcaa	25686
gtgaagagtg	actagtcttc	aggcttggag	ggaggggaaa	ggacagggac	agacccccat	25746
caaatgttcc	gtatgctggg	gcctatgctg	ggcacgcctt	gacagcaggt	gctgctggag	25806
tgccagcacc	cggtgctgtc	cctggcatgg	aagagggtgcc	ccctccctta	gttggtgagt	25866
gagtgaatac	tcttgtatag	agttactcta	agaattattc	atthgtgttc	taagggtctgt	25926
aagtttttga	agggtgcatta	atggggaaga	aaaaatgtgc	aagattgggt	gaaaaacacc	25986
cctctgcacc	caccagatc	ttgttgggac	ctgcaggaga	gcagctctgg	gtgggagggg	26046
ctggggctgt	ttgccgtgtc	tccaaggggt	tggggctggg	gctcggcggt	gtgaggccct	26106
gcccttctgg	agcttgctgg	ggcttgtctc	ctggttacag	ctctgccgtg	cgattcagat	26166
cctctctgcc	tcctttggct	ggacgtgcct	cagccagagt	gagactgtgg	caggctggag	26226
ctgttttcaa	ggcctccttc	acctaggctg	tgcatacaaa	aggttgaaga	aagtataagg	26286
agacttaatg	gacgcttggt	ggacagacat	cacgaagctt	catgccctgc	agtaagctga	26346
agctatgaag	tcgaaggagt	catagtccct	gttcttgggg	ctctcagtat	aatgggggtg	26406
gggtgggctg	cacagacaga	cttgggaacg	agggaatgtc	agtgtggcag	agctgtagct	26466

- 33 -

gcctcggagc	agcactatg	gaccttaggc	agggccaggt	gggcagggtac	acagtgcacag	26526										
caggggggatg	ctgggaccag	gttctgggtg	gcgacgtggc	cttccacctt	ctcactcctt	26586										
tgccatatat	gctgcagccc	ggtgatgtct	gtggcacgag	ttttaaaaaa	ctcaactaat	26646										
tggtgctctt	ccagaccaca	aatgaagaac	tttaaactgg	gggttatagt	gggagaattt	26706										
gggggggtcc	cagaaaggac	ttaaaccat	tccatgggtca	gggcctttca	aatgcattca	26766										
tccctctgtg	tgccctctgtt	ctgccccagc	cttgtaagag	ggtcctctgc	attcttctag	26826										
agccagacag	cctgatttca	aatcctgaat	ccatcgcttt	tcagatttgt	gatcttggtc	26886										
aagtaactga	cctctgtgag	cctcaaattc	tccatctctg	aaagttgggg	agggtgctag	26946										
tagtaccac	ctaagagtta	gggtgaagct	gaaattgatc	atccatataa	attgctcagc	27006										
acggggccctg	acaggccatc	agcactcatt	agccgcgcgt	catctccacc	ctcatcatca	27066										
ttacgggtcca	ggtggctccc	ggagggcacg	tctctctggg	aaactggacc	tggagctttt	27126										
cttcccttcc	tctcttggca	g ac	aat	ggc	gat	gac	cac	tca	gaa	gga	ggc	27176				
		Asp	Asn	Gly	Asp	Asp	His	Ser	Glu	Gly	Gly					
				150					155							
ctg	gtg	gag	aac	cac	gtg	gac	agc	acc	atg	aac	atg	ttg	ggc	ggg	gga	27224
Leu	Val	Glu	Asn	His	Val	Asp	Ser	Thr	Met	Asn	Met	Leu	Gly	Gly	Gly	
		160						165				170				
ggc	agt	gct	ggc	cgg	aag	ccc	ctc	aag	tcg	ggt	atg	aag	gag	ctg	gcc	27272
Gly	Ser	Ala	Gly	Arg	Lys	Pro	Leu	Lys	Ser	Gly	Met	Lys	Glu	Leu	Ala	
		175				180					185					
gtg	ttc	cgg	gag	aag	gtc	act	gag	cag	cac	cgg	cag	atg	ggc	aag	ggt	27320
Val	Phe	Arg	Glu	Lys	Val	Thr	Glu	Gln	His	Arg	Gln	Met	Gly	Lys	Gly	
190					195					200					205	
ggc	aag	cat	cac	ctt	ggc	ctg	gag	gag	ccc	aag	aag	ctg	cga	cca	ccc	27368
Gly	Lys	His	His	Leu	Gly	Leu	Glu	Glu	Pro	Lys	Lys	Leu	Arg	Pro	Pro	
				210					215					220		
cct	gcc	agg	gtcagtgagg	gtcaggtctg	gtggaagggg	tgaggaggaca										27417
Pro	Ala	Arg														
aggaaagtgg	ggtctcagct	ggaggagggc	atcctaataa	gaccctcatc	tggtgtgacc	27477										
tgtaggcaaa	gcacttttct	ttccacaaac	atagttgtgg	aacatagtta	gtgacctttg	27537										
gggcagtcag	tatctctggc	tgtgaaatag	actggacatg	tggtttcttg	atgttctttc	27597										
cttctaaaaac	cttcacattt	ctgtatggtt	ttggaacata	gacacagaaa	atgaatccca	27657										
gagatgaaga	cagagtcctt	gaaacttgct	tactcttttt	tttttctctc	ccctgagatg	27717										
gggtctcact	ctggtgcccc	ggctggagtg	taatggtgcc	atcacacctc	actgctgcct	27777										
ccaactcctg	ggctcaagtg	atcctccttc	ctcagcctcc	tgaacagctg	ggactatagg	27837										
catgcaccac	cacacctggc	cagttttgta	ttttttgggtg	gaaatgtggg	tctcactatg	27897										

- 34 -

ttgtccaggc	tggtctcaaa	ctcctggact	caagcaatcc	tcccacctcg	gcctcccgaa	27957
gcgctgggat	tacaggcgcc	agccactgcg	cctggcctga	aactcagtct	tggtgccata	28017
tgcttctctc	actgagctac	ccctcccctc	tttcctgccc	agctctgcca	tcttgggtcc	28077
tggccctggt	tggttttatg	gaaagaagtg	gagcttgggc	atgggggtggg	ggcatggaga	28137
ctcgagacgg	ccacttagat	ggatatattg	aggcagagcc	cattctgaca	catgaaagcc	28197
acggtcacag	aacaaggaga	ggagtgaaca	ttcccatcca	tacaattttc	tttaggggct	28257
ggggttgggc	accagcatg	gcagggagat	ccccgggcag	gctgtcagaa	gtccctgtgc	28317
cccctgctgg	ctgtgtgacc	atgggaaagt	cccctccctg	tgcagcagct	tctcgtctgag	28377
cttgcgctctg	gcgcgtgctt	cgtagggcctg	ctgtcctcac	tccgggcgtc	ccctgctgtc	28437
tgtgctgca	g act ccc tgc caa cag gaa ctg gac cag gtc ctg gag cgg					28487
	Thr Pro Cys Gln Gln Glu Leu Asp Gln Val Leu Glu Arg					
	225		230		235	
atc tcc acc atg cgc ctt ccg gat gag cgg ggc cct ctg gag cac ctc						28535
Ile Ser Thr Met Arg Leu Pro Asp Glu Arg Gly Pro Leu Glu His Leu						
	240		245		250	
tac tcc ctg cac atc ccc aac tgt gac aag cat ggc ctg tac aac ctc						28583
Tyr Ser Leu His Ile Pro Asn Cys Asp Lys His Gly Leu Tyr Asn Leu						
	255		260		265	
aaa cag gtgagcatgg tgccagcctg ggccagagca gtcctcctc agccctgggc						28639
Lys Gln						
270						
cccagatgtg ccttgtttct gccccacccg cctatgatcc tctgaggctc gagctgagtg						28699
agagactcag actcctgtca ccatggggat tgggatgcc a gctgccaggc cggggagggt						28759
gcagctcttc tccctgcctc cgacgggtca gttgctggct ccacttgccc agctgcccac						28819
cggcctcact tggagtccag gttgggagga ggctcttgga gaagggaagt ggcttaaacc						28879
aagcatcttt gctttgatcg gacattgaca tcacctggag ctcttcctgg gcccgcccc						28939
aaattgccat gtggtaggtc aggtttacag ctctaacaag cctcaggtga ggctcataat						28999
ctgtgagcca cactcccacc atcattgatt tcaaccactg gccgagttgt cttcatgggt						29059
tcgaagtatc tcagggaatg aagagtcagg catggagaaa tgccgttgga aagattctga						29119
aaagccatct agaacaccat tgtaaataca ttggagaaaa tgaagtttaa gtaaaccact						29179
caggagccct tctccctcct ctatccacct tctgttcata tgcattttaa cagtcaactgt						29239
gcatatgcaa tattttccct gtaacatact tttttttttt ttttttttga gacggagtct						29299
cgctcttgtc tcccaggctg gagtgcagtg gcgtgatctc agctcactgc aacctccgcc						29359
tgccgtgttc aagcaattct cctgcctcag cctcctgagt agctgggatt acagggtgcct						29419
gccaccatgc ctggctaatt tttgtatttt tagtagagat ggggtttacc atgttggcc a						29479

- 35 -

```

ggctgggtctt gaactcctaa cctcagatga tccccccacc tgcacctccc aaagtgtctgg 29539
gattacaggc atgagccacc acacctggct gggcattggg atttttataa agctaccctg 29599
gtggtttctaa tggcagtcctg ggctgacctt aagtgtggat gtgtgaagcc aggagatggg 29659
aacagggctc tgctgatggc ttaggggtct cacctctcca ccccttcac ccaggcacct 29719
tgacctcta aatattagtt tagtattaaa agctatttgt gtacatgccc tctaaatgta 29779
agctggctaa ctccatttgg agctcagaag aaaaagtctc gatcacttct catgggaaac 29839
aggctgtctg ctgcaccttt gggtaactaa agtgatttgc aggagtagtt agcttatgca 29899
taaaacagag accttggagt gggaatgcct ggcttccatc tcagctgtgc ttcttaccag 29959
ctgtgtgacc ttgggcaagt tgcttagccc atctgtgctt cagttttatc atctgtaaac 30019
cagggataat aatggcatct aattcacaaa gtggttgtga ggattaaatg actatatattg 30079
ttagaaactg aactagcagt gtgtcttgca cacacagtgc ctggcacaca ctgattttga 30139
ttgcaacatg aggttttaca cctgacgcta tgactaagct tcagtatgct ggggtcccccc 30199
cactggatgg gacctctttg aggctgggga ctgagtcttt tcactctcgg gtgtcctgaa 30259
tggccttgct aatcagaggg gtccctgggc gggcagcatc agcatcacgt tggagctcgc 30319
tagcgatgca gaatttccag ctctccaggg acctactgca tgggaatctg cattttatca 30379
aggtttctg gcgcataatt gaagttgcga agctccaccc ggcagcgcac gggtagctgc 30439
aaggggtggc tgctcagtgg acgccgggtt gagggacaga aggaaagttg ctggctgcgg 30499
gctcctccat gctcttctcc tctctcccca g tgc aag atg tct ctg aac ggg 30551
                                Cys Lys Met Ser Leu Asn Gly
                                275

cag cgt ggg gag tgc tgg tgt gtg aac ccc aac acc ggg aag ctg atc 30599
Gln Arg Gly Glu Cys Trp Cys Val Asn Pro Asn Thr Gly Lys Leu Ile
    280                                285                                290

cag gga gcc ccc acc atc cgg ggg gac ccc gag tgt cat ctc ttc tac 30647
Gln Gly Ala Pro Thr Ile Arg Gly Asp Pro Glu Cys His Leu Phe Tyr
    295                                300                                305                                310

aat gag cag cag gag gct cgc ggg gtg cac acc cag cgg atg cag 30692
Asn Glu Gln Gln Glu Ala Arg Gly Val His Thr Gln Arg Met Gln
                                315                                320                                325

tagaccgcag ccagccgggtg cctggcgccc ctgcccccg cccctctcca aacaccggca 30752
gaaaacggag agtgcttggg tgggtgggtgc tggaggattt tccagttctg acacacgtat 30812
ttatatattg aaagagacca gcaccgagct cggcacctcc ccggcctctc tcttcccagc 30872
tgcagatgcc acacctgctc cttcttgctt tccccggggg aggaaggggg ttgtggtcgg 30932
ggagctgggg tacaggtttg gggaggggga agagaaattt ttatttttga acccctgtgt 30992
cccttttgca taagattaaa ggaaggaaaa gt 31024

```

- 36 -

<210> 10
 <211> 325
 <212> PRT
 <213> Homo sapiens

<400> 10

Met Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu Pro Pro Pro Pro
 1 5 10 15

Leu Leu Pro Leu Leu Leu Leu Leu Leu Gly Ala Ser Gly Gly Gly Gly
 20 25 30

Gly Ala Arg Ala Glu Val Leu Phe Arg Cys Pro Pro Cys Thr Pro Glu
 35 40 45

Arg Leu Ala Ala Cys Gly Pro Pro Pro Val Ala Pro Pro Ala Ala Val
 50 55 60

Ala Ala Val Ala Gly Gly Ala Arg Met Pro Cys Ala Glu Leu Val Arg
 65 70 75 80

Glu Pro Gly Cys Gly Cys Cys Ser Val Cys Ala Arg Leu Glu Gly Glu
 85 90 95

Ala Cys Gly Val Tyr Thr Pro Arg Cys Gly Gln Gly Leu Arg Cys Tyr
 100 105 110

Pro His Pro Gly Ser Glu Leu Pro Leu Gln Ala Leu Val Met Gly Glu
 115 120 125

Gly Thr Cys Glu Lys Arg Arg Asp Ala Glu Tyr Gly Ala Ser Pro Glu
 130 135 140

Gln Val Ala Asp Asn Gly Asp Asp His Ser Glu Gly Gly Leu Val Glu
 145 150 155 160

Asn His Val Asp Ser Thr Met Asn Met Leu Gly Gly Gly Gly Ser Ala
 165 170 175

Gly Arg Lys Pro Leu Lys Ser Gly Met Lys Glu Leu Ala Val Phe Arg
 180 185 190

Glu Lys Val Thr Glu Gln His Arg Gln Met Gly Lys Gly Gly Lys His
 195 200 205

His Leu Gly Leu Glu Glu Pro Lys Lys Leu Arg Pro Pro Pro Ala Arg

- 37 -

210	215	220
Thr Pro Cys Gln Gln Glu Leu Asp Gln Val Leu Glu Arg Ile Ser Thr 225 230 235 240		
Met Arg Leu Pro Asp Glu Arg Gly Pro Leu Glu His Leu Tyr Ser Leu 245 250 255		
His Ile Pro Asn Cys Asp Lys His Gly Leu Tyr Asn Leu Lys Gln Cys 260 265 270		
Lys Met Ser Leu Asn Gly Gln Arg Gly Glu Cys Trp Cys Val Asn Pro 275 280 285		
Asn Thr Gly Lys Leu Ile Gln Gly Ala Pro Thr Ile Arg Gly Asp Pro 290 295 300		
Glu Cys His Leu Phe Tyr Asn Glu Gln Gln Glu Ala Arg Gly Val His 305 310 315 320		
Thr Gln Arg Met Gln 325		

<210> 11
 <211> 10884
 <212> DNA
 <213> Homo sapiens

<220>
 <221> promoter
 <222> (102) .. (1905)
 <223>

<220>
 <221> mRNA
 <222> (1906) .. (2440)
 <223> Exon 1

<220>
 <221> mRNA
 <222> (5726) .. (5952)
 <223> Exon 2

<220>
 <221> mRNA
 <222> (6497) .. (6616)
 <223> Exon 3

<220>
 <221> mRNA

- 38 -

<222> (8212) .. (10775)
 <223> Exon 3

<220>
 <221> CDS
 <222> (2038) .. (2440)
 <223>

<220>
 <221> CDS
 <222> (5726) .. (5952)
 <223>

<220>
 <221> CDS
 <222> (6497) .. (6616)
 <223>

<220>
 <221> CDS
 <222> (8212) .. (8334)
 <223>

<400> 11
 ctgcagacct gggacctcaa gaattgcatt tgatgccgaa cccagctcta atttcagagt 60
 caaggtctct gcgagtatct aaggaacgga tgtaaacctg ggggattcgt tttgtttcct 120
 tcaattttcc aatgaaatca gagatcctgt tcttggtgt caacgcagat actagaagga 180
 ggtgatacaa gagaaaggaa acagcaagcg acgattatgg cacgggtttcc tgtaaacaag 240
 gttgagtgt gccacagcct gagcactgtg ggagaagagc tcataagaaa atgacgggtgc 300
 tgggccttcg tcaccccggg gccctccatt gttcttgtct ttggtctctt tttatttgta 360
 gaggtccaat tattttattta tttagtacaa gagggaacga aattgatctt tccattctaa 420
 aaggagagta tatatgtata aaaggaagct gtatagatat gggggaagag gtggacaggg 480
 ggaaaagggg agaggacgag agagagaaaag ggaggagag ggacaaggag agacactggg 540
 cgagagatcg attaggagag acagaaatga tgaatgaaga ttaacttcac ccaaggcttc 600
 gtcgctggag ggggaatggag gagctcctga tttgctatta ctactccaaa ctgcaaaggg 660
 ctcttcaag tcacctatcc acctcctaag gcaagcgtcc aatttcaaca gcgttcagga 720
 aagtctctc cgcggagggt ctacccgctt cccactccac cccacaaaac tctttggaaa 780
 agtgccttga aaaattttaat cctcaatcca atcctggacc accagcgtcc tctgttggtc 840
 accgaaggag ggggtgcgca gacaaaactg aagaaactcg agtgccagag aaggccgaca 900
 ggagttacag cgacctcagc gcgcaattgc gcccgaact ttactgaaaa gtgttttagat 960
 tgagagata agctagaatc ccaacgcac gagaaatag taatacgaag tcgccttcaa 1020

- 39 -

aaaatgacaa tgaaaattgc ctattaaagg actatttgggt taattacggt tcagcagtgc	1080
ccagtttatt gtctttatta ttcttttgtc gtgggtgtaa actccatttg aaaacataat	1140
cagggagaat acccaagaca agaagaacag ttgtcattta aaatatttga aaagccctgc	1200
cttaaggagc attcgcttgc cggtcactc ttaattgggg acttgcggtg tagcaacacg	1260
tgagagtctt cttgcgttga gaagtaagcc tggaaaggcg aaggcccccg ggcattctca	1320
gatgcgtatt tgtgggcccc tggggatata aacagcccag cgggtgtaaa ttaaaccctg	1380
cagtgccttg gctccctgag acccaaattgt aagtcagaaa tgtcccaaga cttcgcttgc	1440
caacggaatt aaattttaga aagctccacg aggtacacac gaatgcggag cgctgtatgc	1500
cagtttcccc gacaccggct cgccgcaggg agacctcacc ccgagagcgg aaggggtaag	1560
ggcggcgggg tcaaggagat cgggggtgct gagttggcca ggagtgactg gggtgaccgg	1620
gggtgctgag gtggcctgga gtgccgggggt ggccgggcac accttggttc ttgtagacga	1680
caaggtgacg ggctccgggc gtgagcacga ggagcaggtg cccgggagag tctcgagctg	1740
cacgcccccg agctcggccc cggctgctca gggcgaagca cgggccccgc agccgtgcct	1800
gcgccgaccc gccccctcc caacccccac tcttgggcgc gcgttcggg gcgtgtcctg	1860
ggccaccccc gcttctatat acggggccggc gcgccgggc cggccagatg cgagcactgc	1920
ggctgggcgc tgaggatcag ccgcttcctg cctggattcc acagcttcgc gccgtgtact	1980
gtcgccccat ccttgccgc ccagcctgcc aagcagcgtg ccccggttgc aggcgtc	2037
atg cag cgg gcg cga ccc acg ctc tgg gcc gct gcg ctg act ctg ctg	2085
Met Gln Arg Ala Arg Pro Thr Leu Trp Ala Ala Ala Leu Thr Leu Leu	
1 5 10 15	
gtg ctg ctc cgc ggg ccg ccg gtg gcg cgg gct ggc gcg agc tcg ggg	2133
Val Leu Leu Arg Gly Pro Pro Val Ala Arg Ala Gly Ala Ser Ser Gly	
20 25 30	
ggc ttg ggt ccc gtg gtg cgc tgc gag ccg tgc gac gcg cgt gca ctg	2181
Gly Leu Gly Pro Val Val Arg Cys Glu Pro Cys Asp Ala Arg Ala Leu	
35 40 45	
gcc cag tgc gcg cct ccg ccc gcc gtg tgc gcg gag ctg gtg cgc gag	2229
Ala Gln Cys Ala Pro Pro Pro Ala Val Cys Ala Glu Leu Val Arg Glu	
50 55 60	
ccg ggc tgc ggc tgc tgc ctg acg tgc gca ctg agc gag ggc cag ccg	2277
Pro Gly Cys Gly Cys Cys Leu Thr Cys Ala Leu Ser Glu Gly Gln Pro	
65 70 75 80	
tgc ggc atc tac acc gag cgc tgt ggc tcc ggc ctt cgc tgc cag ccg	2325
Cys Gly Ile Tyr Thr Glu Arg Cys Gly Ser Gly Leu Arg Cys Gln Pro	
85 90 95	
tcg ccc gac gag gcg cga ccg ctg cag gcg ctg ctg gac ggc cgc ggg	2373
Ser Pro Asp Glu Ala Arg Pro Leu Gln Ala Leu Leu Asp Gly Arg Gly	
100 105 110	

- 40 -

ctc tgc gtc aac gct agt gcc gtc agc cgc ctg cgc gcc tac ctg ctg	2421
Leu Cys Val Asn Ala Ser Ala Val Ser Arg Leu Arg Ala Tyr Leu Leu	
115 120 125	
cca gcg ccg cca gct cca g gtgagccgcc cgccaggtgc gctgcgtgca	2470
Pro Ala Pro Pro Ala Pro	
130	
gcaccgccac tggcgccgaa gggcctgggg gttgctgggt gccgctgcgg gagactccgc	2530
ttttcttctc actggagata atatgtgggg aaactgaagg cgctccggga aagggtgaagg	2590
cggtcgccga gggaccctcc ccagccggcc ctctacttgc tcgattctct aagtgcagag	2650
tacttgtaaa ttgcaaagcg ctttcagtga aaatgggtaa aggtttccgg agctgagggg	2710
agcggtagcg atgttttagct gttggaaaga tcctggacac aggagattct cctcgccccg	2770
cacgggtgca cacggactgc aatcccaggg atgcttgggg atggggggat ataggcggat	2830
ttggaccaag gaagggtgggt aggcacgttg taggaaatag tacctctctt taaaataact	2890
gactttgcac agccttttgg tttgcaaagc aatgtctagt cccggtatgt ccaaaaacaa	2950
gtaaagtgga ttcgggtttt gatatcttct gcggttgga aacctgaagc tgaaaaagaa	3010
gtaacttctt aagggttacc agcggccaca acagagtgtg ggtttgaact ccgcgtgcca	3070
ctttcagtac cataccattc ttacaactcg ggccaccctc gcacctgcgc cgacctcaaa	3130
caaacttcca ggtgcgtggg gggcgccggc aatgtggact aagtcaattt caatgacacg	3190
gcaagggaat tggaatcagt cctaggctgt ctcccttctt aatctgaaat gggggggggg	3250
aatgagatgt tgttaagggg agccccagaa gaggaataat gcaaacattt ggcagagtta	3310
ccctcttgct tagccactat cagtatcagg cagacagcga ctctggtaag ggcattcacat	3370
tgttccctta aaaaaaggag cgggggttgt ttaaatggat ttggcagctg ttctttcaag	3430
cattcttagc cagcctcacc tagttatatg agaaataaag ttcttgctt gcacagctga	3490
aggctgggag aattctcccc atcctaattc cccaactcc ccaacgatca cgttggacag	3550
atgtcactgg gcaggcccc atctagggct agcaggatga acagtccctt tataatttat	3610
gtagctgtag agttccacgc ccgggtgaag ttattttctg gctcggcaag gctggctctg	3670
ttcacccttg agaaatgctg gattcatgga aaggcaagat gcctgaaaca tacactggct	3730
ctggtcagct gttaaagctg ctggaggcat ttgtctctcg gggcaaagtt atgtcatttg	3790
ccaagtgtcg tacattattg tgcatttttg ggtattcaaa aagtgatctt agaaatactg	3850
atacacatcg tcattcttgg gcttttagcaa tcatcatgat taccacctta gtagcactgt	3910
agtatagggt gatgtgagtt ataagattat aaaaagatct aagtgacttc tagaatctat	3970
ttgacaaaaa aaggtaaatt ttcgacagtc aaaagtcaca attatctggt gcttaaatag	4030
aactgttttg tcttcatgcc ctagtctgca gcccaggcat taagaagaaa ccaaggaaat	4090

- 41 -

ttaagaaatt actcaagggt cttagaaaag aagtataaat acgtttatatt acatgtttctt	4150
agagtattta cattcttagt atctctttta tctcagtatt tccttgaaaa agaaagcaag	4210
ctaagattaa aagaaattga aaccaaattcc tcgcaggtag ggacctcttc tgtgaggctc	4270
tgtgctggac cctgggaatg tgtgcttccc aaggtagtaa accccttggg gaactttaca	4330
gcaggacctc agtgagctgt ttggcagggtg aggaaactaa gaccagaga ggagaggagac	4390
tttctaagg cctggtgag tgacctgcca gtagccactt ccaggggaga gcagagcatc	4450
tgcagccaaa tcattgcagc cccaggtagc tttctagata gactgtggac cagatgggccc	4510
acctgagctc cctgctaggg ttacacatta tagccctgtt tgtgtagtag agaaatttca	4570
tgactctcaa ttgtggactt aagccgatgc ctccagacct tggcatggtc cacaggccct	4630
gggagcatgg gctctgaatg tagcctttga tccccatagc ggtcttacag cccctccaag	4690
ttcattctga agaaggaatg gagtgagaat cctggctgca gatccagtct tgaatttagt	4750
catatactta aaattccaat tcaactgtta acattccagc atccatttta agcatcagac	4810
tttcttcatt tagcactttt tattataaaa gggagatctg ctggaggggg atttctccta	4870
ccccacccc acccaggga gaaaaagctc tttggcactt agaagtctga gccgtgagtg	4930
attgtctgca tccatgtgct gctgtgttca cccggggtga aaaggactca	4990
cttaggcagg caccagcaag atgcacaggg tctgtgtaga ccttgagttt tagagatgta	5050
acggggacct agaaaacaag ccaccaacat gcttgcata ttctgagccc ctgaggcaaa	5110
acgctttgca ggtaataatt cagttttccc atctgagctg gacaccaagc tcttataagc	5170
gtgtttacct ggtagcattg aggacggtag tggtaacct tgggaattccc ataagggtt	5230
gttacaactc agactcgtgc cgccactcca gcgtttccgg agtgaggagaat gtgcatttct	5290
tccaagtccc cgggctgccc ctgctcccg cgggtgggagg accacacttg gagttgactg	5350
caaaatttct gagccggcgc tgcagcagcc tcccgtggct caggtctgcc ccctgccggt	5410
ggaagatgaa gcatactgcc ttcacctact gaggggcact gaagcgtttg tctgccttct	5470
ttagttgcag ctacttagga agagcacctg tcagattgac tttcaaacag ataacttctt	5530
gaggtagagc aaccaccatg tagtgagtag tatgatggaa taatacttca tgcaggtatt	5590
taaaaaaaaa acctcacttg gattgccaac taatattgtc atttacatgt gacctggttg	5650
caacgttaag atttttaca gactgtgata gatattgatg actctcatgt gtttgtctct	5710
cttgggctgt ttaag ga aat gct agt gag tcg gag gaa gac cgc agc gcc	5760
Gly Asn Ala Ser Glu Ser Glu Glu Asp Arg Ser Ala	
140 145	
ggc agt gtg gag agc ccg tcc gtc tcc agc acg cac cgg gtg tct gat	5808
Gly Ser Val Glu Ser Pro Ser Val Ser Ser Thr His Arg Val Ser Asp	
150 155 160	

- 42 -

ccc aag ttc cac ccc ctc cat tca aag ata atc atc atc aag aaa ggg	5856
Pro Lys Phe His Pro Leu His Ser Lys Ile Ile Ile Ile Lys Lys Gly	
165 170 175	
cat gct aaa gac agc cag cgc tac aaa gtt gac tac gag tct cag agc	5904
His Ala Lys Asp Ser Gln Arg Tyr Lys Val Asp Tyr Glu Ser Gln Ser	
180 185 190	
aca gat acc cag aac ttc tcc tcc gag tcc aag cgg gag aca gaa tat	5952
Thr Asp Thr Gln Asn Phe Ser Ser Glu Ser Lys Arg Glu Thr Glu Tyr	
195 200 205 210	
gtgagagctt ttcctcttgt taaaggagga gggcaagacc tgccaagcct ggggtactcag	6012
agcctcttga gggcaattct tactcaacaa accccagcgc ctggctgatg ggtgggcaac	6072
ccctagcccc tctgtgccct acctctctcc tctccttaca taaagaatat tgaccctttt	6132
ggagaatctt atgaggatca agctgaaata acactcttaa aagcatatgg gatgtcataa	6192
agacctctgc agataatgaa aatattctca taaagatagt tttatcttact tcatcctcta	6252
tgcttggtga cctgctattg gttccatgcc agcttctgtg ccttactctg ggaagagcaa	6312
aaaggagaca gggagtgatg gttagcttat tcgggggact ttcgtgctac atcagacata	6372
aggtatctga ggagcaaatt acagggtccca cttttggtag ttgtgcagca tcgtaagatt	6432
tttaaagcac acattctaga gtaaaaactg tgactctggt gctctgggtcc ttctgatcc	6492
ccag ggt ccc tgc cgt aga gaa atg gaa gac aca ctg aat cac ctg aag	6541
Gly Pro Cys Arg Arg Glu Met Glu Asp Thr Leu Asn His Leu Lys	
215 220 225	
ttc ctc aat gtg ctg agt ccc agg ggt gta cac att ccc aac tgt gac	6589
Phe Leu Asn Val Leu Ser Pro Arg Gly Val His Ile Pro Asn Cys Asp	
230 235 240	
aag aag gga ttt tat aag aaa aag cag gtgagtgagg tcctcagtgt	6636
Lys Lys Gly Phe Tyr Lys Lys Lys Gln	
245 250	
gttttcttcc tcttctgttg acacagagga gaaacccatg tcaccagcgc ccaggctctt	6696
gtggccatag ctctaactct gagcctgtgc agcaccagtg ccaggactt ggtgccagtc	6756
tcaggaggtc agaccaaggg ctgctttgac ttgttgctct gagtgctgct atattggcca	6816
taatcctcaa ccctagtgcc ttccaccac ccgcttccca ctctgtcct ttcaatggtt	6876
caccacagg cggacaagat gctgcccagt ggcacccttt ataaactgca agtggacatg	6936
ttaacacatt tgttaatgct gcgtcaggga gtgacatttc aaacaactat tatagtcagt	6996
ttccaagaag tgtgacatga ggtcatacca caaaaaagct taccctgaaa tcccacaatc	7056
gtcccctttc ctactgatgc cttcccagata gtgagcaggt tgcaatatta agattttgaa	7116
aaggctgttg ctagatgttg gtgactcgtg tgtctctgtc tcccttgggc ttttcaagga	7176
aatgctagtg agtgggggga tgactgcagc atggccagct tggagagccc agccatcccc	7236

- 43 -

agcacataacc aggtgtctgt cttggcgtgg aggggatgga acttgaaatc agacactcgg	7296
tccatgctgg ggatggccag tctctccaaa ctggcatgtg gtcttctctcc gagtcactgg	7356
catttcctta gaaagtccaa gtgagaagaa ggcatgagag tcatcaacat caaacaacag	7416
tcttttcaaa atctttatat tgcaacatag tcccattcct ggaaaaggaa tggagtgaga	7476
atcctggcta cacatcagcc ccaaatgtag tcattgccta aaatcccaat taacctgaaa	7536
atgatcaaac aaatttaaga tatagtaata ttaagctgta ataaatatgc ttctataggc	7596
tttgtgttat gtgatggcac tatttcaatt ggctttctaa ttggacaatt gatactatgc	7656
tatctacaga attggccttt ggagacctaa gtgagccaca gtggcctcag ggtgaccata	7716
tactaggatt catagcagtg gccacagtca gaagcctaag ctttctctcca ttgccattgc	7776
tcgtttatac cacgtttctg tcaaagtcatt attcattcaa caaagtcata ctgagaaggt	7836
gtcatgtgag gctggatgtg ggctccaaag tcatagctgt gacattcgca ggcagcggga	7896
tgttctcagt tccacatttg gcagagaagt cagtcaagag gttctacaag ggctggtgtc	7956
caccttatac tcctagaaac acaaaactgc cccaccccc gctttcttgg agcaggaagt	8016
tacaccacaca cgcattgcaca ggcgcacact cagcgggcct aggcagcgtg gctcttgtgt	8076
tgcttagct gaaatttctg ttgtgctttc tcagcatagc agagtcacgc tggcaaacca	8136
tcatgcgccc tggccaccga cctgacacca gaccaggag cattcacttc tctgtcttct	8196
gtttctctcc cacag tgt cgc cct tcc aaa ggc agg aag cgg ggc ttc tgc	8247
Cys Arg Pro Ser Lys Gly Arg Lys Arg Gly Phe Cys	
255 260	
tgg tgt gtg gat aag tat ggg cag cct ctg cca ggc tac acc acc aag	8295
Trp Cys Val Asp Lys Tyr Gly Gln Pro Leu Pro Gly Tyr Thr Thr Lys	
265 270 275	
ggg aag gag gac gtg cac tgc tac agc atg cag agc aag tagacgcctg	8344
Gly Lys Glu Asp Val His Cys Tyr Ser Met Gln Ser Lys	
280 285 290	
ccgcaagggg gagtactcag gaggggcagc ctgggctcca gggcctcact gtccttggac	8404
cagcctcagg ggctgggcgt ggccactggc cttccccagg cttacagacc caggagctgc	8464
agctcagggc cagaaagagc aaagcaaata ggacagagcc ctcagaaggg tgcagggaga	8524
gggagacccc atcaacccaa ccaacaagt gtggggaagg aggccggcca gtgcacctca	8584
gggacactct gctttatctc agatacctca cagcacctaa gctatcattc atccacacac	8644
aaagtgaaga ttttcaaagt taggctttac ccgtgagtct ggaggtcatt tatcttcaca	8704
gagaacgttt atcgagact gctaagatac atgttctaata taagatgtga tgtgagaacy	8764
ctgaatgctc gttggagact cagttgaagt gcagcttttt ttctgtcaaa tatataatga	8824
atattctgtt agtctgtggc taatataatt ttaataaagt taatttaaata ctgatagaaa	8884

- 44 -

aatgaaat	ttt	taa	acgataa	tttt	tagagaa	tgctattata	tccagtcttc	ttttttcttt	8944
taataaatga	gggaactatt	gggggaaagg	aataaataca	ttttctttca	ttttattaag				9004
acaaat	tttag	taagcagaag	aaat	ttgcat	gttttagttat	aagggtttct	tttttcctta		9064
caagttggaa	aaaataattc	taatttaagg	gtaactcttt	gacaatgaac	actgtgagca				9124
gcatctggta	ctcgttgctt	tgtttgaaaa	catgagttga	gacccagcc	gcacttgag				9184
cctagtgcc	ttagcctgca	ggctgtgctg	gatctctcag	ggcaagagtc	gagccctttt				9244
gattttgggg	ggattat	tttc	aatatatttg	ctttttcttt	ttgttttagt	taatgtggag			9304
ctcaa	atg	ccttattttg	cacaaaagac	tgccaaggac	atgaccagca	gctggctaca			9364
gcctcgattt	atatttctgt	ttgtggtgaa	ctgatttttt	ttaaaccaaa	gtttagaaaag				9424
aggtttttga	aatgcctatg	gtttctttga	atggtaaact	tgagcatctt	ttcactttcc				9484
agtagtcagc	aaagagcagt	ttgaattttc	ttgtcgcttc	ctatcaaat	attcagagac				9544
tcgagcacag	caccagact	tcatgcgccc	gtggaatgct	caccacatgt	tggtcgaagc				9604
ggccgaccac	tgactttgtg	acttaggcgg	ctgtgttgcc	tatgtagaga	acacgcttca				9664
ccccactcc	ccgtacagtg	cgcacaggct	ttatcgagaa	taggaaaacc	tttaaacc				9724
ggcatccgg	acatcccaac	gcatgctcct	ggagctcaca	gccttctgtg	gtgtcatttc				9784
tgaacaagg	gcgtggatcc	ctcaaccaag	aagaatgttt	atgtcttcaa	gtgacctgta				9844
ctgcttgggg	actattggag	aaaataagg	ggagtcctac	ttgtttaaaa	aatatgtatc				9904
taagaatgtt	ctagggcact	ctgggaacct	ataaaggcag	gtatttcggg	ccctcctctt				9964
caggaatctt	cctgaagaca	tggcccagtc	gaaggccag	gatggctttt	gctgcggccc				10024
cgtagggtag	gaggacaga	gagacgggag	agtcagcctc	cacattcaga	ggcatcaca				10084
gtaatggcac	aattcttcgg	atgactgcag	aaaatagtgt	ttttagattc	aacaactcaa				10144
gacgaagctt	atttctgagg	ataagctctt	taaaggcaaa	gctttatttt	catctctcat				10204
cttttgcct	ccttagcaca	atgtaaaaaa	gaatagtaat	atcagaacag	gaaggaggaa				10264
tggcttgctg	gggagcccat	ccaggacact	gggagcacat	agagattcac	ccatgtttgt				10324
tgaacttaga	gtcattctca	tgcttttctt	tataattcac	acatatatgc	agagaagata				10384
tgttcttggt	aacattgtat	acaacatagc	cccaaatata	gtaagatcta	tactagataa				10444
tcctagatga	aatgttagag	atgctatatg	atacaactgt	ggccatgact	gaggaaagga				10504
gctcacgcc	agagactggg	ctgctctccc	ggaggccaaa	cccaagaagg	tctggcaaaag				10564
tcaggctcag	ggagactctg	ccctgctgca	gacctcggtg	tggacacacg	ctgcatagag				10624
ctctccttga	aaacagaggg	gtctcaagac	attctgccta	cctattagct	tttctttatt				10684
tttttaactt	tttgggggga	aaagtatttt	tgagaagt	gtcttgcaat	gtatttataa				10744

- 45 -

atagtaaata aagtttttac cattaaaaaa atatctttcc ctttggttatt gaccatctct 10804
 gggctttgta tcactaatta ttttatttta ttatataata attattttat taaaatgttc 10864
 cctgctttcc ctttttagcaa 10884

<210> 12
 <211> 291
 <212> PRT
 <213> Homo sapiens

<400> 12

Met Gln Arg Ala Arg Pro Thr Leu Trp Ala Ala Ala Leu Thr Leu Leu
 1 5 10 15

Val Leu Leu Arg Gly Pro Pro Val Ala Arg Ala Gly Ala Ser Ser Gly
 20 25 30

Gly Leu Gly Pro Val Val Arg Cys Glu Pro Cys Asp Ala Arg Ala Leu
 35 40 45

Ala Gln Cys Ala Pro Pro Pro Ala Val Cys Ala Glu Leu Val Arg Glu
 50 55 60

Pro Gly Cys Gly Cys Cys Leu Thr Cys Ala Leu Ser Glu Gly Gln Pro
 65 70 75 80

Cys Gly Ile Tyr Thr Glu Arg Cys Gly Ser Gly Leu Arg Cys Gln Pro
 85 90 95

Ser Pro Asp Glu Ala Arg Pro Leu Gln Ala Leu Leu Asp Gly Arg Gly
 100 105 110

Leu Cys Val Asn Ala Ser Ala Val Ser Arg Leu Arg Ala Tyr Leu Leu
 115 120 125

Pro Ala Pro Pro Ala Pro Gly Asn Ala Ser Glu Ser Glu Glu Asp Arg
 130 135 140

Ser Ala Gly Ser Val Glu Ser Pro Ser Val Ser Ser Thr His Arg Val
 145 150 155 160

Ser Asp Pro Lys Phe His Pro Leu His Ser Lys Ile Ile Ile Ile Lys
 165 170 175

Lys Gly His Ala Lys Asp Ser Gln Arg Tyr Lys Val Asp Tyr Glu Ser
 180 185 190

- 46 -

Gln Ser Thr Asp Thr Gln Asn Phe Ser Ser Glu Ser Lys Arg Glu Thr
195 200 205

Glu Tyr Gly Pro Cys Arg Arg Glu Met Glu Asp Thr Leu Asn His Leu
210 215 220

Lys Phe Leu Asn Val Leu Ser Pro Arg Gly Val His Ile Pro Asn Cys
225 230 235 240

Asp Lys Lys Gly Phe Tyr Lys Lys Lys Gln Cys Arg Pro Ser Lys Gly
245 250 255

Arg Lys Arg Gly Phe Cys Trp Cys Val Asp Lys Tyr Gly Gln Pro Leu
260 265 270

Pro Gly Tyr Thr Thr Lys Gly Lys Glu Asp Val His Cys Tyr Ser Met
275 280 285

Gln Ser Lys
290

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU02/00558

A. CLASSIFICATION OF SUBJECT MATTER												
Int. Cl. ⁷ : C12Q 1/68												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols)												
SEE ELECTRONIC DATA BASES												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
SEE ELECTRONIC DATA BASES												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)												
Medline, CA:IGFBP, insulin like growth factor binding protein, liver, hepato, HCC, cancer, tumour, tumor, neoplasm, carcinoma, malignant												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
X	WO 99/46597 A1 (DIAGNOSTIC SYSTEMS LABORATORIES INC) 16 September 1999 Whole Document	1 - 18										
P, X	WO 01/53837 A1 (DIAGNOSTIC SYSTEMS LABORATORIES INC) 26 July 2001 Whole Document	1 - 18										
X	WO 00/69454 A1 (BOARD OF REGENTS, THE UNIVERISTY OF TEXAS SYSTEM) 23 November 2000 Whole Document	27 - 29										
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex												
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent but published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 16 May 2002		Date of mailing of the international search report 12 JUN 2002										
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer CRAIG ALLATT Telephone No : (02) 6283 2414										

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU02/00558

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JG Reeve et al <i>Int J Cancer</i> (1992) 51(5) pp 818 - 21 "Insulin-like growth-factor-binding protein gene expression and protein production by human tumour cell lines" Whole Document	1 - 18
X	SA Weinzimmer et al <i>J Clin Endocrinol Metab</i> (2001) 86(4) pp 1806 - 13. "Transferrin is an insulin-like growth factor-binding protein-3 binding protein" Whole Document	24
X	T Yamashita et al <i>Biochem Biophys Res Commun</i> (2001) 282(2) pp 647 - 54. "Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma" Whole Document	1 - 18
X	N Kondoh et al <i>Cancer Res</i> (1999) 59(19) pp 4990 - 6 "Identification and characterization of genes associated with human hepatocellular carcinogenesis" Whole Document	1 - 18
X	JG Scharf et al <i>Lab Invest</i> (2000) 80(9) pp 1399 - 411 "Analysis of the IGF axis in preneoplastic hepatic foci and hepatocellular neoplasms developing after low-number pancreatic islet transplantation into the livers of streptozotocin diabetic rats" Whole Document	1 - 18
X	Y Gong et al <i>Mol Cell Biochem</i> (2000) 207(1-2) pp 101 - 4 "The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma" Whole Document	1 - 18
X	M van Kleffens et al <i>Endocrinology</i> (1999) 140(12) pp 5944 - 52 "Generation of antisera to mouse insulin-like growth factor binding proteins (IGFBP)-1 to -6: comparison of IGFBP protein and messenger ribonucleic acid localization in the mouse embryo" Whole Document	24
X	Y Shiota et al <i>Hepatology</i> (2001) 33(4) pp 832 - 40 "Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays" Hepatology" Whole Document	1 - 18
X	SG Gray et al <i>Br J Cancer</i> (2000) 82(9) pp 1561 - 7 "Altered expression of members of the IGF-axis in hepatoblastomas" Abstract, pp 1565 - 7	1 - 18
X	H von Horn et al <i>Cancer Lett</i> (2001) 162(2) pp 253 - 60 "Expression levels of insulin-like growth factor binding proteins and insulin receptor isoforms in hepatoblastomas" Whole Document	1 - 18
X	L Xu et al. <i>Cancer Res</i> (2001) Apr 1 61(7) pp 3176 - 81 "Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma" Figure 5	1 - 18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU02/00558

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos : 19 - 23, 25, 26, 30 - 37
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The claims are not limited to the technical features that define the invention.

3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Claims 1 - 18 are directed toward a method for detecting the presence of liver cancer by detecting the aberrant expression of a gene encoding an insulin like growth factor binding protein (IGFBP).

Claims 19 - 37 are directed toward methods of treating liver cancer by modulating expression of an insulin like growth factor binding protein.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU02/00558

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member	
WO	99/45697	EP	1066716	SE	9800686
WO	2001/53873	FR	2803918		
WO	2000/69454	NONE			
END OF ANNEX					